



**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIRECTOR'S OFFICE  
OFFICE OF MINORITY HEALTH & EQUITY**  
555 E. Washington Avenue, Suite 4800  
Las Vegas, Nevada 89101  
Telephone (702) 486 - 2151 • Fax (702) 486 - 3586  
<http://dhhs.nv.gov/Programs/CHA/MH/>

**November 8, 2019**

**Memorandum**

To: Dr. Jon Pennell, Chair  
Nevada State Board of Health

From: Tina Dortch, Program Manager  
Nevada Office of Minority Health and Equity (NOMHE)

Re: NRS.232.482 There is hereby created in the Office an Advisory Committee consisting of nine voting members appointed by the Department and State Board of Health.

In accordance with Nevada Revised Statutes (NRS) 232.482, it is the responsibility of the State Board of Health to appoint six members of the Nevada Office of Minority Health and Equity (NOMHE) Advisory Committee on Minority Health (i.e. AC), as detailed below:

1. The Director of the Department shall appoint three members who have an interest in health issues related to minority groups.
2. **The State Board of Health shall appoint:**
  - a. Three members representing each geographic region of the State, including one member who resides in southern Nevada, one member who resides in northern Nevada and one member who resides in rural Nevada;
  - b. One member who is a representative of a non-profit organization located in the state;
  - c. One provider of health care in this state; and
  - d. One member of the public at large.
3. One Legislator who is appointed by the Legislative Commission shall serve on the Advisory Committee in an ex-officio, nonvoting capacity.

As of this writing, three of the nine NOMHE Advisory Committee seats are currently vacant. By virtue of this correspondence, one candidate is being proposed to fill one of the vacancies. With this requested action (if approved), five of the six seats required to be filled by Board of Health appointments would be achieved. With this requested action (if approved), two of the nine NOMHE Advisory Committee seats remain open; one a Director of Health and Human Services appointment and one a Board of Health appointment.

#### NOMHE Staff Recommendation

Staff recommends that, effective with your ruling, the Nevada Board of Health appoint the following person to the Nevada Office of Minority Health and Equity Advisory Committee on Minority Health, to serve a two-year term:

- **Dr. Gillian Barclay** (Academic Health Center Specialist, UNLV – Office of the President)
  - *Representative based in S Nevada (Board of Health appointment)*

A copy of the candidate's resume is attached and a matrix denoting a selection process which addresses statutorily required ethnic, geographic and professional diversity.

#### Presenter

Tina Dortch, Program Manager, Nevada Office of Minority Health and Equity

Executive-level leadership with 25+ years of experience building and transforming the organizations, programs, policies and partnerships to advance health and economic development in the United States (US) and abroad. Exhaustive knowledge of strategies to advance health and economic development in low and middle-income countries (LMICs), regional and local economies in the US. Strong expertise in approaches to structure organizations and engage staff to meet business objectives and organizational goals. Highly skilled in establishing collaborative and strategic relationships among private and corporate philanthropic, private sector entities, academic, government and non-profit stakeholders in the US and LMICs. Proven track record as an innovator and team leader dedicated to helping others grow professionally. A visionary leader and innovator with a personal commitment to life-long learning.

- **Visionary Leader & Strategist** – experienced establishing and championing bold strategies designed to move organizations forward, ignite passion and meet aggressive but achievable goals.
- **Alliances & Strategic Partnerships** – expert and politically-astute collaborator, spokesperson and advocate, building alliances and raising organizational profiles.
- **Staff & Values Alignment** – skilled at building systems, staff development and nurturing organizational cultures that bring all working parts – internal and external – into alignment to meet objectives.
- **Strategic Communications and Outreach** – expert building and nurturing strategic and mutually-beneficial alliances, promoting effective communication in multicultural environments,
- **Programs, Organizational Learning & Impact** – expert establishing innovative programs, operations, impact and learning systems, using evidence-driven knowledge to improve conditions and opportunities for those who are most vulnerable.

- |                               |                                    |                                      |
|-------------------------------|------------------------------------|--------------------------------------|
| • Strategic Planning & Vision | • Private & Corporate Philanthropy | • Health Systems Strengthening       |
| • Health Equity               | • Policy Development & Analysis    | • Economic Development               |
| • Evaluation & Impact         | • Social Determinants of Health    | • Social Impact Investing            |
| • Business Strategy           | • Governance & Compliance          | • Strategic Partnerships & Alliances |
| • Strategic Communications    | • Budgets & Financial Management   | • Staff Development & Hiring         |
| • Government Relations        | • Board Engagement                 | • International Relations            |

## LEADERSHIP EXPERIENCE

---

**UNIVERSITY OF NEVADA, LAS VEGAS (UNLV), OFFICE OF THE PRESIDENT**– Las Vegas, Nevada

**Academic Health Center Specialist** 2019– present

Responsible for the planning and coordination of the UNLV's new Academic Health Center (AHC), as well as its growth strategy. Advise senior leadership on strategic, structural and operational matters and work on an overall plan for an integrated, collaborative AHC. Foster relationships within the business sector, community and other stakeholders to promote the value of the AHC. Work with the new UNLV School of Medicine through its transition to accreditation, including addressing operational, structural and strategic challenges related to its growth and leadership transitions.

Successes to date include;

- Secured the Small Business Innovation Research-Small Business Technology Transfer (SBIR-STTR) Biennial Federal Seed Fund Conference for April 2020. This 3-day regional conference will be co-led by the UNLV and the National Institutes of Health, with 8 other federal agencies attending.
- Second annual Nevada business symposium on Aging in Place- Smart and Connected Health scheduled for February 2020.
- Inaugural Nevada symposium on Innovations for Population Health Equity- Role of Academic Health Centers scheduled for January 2020.

**WIYZIP, LLC – Ann Arbor, Michigan**

*(Global social enterprise building and supporting health and economic development in the United States (US) and Low and Middle-Income Countries (LMICs))*

**Founder and Board Chair**

2015– present

Founder of global social enterprise dedicated to economic diversification in low and middle-income countries (LMICs) and the US. Lead diverse team of corporate, philanthropic and academic executive leaders to identify and grow social enterprises with Lean startup approaches to meet the United Nations Sustainable Development Goals (SDGs). Successes to date include;

- New local infrastructure in 3 LMICs using data and evidence-driven approaches to address social, health and economic priorities- led to the development of first SMART Academy in sub-Saharan Africa.
- Three sessions with policymakers in the US Virgin Islands on data and evidence-driven policy formulation for communicable diseases- led to new policies to use technology, data and analytics for surveillance, monitoring and response for zika, dengue and vector-borne illnesses in the US Virgin Islands.
- Inaugural leadership program launched to grow woman-owned technology and engineering social enterprises in Latin America and the Caribbean; Six 2-day technical assistance sessions in 4 LMICs on the nuts and bolts of Lean startups and social enterprises.
- Five interprofessional education and collaborative practice strategic sessions with LMIC health and tertiary education institutions as economic development strategies to meet the SDGs.
- Seven hubs planned in 4 LMICs with data and evidence-driven social enterprise digital technology solutions to meet the SDGs.

**STATE OF NEVADA, GOVERNOR'S OFFICE OF ECONOMIC DEVELOPMENT (GOED)- Las Vegas, NV**

*(State governor's office dedicated to multi-sectoral strategies to advance economic development for the state of Nevada)*

**Health Care Industry Specialist**

2017– 2019

Brought in to catalyze state's economic growth through new health sector investments. Advanced necessary and appropriate evidence-driven changes in law, regulation, policies or processes to stimulate health sector growth to improve economic and population health outcomes. Identified and led opportunities to incentivize new private industry investments in health to diversify and strengthen the state's economic infrastructure. Served as external representative for audiences in academia, the private sector, philanthropy, governments and the non-profit sector. Successes included;

- Organized and led inaugural Nevada symposium on technology and biomedical research and development and product commercialization for the health sector.
- Four new state-level training programs for a 21<sup>st</sup> century workforce skills and competencies in the use of digital technology; new state programs in data analytics, telehealth, mobile health and health information systems to reduce the cost of care, strengthen health system infrastructure, and improve patient health outcomes
- Three new initiatives to test the use of unmanned autonomous systems in health including for emergency preparedness and disaster response; led to 2 new initiatives with smart solutions and data analytical approaches for transitional care and chronic non-communicable disease management.
- New policies to train the health and human services workforce for aging in place strategies in southern and rural Nevada; led to over USD\$750,000 in new investments to improve transitional care, created 112 new jobs in southern Nevada.
- New approaches and stakeholder engagement for interprofessional education and collaborative practice; inaugural Nevada policy stakeholder meetings on interprofessional education and collaborative practice for primary care and behavioral health.
- Opportunities identified for R&D growth in Nevada; led to \$1.75M in GOED investments to grow sports R&D in Nevada; led to 1 new training certificate for health R&D at UNLV.
- Served as the state's external representative and spokesperson for health and economic development- led to new state stakeholder alliances with external stakeholders.

**AETNA FOUNDATION – Hartford, Connecticut**

*(Corporate foundation supporting and funding local, national and international initiatives to improve health and wellness)*

**Vice President, Aetna Foundation**

2010 – 2015

Provided the leadership that transformed the foundation's organizational infrastructure and brand; led foundation's organizational and programmatic strategic planning; expanded foundation's profile and footprints domestically and abroad; conceptualized and led board-approved national and international program investments in digital technological innovations, reducing racial and ethnic health inequities, promoting quality health and community wellbeing, growing 21<sup>st</sup> century leadership for health; turned USD\$18M of charitable giving into more strategic \$18M funding investments. Successes included;

- Advised foundation board and corporate leadership on critical changes in the philanthropic and business landscapes- led to timely discussions and decisions to restructure funding investments and initiatives.

- Established formalized budget and contracting procedures and managed foundation national and international budgets - resulted in a dramatic improvement in financial controls, legal compliance and due diligence requirements for USD\$18M in strategic investments in the United States and abroad.
- Supervised the foundation's balanced scorecard, and its alignment to overall organizational business metrics- led to comprehensive overview of foundation's contribution to overall business accomplishments over a 5-year period
- Developed strategic partnerships with private and corporate foundations, governmental, private and non-profit stakeholders- generated new partnerships with USD\$7M in co-investments over 3 years for small business and policy solutions to reduce food insecurity; led to USD\$2M in co-investments to develop inaugural state survey in the US (Connecticut Health Care Survey) on quality health care and health equity; led to a shift in health system approaches to meet the Triple AIM goals by addressing racial and ethnic health inequities.
- Partnered with national and regional foundations on strategies to strengthen primary care infrastructure in the United States- led to partnerships with the National Academies of Medicine and the Association of Academic Health Centers for new policy-centered strategies to increase graduate medical education financing and expansion in the United States; led to new primary care-centered care coordination and integrated health care to reduce health disparities across 7 health systems in 6 states.
- Conceptualized and led leadership initiatives to address the social determinants of health- led to engagement of over 27 academic health centers resulting in strengthened infrastructure to address population health inequities; led to 35 underrepresented minority faculty fellows in tenured- track positions over 5 years; led to new interprofessional education and collaborative practice models across 14 health systems and 9 academic health centers.
- Conceptualized and led first ever US strategy in digital technology to reduce racial and ethnic health disparities- led to first national symposium on digital technology solutions to reduce racial and ethnic disparities in partnership with the National Academies of Medicine Science and Engineering; led to USD\$7M in investments in Lean strategies to develop digital technology tools for chronic disease prevention and management in vulnerable populations in the US and abroad; established first US program for underrepresented minority faculty leadership in health technology with 32 fellows in partnership with the National Science Foundation.
- Supported strategic investments for White House Initiatives, Let's Move and Partnerships for a Healthier America (PHA)- led to new cohort of foundation grantees over 3 years, specifically dedicated to support these initiatives, and Aetna employee engagement to support White House Let's Move strategies.
- Hired staff, served as organizational mentor and coach, directed staff development opportunities- led to 3 staff members accepted into competitive national professional development programs; 3 Aetna Inc. business staff mentored and promoted into management roles.
- Spearheaded strategies with communications to scale and brand the work of the foundation- increased social media, television and radio presence; timely impact reports for 8 board meetings and 5 annual reports, over 50 external meeting presentations; 3 congressional briefings; 4 peer-reviewed journal issues; 3 books; 6 peer-reviewed articles; 3 magazine articles.
- Served as the foundation's external representative and spokesperson for media events, audiences in philanthropy and the non-profit sector, business, government and academia.

## **PAN AMERICAN HEALTH ORGANIZATION/ WORLD HEALTH ORGANIZATION – Washington, DC**

*(Regional Office of the World Health Organization (PAHO/WHO))*

### **Advisor, Health Systems Strengthening**

2006 – 2010

Brought in as an upstream policy advisor for new WHO regional office to advise government officials, policymakers and other stakeholders on development strategies for 15 low and middle-income countries (LMICs). Advanced evidence-driven changes in policies, processes and regulations to stimulate health sector growth to improve health and economic outcomes. Facilitated policy discussions and initiatives to strengthen regional and country health, education and social systems grounded in the determinants (income inequality, poverty, gender, human rights, geography, culture). Successes included;

- Optimized strategic planning sessions in partnership with WHO country and regional offices – legislatively-approved national health strategic plans with budget allocations for 10 LMICs; budgetary allocations legislated to build human resources capacity and infrastructure for health systems planning across 6 countries.
- Facilitated policy discussions to identify health and economic development priorities across 7 countries- led to new social sector policies for aging in place across 3 countries, new policies for the use of data to identify and address health disparities.
- Served as the PAHO-WHO organization co-lead in the Region of the Americas for interprofessional education and collaborative practice- led to new intersectoral policies in 5 countries to support interprofessional education and collaborative practice for chronic disease prevention and management; 2 new regional interprofessional programs for “aging in place”; emergency preparedness and disaster response; 2 new regional graduate degree programs in public health and health care management; one accredited school of medicine; one new academic health center and 4 new academic health departments.

- Spearheaded regional meetings to build leadership for health- led to signed regional collaborative agreements for leadership development across 15 countries to meet guidelines of the WHO Commission of the Social Determinants of Health, funding from the National Institutes of Health to build LMIC research and interprofessional education capacity in partnership with the Harvard Medical School.
- Led development of strategic partnerships among Canadian, US and UK donor agencies, LMIC government officials, business stakeholders – led to growth of new academic-business partnerships for new drug discoveries and technologies; 2 multi-lateral agreements for shared industry and human resources for health among 5 LMICs.
- Achieved technical assistance agreements between US-based and Canadian-based academic stakeholders and LMIC governments- ensured sustained strategies to strengthen public sector skills and knowledge to meet economic development goals across 4 LMICs; new policies and training models to integrate primary care and mental health services; new WHO Collaborating Center for Nursing.
- Built consortia with United States and European Union stakeholders, non-governmental organizations, universities, and private sector entities – led to 3 multinational meetings resulting in unified benchmarks to build LMIC leadership for health and economic development; led to USD\$150,000 co-investments from the US National Institutes of Health and the UK Development Fund for International Development.
- Grew initiative in the region of the Americas to highlight global best practices for the social determinants of children's health- successfully secured \$100,000 in investments from the W.K. Kellogg Foundation; co-edited 2 peer-reviewed publications in partnership with the Centers for Disease Control and Prevention on US and global best practices to address the social determinants of children's health.
- Led development of strategic approaches for global scaling and dissemination of best practice models for health and economic development across 3 LMICs- led to scaling of quality health care models in primary care, strategic business alliances for human and economic development, health workforce development, technology use to strengthen health systems and distance education.
- Served as external representative and spokesperson for audiences in government, business, academia, philanthropy, non-profit sector and other United Nations agencies.

#### **W. K. KELLOGG FOUNDATION – Battle Creek, Michigan**

*(Private foundation with place-based, national and international funding to improve the wellbeing of children, their families and communities.)*

#### **Evaluation Manager, Health**

2003 – 2006

Brought in for the foundation's strategic focus to integrate policy-centered impact evaluation and systems approaches through then lens of racial and ethnic equity. Hired and supervised external evaluation consulting staff. Restructured and revised all impact evaluation processes and systems for over USD\$85M in health and related cross-foundation funding investments. Presented updates at monthly board meetings, followed up on board responses and recommendations; developed strategic partnerships with other foundations, non-profits, private sector, government, non-governmental organizations and academia. Successes included;

- Aligned the foundation's health programs and initiatives to policy-centered systems change models- led to over USD\$20M annually of board-approved funding investments done through the lens of racial and ethnic equity; led to board-approved performance measurement frameworks aligned to organizational learning and business objectives.
- Developed and managed impact budgets and contracts for health and cross-foundation investments- led to adherence to financial due diligence and compliance, and timely financial updates for over USD\$26M in annual program investments.
- Steered feasibility assessments for new health investment models- led to board-approved commitments of \$3M annually for new mission-related investments on business innovations to reduce food insecurity through the lens of health equity; led to growth of new academic-business partnerships for innovations to reduce racial and ethnic health disparities across 8 states..
- Represented foundation in national stakeholder meetings in foundation's core interest areas– led to board-approved partnership in 7-member national funder convergence with over USD\$45M in initial combined investments to reduce food insecurity nationally.
- Conceptualized new strategies with national and local stakeholders to grow and improve health outcomes among tribal nations in the United States; led to inaugural investments to develop and expand the dental therapist model in partnership with the Alaska Native Tribal Health Consortium; led to enhanced approaches to use digital technology to improve education and clinical practice among low-income and vulnerable communities in the United States.
- Assessed prospective and current grantee capacity and infrastructure- led to partnerships with think tanks and community organizations with technical assistance delivered to over 70 grantees annually; led to timely decisions on grantee selections for new initiatives totaling USD\$9M annually.

- Restructured and led the foundation's programs to build leadership for academic health- led to over 60 leadership fellows and scholars within 4 national program offices and 10 academic health centers over 3 years; led to new interprofessional education and collaborative practice models to reduce racial and ethnic health and health care disparities.
- Hired and supervised all impact assessment consultants for health and cross foundation programs- over USD\$4M invested with 11 think tanks and academic institutions annually; led to timely impact reports and improved organizational learning; led to identification and publicizing of the impact of over USD\$60M of foundation's investments over 3 years..
- Served as external representative and spokesperson for audiences in philanthropy, government, private and non-profit sectors and academia.

*Additional previous experience includes senior strategic planning, program and business development, research and evaluation, teaching and clinical roles for:*

**Department of Health and Human Services/Health Resources Services Administration Region 1, Harvard School of Public Health, Dana Farber Cancer Institute, Brigham and Women's Hospital, Channing Laboratory (Boston), Robert Wood Johnson Foundation, Detroit Medical Center, New York Hospital, University of the West Indies, City University of New York, National Institutes of Health.**

## EXPERT PROFESSIONAL RESPONSIBILITIES

---

**Expert reviewer for:**

**The National Science Foundation**, Arlington, VA, 2014- present

**The National Institutes of Health**, Bethesda, MD, 2014-present

**The Council of Education in Public Health**, Washington, DC, 2009- present

**The Journal of Health Care for the Poor and Underserved, Johns Hopkins Press**, Baltimore, MD, 2007- present

**The Journal of the American Public Health Association**, Washington, DC, 2005- present

**The United States Department of Agriculture**, Washington, DC, 2014-2015

**The Aetna Foundation**, Hartford, CT, 2010-2015

**The W. K. Kellogg Foundation**, Battle Creek, MI, 2003-2008

**The Dentaquest Foundation**, Boston, MA, 2001-2004

**The Robert Wood Johnson Foundation**, Princeton, NJ, 1995-1999

## KEY CURRENT AFFILIATIONS AND BOARD APPOINTMENTS

---

**Board Member** – Hip Hop Public Health– Manhattan, NY

**Editorial Board Member** – Journal of Health Care for the Poor & Underserved, John Hopkins Press – Baltimore, MD

**Nevada Commissioner** – Western Interstate Commission for Higher Education– Boulder, CO

**Member** – American Public Health Association – Washington, DC

**Board Chair** – WiYZIP, LLC - Ann Arbor, MI

**Supervisory Faculty** – Doctoral Degree in Business Administration, UWI– Jamaica, WI

**Member** – State of Nevada Graduate Medical Education Taskforce- Las Vegas, NV

**Member** – Advisory Committee, School of Public Health, University of Nevada – Las Vegas, NV

**Member** – Advisory Committee, School of Social Work, University of Nevada – Las Vegas, NV

**Board Member** – Nevada Chapter, Health Occupations Students of America – Carson City, NV

**Board Member** – Las Vegas HEALS (Health, Education, Advocacy, and Leadership)– Las Vegas, NV

**Co-Chair** - Global Affairs Committee, International Association for Interprofessional Education and Collaborative Practice (InterEd), Geneva, Switzerland

## KEY PAST AFFILIATIONS AND BOARD APPOINTMENTS

---

**Member** – Advisory Committee, Kaiser Permanente Center to Build Leadership for Equity, University of California – Los Angeles, CA

**Member** – Advisory Board, Center for Innovation in Mental Health, City University of New York – Manhattan, NY

**Member** – Advisory Board, Harvard School of Dental Medicine – Boston, MA

**Member** – Consultant Working Group on HHS Data Access and Use, United States Department of Health and Human Services, National Committee for Vital and Health Statistics – Washington, DC

**Board Director** – Rebuilding Together – Washington, DC

**Member** -Advisory Board, Primary Care Policy Council, Connecticut Primary Care Innovation Center, Hartford, CT

**Member** – Roundtable on Population Health Improvement – Health and Medicine Division, National Academy of Sciences, Engineering and Medicine – Washington, DC

**Member** – Roundtable on Health Equity – Health and Medicine Division, National Academy of Sciences, Engineering and Medicine – Washington, DC

**Member** - Global Forum on Innovations in the Health Professions, Health and Medicine Division, National Academy of Sciences, Engineering and Medicine – Washington, DC Washington, DC

**Board Member** - National Education Association, Healthy Futures - Washington DC

**Member** - Association of Black Foundation Executives - New York, NY

**Member** -The Conference Board, Research and Evaluation Working Group - Manhattan, NY

**Board Member** -The Oral Health (Dentaquest) Foundation – Cambridge, MA

**Member** - Research and Evaluation Committee, The Medical Foundation – Boston, MA

## EDUCATION

---

**Doctor of Public Health** – Harvard University- Boston, MA  
Major Concentrations: Policy; Social Determinants of Health

**Master of Public Health** – University of Michigan- Ann Arbor, MI  
Major Concentration: Health Behavior and Health Education

**Residency** – New York Hospital – Queens, NY

**Doctor of Dental Surgery** – University of Detroit Mercy – Detroit, MI

**Bachelor of Sciences** – University of the West Indies – Jamaica, WI

## LANGUAGES

---

**English** – Fluent

**Spanish** – Conversant



**December 2019**

**NOMHE Advisory Committee on Minority Health (Board Composition)**

**a Board of Health Recommended Appointment**

submitted for consideration – December 6, 2019

	<b>Name</b>	<b>Ethnicity</b>	<b>N NV, S NV or Central NV</b>	<b>Notable Interest in Health Issues Re to Minorities</b>	<b>Nonprofit</b>	<b>Healthcare Provider</b>	<b>Representative from Public at Large</b>
	Dr. Gillian Barclay	African American	Southern, NV	Academic Health Center Specialist, Office of UNLV President			

## NOMHE Advisory Committee on Minority Health Board Composition as of Sept 2019

	Name	Ethnicity	N NV, S NV or Central NV	Notable Interest in Health Issues Re to Minorities	Nonprofit	Healthcare Provider	Representative from Public at Large
1	Cassandra Cotton (BoH Appointed; June 2018)	African American	Southern NV	Former NOMH Advisory Bd Mbr	Nathan Adelson Hospice and Donor Network		
2	Sam Lieberman (Director Appointed; June 2018)	Caucasian	Southern NV	Easter Seals; NV PEP, Alzheimer's, Independent Mobility			
3	Andre Wade (Director Appointed; June 2018)	African American	Southern NV	LGBTQ awareness, disparities, resources			
4	Erik Jimenez (BoH Appointed; Sept 2019)	Latino	Northern NV	ABLE Savings Account (for Differently Abled)			
5	Dr. Jennifer Kawi (BoH Appointed; June 2018)	Asian/Pacific Islander	Southern NV	Chronic Pain and Opioid Management		FQHC	
6	Andrea Gregg (BoH Appointed; Dec 2018)	Caucasian	Northern NV		Workforce Development		

STEVE SISOLAK  
*Governor*



LISA SHERYCH  
*Administrator*

RICHARD WHITLEY, MS  
*Director*

IHSAN AZZAM, Ph.D., M.D.  
*Chief Medical Officer*

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF PUBLIC AND BEHAVIORAL HEALTH  
4150 Technology Way  
Carson City, Nevada 89706  
Telephone (775) 684-4200 • Fax (775) 687-7570  
<http://dpbh.nv.gov>

## MEMORANDUM

**DATE:** November 14, 2019

**TO:** Dr. Jon Pennell, Chair  
Nevada State Board of Health

**FROM:** Vickie Estes, Supervisor, Medical Laboratory Services  
Bureau of Health Care Quality and Compliance

**RE:** NRS 652.170 (1), "Appointment, terms and qualifications of members: compensation of Members and employees." The Board shall appoint members of the Medical Laboratory Advisory Committee.

In accordance with Nevada revised Statutes NRS 652.170 (4) (a-e), it is the responsibility of the State Board of Health to appoint the members of the Medical Laboratory Advisory Committee. The Medical Laboratory Advisory Committee is composed of: (a) Two Pathologists, certified in clinical pathology by the American Board of Pathology. (b) Two medical technologists. (c) One bioanalyst who is a laboratory director. (d) One qualified biochemist from the Nevada System of Higher Education (e) One licensed physician actively engaged in the practice of clinical medicine in this State. Per NRS 652.170 (2) & (3), members are allowed to serve two (2) consecutive terms for three (3) years.

The following members have expressed interest in serving on the Medical Laboratory Advisory Committee; we are requesting that the Board appoint the following:

Christie L. Elliott, M.D., NRS 652.170 (4) (a) who is a pathologist and the laboratory director at Renown Regional Medical Center Clinical Laboratory.

David P Marmaduke, M.D., NRS 652.170 (4) (a) who is a pathologist and the laboratory director at Sunrise Hospital and Medical Center Laboratory.



Nevada Department of  
Health and Human Services  
DIVISION OF PUBLIC AND  
BEHAVIORAL HEALTH

*Helping People --  
It's Who We Are And What We Do*

**Gayle L. Petersen, MT ASCP., (To be reappointed) NRS 652.170 (4) (b) is a medical technologist and the laboratory manager at Laboratory Corporation of America in Reno.**

**Jill Brown, MLS (ASCP)., NRS 652.170 (4) (b) is a medical technologist and a laboratory supervisor at Northeastern Nevada Regional Hospital in Elko.**

**Alexander Stojanoff, Ph.D., NRS 652.170 (4) (c) who is a bioanalyst and the laboratory director at MD Labs in Reno.**

**Iain L. O. Buxton, PHMD., NRS 652.170 (4) (d) who is a biochemist & Doctor of Pharmacy (PHMD) at the University of Nevada School of Medicine.**

**Victor M. Muro, M.D., (To be reappointed) NRS 652.170 (4) (e) who is a physician actively engaged in the practice of clinical medicine in Nevada.**

**Of this writing, five of the seven seats are currently vacant and two of the seven are to be reappointed for a second term.**

**A copy of each member's Curriculum Vitae is attached.**

**Presenter: Vickie Estes, MT (ASCP), Supervisor, Medical Laboratory Services**

*ALEXANDER STOJANOFF, PhD, MSc, HCLD*  
*Résumé*

---

**EXECUTIVE MANAGEMENT**  
Biotech and Clinical Diagnostic Testing

---

# Alexander Stojanoff, PhD, MSc, HCLD

6069 South Fort Apache Road, Suite 100 • Las Vegas, NV 89148

▪ alexstojanoff@aol.com

---

## EXECUTIVE MANAGEMENT

Biotech and Clinical Diagnostic Testing

---

Very passionate professional focused on all the concerns of individuals, families and communities so they attain, maintain or recover optimal wellbeing and quality of life from birth to end of life. Extensive experience in a variety of specialties as program director or as part of a team to assess, plan, implement and evaluate all arenas of medical care. Professional in the science and art of preventing disease, prolonging life and promoting health. Direct the overall operation and administration of the laboratory, including the employment of competent qualified personnel. Govern policies, processes, procedures, research, and resources needed to achieve consistent, high quality testing services. Masterful at integrating medical health information services, regulation compliance, medical education, cost control, and project management to achieve organizational goals. Develop, design, improve, and manage systems that create and deliver the organization's products or services. Ensure quality care for all, while maintaining credentials, code of ethics, standards and competencies, and continuing education. Provide academic, vocational, behavioral, and social education generating overall enrichment.

- Academic Instructor
- Curriculum Design
- Process Improvement
- Health/Safety Programs
- Financial Management
- Found Businesses
- Method Improvements
- Hospital/Clinic/Lab/Field
- Fertility/Toxicology/Pain
- Pathology/Immunology
- OBGYN/Biochemistry
- Infection/Disease Control
- Multi-site Management
- JCAHO/CLIA/HIPAA
- Budget Administration
- R&D/Staff Supervision
- Publish/Present Data
- HR/Best Practices
- C-Level Client Relations
- High-Yield Profits
- TQM/Lean Six Sigma

---

## CAREER EXPERIENCE

---

CLINICAL LABORATORIES HOLDING COMPANY, INC; Las Vegas, NV 2008-Present  
Provides its fertility centers with finance, HR, risk management, legal and sales support services

### **CEO and Laboratory Director**

#### Key Accomplishments and Responsibilities

Established successful clinical management firm acquiring and growing fertility practices nationwide including clinical diagnostic and toxicology labs. CLIA Lab Director for: MD Labs,, Reno, NV #29D2032647, Nevada Advanced Pain Specialists, Reno, NV #29D2058647, Innovative Pain Care Specialists, Las Vegas, NV #29D2076312

#### Fertility Labs:

- Created a 7500-sq. ft. state-of-the-art reproductive fertility clinic in Fairfax, VA.
- Provide complete ambulatory surgery center operations conducting in excess of 200 invitro fertilization procedures and transfers annually.
- Established consistent, outstanding pregnancy rates ( $\geq 50\%$ ) for fresh and frozen embryo transfers for infertile couples.
- Increased year-over-year net profit 20% by initiating Internet, print, radio, TV campaigns.
- Liaison with teams ensuring support for corporate mission, vision, values, and objectives.
- Increased new patient volume and transaction price via new incentive programs.
- Initiated genetic testing – preimplantation genetic diagnosis and screening on older female patients and patients with multiple cycle failures.

6069 South Fort Apache Road Suite 100 ▪ Las Vegas, NV 89148  
▪ alexstojanoff@aol.com

Toxicology Labs:

- Established a 10,000-sq. ft. high complexity laboratory with emphasis on drug testing, metabolism and pharmacology in urine using EIA and LC-MS instrumentation.
- Setup high-tech main labs supporting testing menu encompassing over 40 analytes with more than 150,000 requisitions annually.
- Supervised, trained, mentored, and evaluated over 15 state licensed lab technologists.
- Validated for oral fluid (24-analytes panel) and initiated pharma genetics panel.

CONSOLIDATED LABORATORY SERVICES, INC; Las Vegas, NV 1997-2007  
Provides clinical laboratory testing on human specimens, tissue, blood, urine, stool, sputum.

**CEO and Laboratory Director**

Key Accomplishments and Responsibilities

- Built successful, high complexity 24/7 clinical reference laboratory with multiple Las Vegas sites along with facilities in 3 other Nevada cities.
- CLS certifications: hematology, chemistry, immunohematology, diagnostic immunology, bacteriology, parasitology, and histocompatibility.
- Hired, mentored, and supervised up to 150 staff/management personnel.
- Created a 17,000-sq. ft. lab to support menu of 100 plus testing options; conducted over 500,000 tests with more than 50,000 requisitions annually.
- Generated preeminent market positioning achieving \$4.5 million annually outproducing the largest lab worldwide.
- Drove YOY revenue 37% while improving lean management operational profit 21%.
- Initiated first national FDA-approved fertility screening testing program for all potential egg and sperm donors in the U.S.
- Initiated first Nevada successful mobile phlebotomy service and molecular lab testing facility.
- Developed molecular lab testing for infectious diseases.
- Performed initial fetal fibronectin lab test in Nevada.
- Designated preferred testing lab for Nevada Donor Network.
- Positioned to acquire largest lab in the world – Sonic Health Care of Australia in 2007.

UNIVERSITY of NEVADA-RENO; Las Vegas, NV 1993-1997  
School of Medicine is located next to 2 hospitals – one of which has the only Level I trauma center in Nevada

**Scientific/Laboratory Director – Asst. Professor OBGYN Dept.**

Key Accomplishments and Responsibilities

- Recruited specifically to established new IVF program for the university which encompassed all aspects of embryology and andrology.
- Instructed 50 one-three year medical students and 7 OBGYN residents.
- Applied expertise to Guadalajara, Mexico and obtained 55% pregnancy rate – highest ever for women under 35.

ALVARADO HOSPITAL and MEDICAL CENTER; San Diego, CA 1993  
A 306-bed acute care hospital offering advanced, specialized healthcare services

**Scientific/Laboratory Director**

Key Accomplishments and Responsibilities

- Setup hospital's first IVF program and IVF lab; and managed all functions including staffing, training, quality control measures, SOP's, and regulation compliance.
- Competed successfully with 5 other IVF programs in San Diego area; achieved exceptional pregnancy rates exceeding 40% overall.

---

6069 South Fort Apache Road Suite 100 • Las Vegas, NV 89148  
• alexstojanoff@aol.com

---

FORMAL EDUCATION (all degrees are US accredited)

---

UNIVERSITY of MELBOURNE Victoria, Australia  
**Doctor of Philosophy Degree in Obstetrics and Gynecology**  
**Bachelor of Science Degree in Pathology (w/Honors)**

MONASH UNIVERSITY Victoria, Australia  
**Master of Science Degree in Obstetrics and Gynecology**  
**Bachelor of Science Degree in Immunology and Biochemistry**

---

LICENSURE/CERTIFICATION

---

American Board of Bioanalysis – High Complexity Laboratory Director  
Nevada Laboratory State License  
CLIA Laboratory Certificate of Compliance  
Nevada Licensed Laboratory Director

---

PROFESSIONAL AFFILIATIONS

---

Society for Study of Reproduction  
American Society for Reproductive Medicine  
Fertility Society of Australia

---

PRESENTATIONS (select)

---

AAB College of Reproductive Biology's Andrology and Embryology Review Course and Quality Assurance/Quality Control Workshop, ART Laboratories, Grapevine, TX (2004)

Workshop Director, Challenges toward the Year 2000, Micromanipulation Workshop, Las Vegas, NV

Alvarado Hospital Medical Center, Dr. Steven Brody, San Diego, CA (1993)

IVF Clinic, Director, Carl Hamilton, MD, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia (1992)

Department of Veterinary Physiology, Professor M. Mattioli, University of Bologna, Italy (1989)

---

PUBLICATIONS (select)

---

The Phospholipid Composition of Isolated Guinea Pig Plasma Membrane and Outer Acrosome Membranes during Capacitation in Vitro. Stojanoff, A. Bourne, H. Andrews, A.G. Hyne, R.V. Garn, Res. 21297-311, 1988

Pregnancy from Vitro Fertilization of Human Eggs after Separation of Motile Spermatozoa by Density Gradient Centrifugation. Hyne, R.V., Stojanoff, A., Clarke, G.N., Lopata, A. Johnston, W.I.H., Fertility and Sterility, 45:93-96, 1986

The Immunoglobulin Class of Antispermatozoal Antibodies in Serum, Clarke, G.N., Stojanoff, A., Cauchi, M.N., Johnston, W.I.H, Am. J.Reprod. Immunol. And Microbiol. 7:143-147, 1985

Detection of Sperm-Bound Antibodies, Australian Society of Immunology, Clarke, G.N., Stojanoff, A., Cauchi, M.N., Canberra, 1981, pp.73



## **Christie L. Elliott, M.D.**

---

### **Work Experience**

July 2008 – Present  
Sierra Pathology Associates, Inc.  
Surgical Pathologist  
Staff Pathologist – Renown Regional Medical Center  
Medical Director of Lab, 2013 - Present

July 2007 – July 2008  
Assistant Professor of Pathology  
University of Nevada School of Medicine  
Surgical pathologist & pathology instructor

September 2006 – June 2007  
Christie L. Elliott, M.D., LLC  
Independent contractor with Sierra Pathology Associates, Reno, NV  
Surgical pathologist

July 2002 – August 2006  
Forensic Pathology Consultants, Reno, NV  
Forensic pathologist

### **Medical Directorships:**

Renown Regional Medical Center Laboratory – 2013 to Present  
Renown Rehabilitation Hospital – 2013 to Present

### **Training/Education**

July 2001- 2002  
Fulton County Medical Examiner, Atlanta, GA  
Forensic Pathology Fellowship

July 1996 –2001  
University of Colorado Pathology Residency, Denver, CO  
Anatomic and Clinical Pathology Residency

August 1992 – May 1996  
University of Nevada School of Medicine (UNRSOM)  
M.D. completed May 1996

August 1987 – May 1992  
University of Nevada, Reno  
B.S. in Pre-medical Studies, completed May 1991

### **Teaching Activities**

2005 - present  
Clinical Faculty – UNRSOM Dept. of Pathology (Clinical Associate Prof)

2002 – 2006

Guest lecturer

- UNSOM 2<sup>nd</sup> year class
- National Judicial College, Reno, NV

2002 – 2006

Provided hands-on instruction of 3<sup>rd</sup> & 4<sup>th</sup> year medical students rotating in pathology, paramedic & nursing students, and coroner trainees Washoe County Coroner's Office, Reno, NV

2003 – 2006

Noon conferences and Morbidity & Mortality conferences  
UNSOM Internal Medicine Residency

2003 – 2006

Mentor for Carson High School Senior Project students

1997 – 2001

Lab instructor Pathology 6000 (2<sup>nd</sup> year medical students)  
University of Colorado School of Medicine

***Received Excellence in Teaching Award: 1997 thru 2001***

## **Invited Lectures**

“Who says the autopsy isn't useful?”

UNSOM Internal Medicine Residency

“Forensic Pathology Primer”

Annual Scientific Evidence & Expert Testimony Course  
National Judicial College, Reno, NV

“Meningitis mimicking shaken baby syndrome”

American Academy of Forensic Sciences Annual Meeting  
Dallas, TX February 2004

Leukocyte-reduced Blood Products: Indications and Benefits. Colorado Society of Clinical Laboratory Sciences,  
May, 1999

Continuing Medical Education lecture series for the University of Colorado at Boulder Student Health Services laboratory staff,  
1996 – 1999

## **Licensures & Certifications**

Nevada State Medical License – 2002 (Active)

California State Medical License – 2008 (Active)

Georgia State Medical License – 2001 (Inactive)

Board Certifications:

-Forensic Pathology – 2002

-Anatomic & Clinical Pathology - 2001

**Professional  
Memberships**

American Society of Clinical Pathologists  
College of American Pathologist

**Service**

Secretary of Staff, Renown Regional Medical Ctr , January 2018-present

UNSOM Out of state admissions committee (3 years)

UNSOM Mentor Program

Teaching and mentor activities on volunteer basis

**Publications**

Elliott, C, Thompson H. Transfusion protocols for optimized blood usage during orthotopic liver transplantation. ASCP Check Sample, Transfusion Medicine No. TM 01-1 (TM-245).

Stephens J, Everson G, Elliott C, et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. *Transplantation*. 2000 July 15; 70 (1);232-6. Abstract presented at U.S. and Canadian Academy of Pathology annual meeting Feb/March 1998, Boston, MA.

**Business Address:**

Laboratory Medicine Consultants  
7455 W. Washington Ave., Ste 301  
Las Vegas, NV 89128  
Phone: 702-732-3441  
Email: [marmaduke@lmclabs.com](mailto:marmaduke@lmclabs.com)

# David P. Marmaduke, M.D.

---

**Current Position:** **Chair, Department of Pathology and Laboratory Director, Sunrise Hospital Medical Center and Sunrise Children's Hospital Director, Point of Care Testing, Sunrise Hospital Medical Center Pathologist, Laboratory Medicine Consultants, Las Vegas, NV**

## Education

1994-1996	<b>Hematopathology Fellow</b> , University of New Mexico Health Sciences Center and Center for Molecular and Cellular Diagnostics, Albuquerque, NM
1993-1994	<b>Hematopathology Fellow and Baba Fellow of Pathology</b> , The Ohio State University Hospitals, Columbus, OH
1988-1993	<b>Resident in Anatomic and Clinical Pathology and Chief Resident (1993)</b> , The Ohio State University Hospitals, Columbus, OH
1984-1988	<b>The Ohio State University College of Medicine, Columbus, OH</b>

## Board Certification

1996	<b>Subspecialty certification in Hematology</b> , American Board of Pathology (SQ-96-053)
1994	<b>Diplomate, American Board of Pathology</b> , Anatomic and Clinical Pathology (94-094)
1988	<b>Diplomate, National Board of Medical Examiners</b> (356965)

## Licensure

2014-present	Alabama (SP.91)
2008-present	Utah (6777760-1205)
2007-present	Arizona (37767)
2002-present	Nevada (10192)
2002-present	California (G86741)
1996-present	Maine (14402)
1994-present	Ohio (66478)
1994-present	New Mexico (94-320)

## Professional Society Memberships Since

2002	Nevada Society of Pathologists
2002	Nevada State Medical Association
2002	The Clark County Medical Society
1996	American Society of Clinical Pathologists
1995	American Society of Hematology
1995	Society for Hematopathology
1992	United States and Canadian Academy of Pathology
1988	College of American Pathologists

## Academic Appointments

1997-2002	<b>Adjunct Professor</b> , Department of Zoology, University of Maine, Orono, ME
1995-1996	<b>Clinical Instructor III</b> , University of New Mexico Health Sciences Center, Albuquerque, NM

## Committee Appointments Since

2015-present	<b>Cancer Committee</b> , Sunrise Hospital, Las Vegas, NV
--------------	---

**David P. Marmaduke, M.D.**

2

2014-present	<b>Medical Executive Committee</b> , Sunrise Hospital, Las Vegas, NV
2008-present	<b>Trauma Committee</b> , Sunrise Hospital, Las Vegas, NV
2006-2010	<b>Medical Laboratory Advisory Committee</b> , State Board of Health for Nevada, Reno, NV
2004-2010	<b>Chair, Infection Control Committee</b> , Sunrise Hospital, Las Vegas, NV
2004-2012	<b>Chair, Blood Usage Committee</b> , Sunrise Hospital, Las Vegas, NV
2000-2002	<b>Cancer Committee</b> , Eastern Maine Medical Center, Bangor, ME
2000-2002	<b>Trauma Committee</b> , Eastern Maine Medical Center, Bangor, ME

**Medical Directorships**

2004-present	<b>Medical Director, Point of Care, Sunrise Hospital, Las Vegas, NV</b>
2004-2012	<b>Medical Director, Blood Bank, Sunrise Hospital, Las Vegas, NV</b>

**Professional Experience**

2014-present	<b>Chair, Department of Pathology and Laboratory Director, Sunrise Hospital Medical Center and Sunrise Children's Hospital</b>
2007-present	<b>Laboratory Director, Comprehensive Cancer Centers of Nevada, 1505 Wigwam Pkwy, Suite 130 Henderson, NV 89074</b>
2004-present	<b>Laboratory Director, Parkway Surgery Center, Las Vegas, NV</b>
2004-2008	<b>Director, CORE Laboratory, Sunrise Hospital and Medical Center &amp; Sunrise Children's Hospital, Las Vegas, NV</b> High complexity laboratory serving 700 bed community hospital and Children's Hospital
2003-2008	<b>Laboratory Director, Surgery Centers of Southern Nevada, Las Vegas, NV</b>
2000-2002	<b>Laboratory Director, Chapman Laboratory, Millinocket Regional Hospital, Millinocket, ME</b> High complexity laboratory serving 50 bed rural hospital.
2000-2002	<b>Laboratory Director, Inland Hospital, Waterville, ME</b> High complexity laboratory serving 50 bed urban Osteopathic hospital.
1996-2002	<b>Pathologist, Dahl-Chase Pathology Associates, Bangor, ME</b>
1996-2002	<b>Medical Director, Flow Cytometry Lab, Dahl-Chase Diagnostic Services, Bangor, ME</b> State of the art lab performing complex flow cytometry studies including leukemia/lymphoma, immunodeficiency, minimal residual disease, peripheral stem cell quantitation and DNA ploidy analysis
1996-2002	<b>Medical Director, Hematology Lab, Affiliated Laboratories Inc., Bangor, ME</b> High volume, high complexity hematology laboratory employing 22 medical technologists serving Eastern Maine Medical Center as well as multiple outside laboratories.

**David P. Marmaduke, M.D.**

3

**Pathology Society Offices Held**

- |           |   |
|-----------|---|
| 1999-2001 | <b>President, Maine Society of Pathologists</b>                         |
| 1990-1992 | <b>Ohio Delegate, College of American Pathologists Resident's Forum</b> |

**Teaching Experience**

- |            |  |
|------------|--|
| 1997- 2002 | <b>Medical Director, Eastern Maine Medical Center Medical Technology Program, Bangor, ME</b>   |
| 1994-1995  | <b>Med II Pathology Laboratory Instructor (Hematology)</b> , The University of New Mexico Health Sciences Center, Albuquerque, NM                  |
| 1994-1995  | <b>Med I Pathology Laboratory Instructor (Phase I-1 and I-2)</b> , The University of New Mexico Health Sciences Center, Albuquerque, NM            |
| 1992-1993  | <b>Pathology 501 (Hematology)</b> , School of Allied Medical Professions, The Ohio State University Hospitals, Columbus, OH                        |
| 1991-1993  | <b>Introduction to Clinical Medicine Tutorials</b> , The Ohio State University College of Medicine, Columbus, OH                                   |
| 1991-1993  | <b>Med II Pathology Laboratory Instructor</b> , The Ohio State University College of Medicine, Columbus, OH  |
| 1988-1993  | <b>Lecture Series, Allied Medicine 505 (Principles of Disease)</b> , School of Allied Medical Professions, The Ohio State University, Columbus, OH |
| 1981-1982  | <b>Chemistry Teaching Assistant</b> , DePaul University, Chicago, IL   |

**Invited Plenary/Symposia Speaker**

- |      |  |
|------|--|
| 1999 | Laboratory Diagnosis of Iron-related Disorders. Northeast Regional Joint Fall Conference, Portland, ME (October)                           |
| 2000 | WHO Classification of Acute Myeloid Leukemia/Myelodysplasia. Northeast Regional Joint Fall Conference, Portland, ME (September)            |
| 1999 | Heparin-induced thrombocytopenia. Northeast Regional Joint Fall Conference. Portland, ME (September)                                       |
| 1997 | Bone Marrow Evaluation. Maine Society for Histotechnology, Saint Joseph's Hospital, Bangor, ME (April)                                     |
| 1997 | Hemolytic anemias. Dahl-Chase Pathology Hematology Network Seminar, Bangor, ME   |
| 1993 | Fc $\gamma$ RII interactions in heparin-induced thrombocytopenia. XIVth International Congress on Thrombosis and Haemostasis, New York, NY |
| 1991 | Cutaneous infections. South Central Association for Clinical Microbiology  |

## David P. Marmaduke, M.D.

4

(SCACM), South Bend, IN

### Lectureship

- |      |   |
|------|---|
| 2000 | Heparin-induced thrombocytopenia. Grand Rounds, Eastern Maine Medical Center, Bangor, ME (November)                                   |
| 1998 | Flow Cytometry in Clinical Diagnosis. Pediatric Conference, Eastern Maine Medical Center, Bangor, ME (May)                            |
| 1996 | Clonality Studies in Histiocytic Disorders. Tumor Marker Conference, University of New Mexico Health Sciences Center, Albuquerque, NM |
| 1996 | Peripheral T-cell Lymphomas. Tumor Marker Conference, University of New Mexico Health Sciences Center, Albuquerque, NM (February)     |

### **Research Experience**

- |         |  |
|---------|--|
| 1994-96 | Application of the Human Androgen Receptor (HUMARA) Clonality Assay to Sinus Histiocytosis with Massive Lymphadenopathy (Rosai - Dorfman Disease). The University of New Mexico Cancer Center, Albuquerque, NM. <b>Cheryl L. Willman, M.D.</b> |
| 1992-93 | Interactions of the Platelet Fc $\gamma$ RII Receptor with Heparin: Relationship to Heparin-Dependent Thrombosis. The Ohio State University Hospitals, Columbus, OH. <b>John T. Brandt, M.D.</b>   |
| 1992-93 | Digital Morphometry of Prostatic Adenocarcinoma: Correlation with Ultrasound Volumetric Measurement, Serum Prostate Specific Antigen, and Clinical Stage. The Ohio State University Hospitals, Columbus, OH. <b>William L. Marsh, M.D.</b>     |
| 1981-83 | Ontogeny of the Hypothalamo-Hypophyseal-Gonadal Axis in the Chick Embryo. DePaul University, Chicago, IL. <b>James Woods, Ph.D.</b>  |

### **Scholarships and Awards**

- |      |  |
|------|--|
| 1995 | College of American Pathologists Scholar's Award (\$25,000)              |
| 1995 | American Cancer Society Clinical Oncology Fellow (COF95-107-1, \$5,000)  |
| 1994 | American Cancer Society Clinical Oncology Fellow (COF94-120-1, \$10,000) |
| 1988 | Emmerich von Haam Pathology Award  |
| 1988 | Department of Medicine Award   |

### **Publications**

#### Original Articles

Peller PA, Young DC, **Marmaduke DP**, Marsh WL, Badalament RA. Sextant prostate biopsies: A histopathologic correlation with radical prostatectomy specimens. *Cancer* 75:530-538, 1995.

**Marmaduke DP**, Greenson JK, Cunningham I, Herderick EE, Cornhill JF. Gastric antral vascular ectasia in patients undergoing bone marrow transplantation. *Am J Clin Pathol* 102: 194-198, 1994.

**Marmaduke DP**, Brandt JT, Theil KS. Rapid diagnosis of cytomegalovirus in the cerebrospinal fluid of a patient with AIDS-associated polyradiculopathy. *Arch Pathol Lab Med* 115:1154-1157, 1991.

## David P. Marmaduke, M.D.

5

### Textbook/Chapters

**Marmaduke DP** and Doing KM. Infections of the central nervous system. In Textbook of Diagnostic Microbiology (2nd ed), Manuvelis and Mahon, editors, W.B. Saunders, pp. 974-995, 2000.

**Marmaduke DP** and Ayers LW. Infections of the central nervous system. In Textbook of Diagnostic Microbiology, Manuvelis and Mahon, editors, W.B. Saunders, pp. 915-934, 1995

### Abstracts

**DP Marmaduke**, J Rosai, R Warnke, K Foucar, MR Emmert-Buck, LA Liotta and CL Willman. Molecular assessment of clonality in sinus histiocytosis with massive lymphadenopathy (SHML): A reactive disorder of polyclonal histiocytes. *Mod Pathol* 9(1):117A, 1996.

NE Joste, RM Feddersen, K Butler, **DP Marmaduke**, E Foucar and CL Willman. Molecular assessment of clonality at the HUMARA locus by microdissection of archival invasive ductal carcinoma. *Mod Pathol* 9(1):172A, 1996

**Marmaduke DP**, Anderson CL, Brandt JT. Heparin potentiates FcR - mediated platelet aggregation. *Thromb Haemostas* 69(6):2320, 1993.

Qualman SJ, Pawel B, Li B, **Marmaduke D**, Sferra T. Putative etiologic factors in Menetrier's disease; evidence of cytomegalovirus infection in pediatric versus adult cases. *Pediatr Pathol* 13:107, 1993.

**Marmaduke D**, Greenson J, Cunningham I, Herderick E, Cornhill F. Superficial antral vascular ectasia in bone marrow transplant patients. *Mod Pathol* 5(1):45A, 1992.

Cunningham I, **Marmaduke D**, Copelan E, Tutschka P. Hyperbilirubinemia as a predictor of post-BMT mortality. *Blood* 78(10), Suppl 1:240a, 1991.

**Marmaduke DP**, Neff JC, Kirkpatrick R. Antibody to hepatitis C virus is not predictive of a characteristic subset of patients with chronic hepatitis. *Am J Clin Pathol* 95:276, 1991.



**Gayle L. Petersen**  
2600 Mill Street Suite 100 Reno Nevada 89502  
(775) 334 3420  
petersg@labcorp.com

Dynamic, results-driven, interpersonal and organizational skills predict continued leadership success in the medical and technical field.

**Objective:** To remain a member of the Nevada State Advisory Committee.

**Professional experience:**

- 1977 – Present      Laboratory Corporation of America (“LabCorp.”)  
(formerly known locally as Sierra Nevada Laboratories)  
Over 40 years of health care experience and committed work at LabCorp, including, but not limited to, the below diverse positions and responsibilities:
- 2000 – Current      Laboratory Branch Manager  
Overseeing multiple departments in Northern Nevada LabCorp facility as well as educating and inservicing doctors/clients on medical necessity requirements specific to the Medicare carrier. Laboratory Management, which includes all aspects of supporting good laboratory services to the community, includes working in Quality Assurance and Patient Service (Phlebotomy).
- 1995- 2000          Assistant Regional Manager of Business Development  
Successful targeting new business, maintaining client base and promoting new testing services. Accounts developed and maintained include Managed Care, IPAs, Hospitals, clinics and doctors.
- 1985 – 1995          Regional Service Manager  
Prior success in laboratory sales includes “good” business, which is defined as “obtaining reimbursement in a timely manner”. Successful management of Key Account Executives in Northern and Southern Nevada.
- 1980 – 1985          Marketing Representative  
Success includes establishing relationships, delivering service, selling laboratory services and competent working knowledge of lab regulations related to providing laboratory services.
- 1977 – 1980          Medical Technologist, MT ASCP  
Completed training, BS degree and boards in 1976. Areas of competency include Blood Bank, Chemistry, Hematology, Microbiology and L/S ratios. Successful Medical Technologist career at both Saint Mary’s Hospital Laboratory and Sierra Nevada Laboratories.

**Awards and Recognition:**

- 2012                      Recipient of the LabCorp Chairman’s Award  
The LabCorp Chairman’s Award is the highest award LabCorp honors an employee. LabCorp is a nation-wide corporation and it bestows the LabCorp Chairman’s Award in annual recognition of an outstanding employee from across the country.
- Prior active member of Kiwanis and Key Club mentor.
- Prior active educator and mentor for Child Assault Prevention (CAP)

**Education:**

- 1974 & 1976              University of Nevada Reno, Nevada  
Bachelor of Science in Premedical, Bachelor of Science in Medical Technology.

**Professional memberships:**

- 2012 – Current          Member of American Society of Clinical Pathologists (ASCP)

# Jill Brown, MLS(ASCP)<sup>cm</sup>

## Northeastern Nevada Regional Hospital

2001 Errecart Blvd.  
Elko, Nevada 89801  
775-748-2110  
775-748-2111

---

**Objective**

To serve on the Medical Laboratory Advisory Committee

---

**Background Summary**

Laboratory supervisor with extensive experience in directing, supervising and coordinating technical functions and activities in all clinical areas of a small rural hospital laboratory. Related areas of expertise are:

- Medical staff consults
  - Investigation of new equipment or methodologies
  - Management of point of care and proficiency testing
  - Establishing and implementing policy and procedure
  - Maintaining compliance with current accreditation and regulation requirements
- 

**Experience**

<b>Northeastern Nevada Regional Hospital</b> General Supervisor	<b>Since 1985</b>
<b>College of Southern Nevada</b> Part-time Phlebotomy Instructor	<b>Since 1999</b>
<b>MLAC member</b>	<b>2000-2006</b> <b>2008-2014</b>

---

**Reference**

George Mardini, MD  
Medical Director  
Northeastern Nevada Regional Hospital  
2001 Errecart Blvd.  
Elko, Nevada 89801

## **Victor M. Muro, M.D.**

OptumCare Primary Care  
56 N. Pecos Rd. Ste B  
Henderson, NV 89052

### **Education**

- Undergraduate  
University of California – San Diego  
Graduated B.A., Biochemistry and Cellular Biology
- Graduate  
San Diego State University  
School of Public Health  
Coursework for MPH., Epidemiology and Biostatistics
- Medical School  
UCLA School of Medicine  
Attend from September 1987 to May 1991  
Medical Doctorate in May 1991
- Internship  
Los Angeles county – USC Medical Center  
California – 1991-1992
- Residency  
Los Angeles County – USC Medical Center  
California – 1992-1994
- Fellowship- General Internal Medicine  
California 1994-1995

### **Appointments/Positions**

- **9/2015** Nevada Board of Medical Examiners
- **9/2016** Nevada Board of Medical Examiners Investigative Committee

### **Employment History**

- **1/2015 – Present** OptumCare Primary Care, Medical Director
- **3/2016 – Present** Neighborhood Program, Medical Director
- **1999 - 2015** Jacobs & Modaber/CareMore Medical Group
- **1996 - 1999** Physician Century Medical Group
- **1994 - 1996** Director of Ambulatory Services, Department of Medicine  
Los Angeles County, USC Medical Center
- **1994 - 1996** Assistant Professor, Department of Medicine  
Los Angeles County, USC Medical Center

*Iain L. O. Buxton*  
*Regents Professor 2011; Foundation Professor 2013*  
Curriculum Vitae

---

**ADDRESS**  
Department of Pharmacology  
Howard Building 166, Mail Stop 318  
University of Nevada School of Medicine  
1664 N. Virginia Street  
Reno, Nevada 89557  
Office Phone: (775) 784-4800  
FAX: (775) 784-4800; Email: [ibuxton@med.unr.edu](mailto:ibuxton@med.unr.edu)

**EDUCATION**  
**Bachelor of Arts, (BA)** University of California, San Diego  
**1972, Major: Cell and Molecular Biology**  
**PhD Graduate Studies, Biochemistry Graduate Program**  
**1975 Major: Enzymology, (PhD pgm.)** North Carolina State, Raleigh, NC  
**Doctor of Pharmacy, (PHMD),** University of the Pacific,  
**1978, Major: Pharmaceutical Sciences**  
**Licenses:** RPh, CA License CS12899 (inactive); US DEA RB0387402 (active)

**EXPERIENCE**  
7/2015-Present **President and CEO, ExCyte Therapeutics**, a Nevada Corporation developing basic research discoveries into new treatments to help patients.  
5/2010-Present **President**, Western Pharmacology Society, Registered non-profit 501(c)3.  
4/2013-Present **Foundation Professor**  
7/2014-1/31/18 **President**, Campus Pharmacy Corporation, University of Nevada School of Medicine  
2/2011-12/2017 **Chair, Department of Pharmacology**  
11/2003-6/2008 Dean (Planning and Implementation) University of Nevada School of Pharmacy  
5/2010-7/2012 Director, UNR Center for Advanced Studies  
7/1995 **Professor**, Department of Pharmacology, University of Nevada School of Medicine, Reno, NV  
12/2001 Professor, Department of Obstetrics & Gynecology, University of Nevada, Southern Campus, Las Vegas, NV  
1/2005-7/2006 President, Pharmaceutical Education and Research Foundation of Nevada (A Nevada Non-Profit Corporation; 501 c3)  
6/2003-2009 Adjunct Professor, Nevada Cancer Institute, 10000 W. Charleston Blvd. Suite 260, Las Vegas, NV  
7/1995-6/2014 Director, School of Medicine Performance Compensation Plan University of Nevada School of Medicine, Reno, NV

**EXPERIENCE** (*continued*)

- 9/2001-7/2003 Director, Biochemistry Graduate Program, University of Nevada, Reno, NV; Interdisciplinary Program; Colleges of Agriculture, Arts & Science and Medicine
- 7/1997-6/2002 Faculty Director, University of Nevada Flow Cytometry Laboratory  
University of Nevada School of Medicine, Reno, NV
- 1/1998-7/2001 Co-Chair, President's School of Pharmacy Task Force
- 7/1996-1/1998 Associate Dean for Research & Director, Office of Medical Research  
University of Nevada School of Medicine, Reno, NV
- 4/1993-6/30/96 Assistant Dean for Research & Director, Office of Medical Research  
University of Nevada School of Medicine, Reno, NV
- 4/1989-4/30/95 Director, Tissue, Cell and Tissue Culture Research Core, UNR  
Program Project in Colonic Motility
- 7/1989-6/30/95 Associate Professor (with tenure), Department of Pharmacology,  
University of Nevada School of Medicine, Reno, Nevada
- 4/1985-6/1989 Assistant Professor, Department of Pharmacology University of  
Nevada School of Medicine, Reno, Nevada
- 5/1984-4/1985 Assistant Research Pharmacologist, Department of Medicine,  
Division of Pharmacology, University of California, San Diego
- 5/1981-5/1984 Postdoctoral Fellow with Dr. L.L. Brunton, Department of Medicine,  
Divisions of Pharmacology & Cardiology, U.C. San Diego
- 7/1980-2/1981 Clinical Pharmacist, Veterans Administration Medical Center,  
San Diego, California *Supervisor*: Drug Information Section  
*Head*: Investigational Drug Studies Section
- 7/1979-6/1980 Clinical Fellow, Veterans Affairs Medical Center, San Diego, CA
- 7/1978-6/1979 Clinical Resident, Veterans Affairs Medical Center, San Diego, CA
- 9/1974-7/1975 Research Associate with Dr. H.L. Leffert, Cell Biology Laboratory,  
Salk Institute for Biological Studies, La Jolla, California
- 7/1973-8/1974 Research Associate (PhD Program) with Dr. R.A. Main,  
Biochemistry Dept. North Carolina State University, Raleigh, NC
- 7/1972-6/1973 Research Assistant with Dr. R. Holley, (*Nobel '68*), Cancer Biology  
Laboratory, Salk Institute for Biological Studies, La Jolla, CA

**TEACHING EXPERIENCE**

- 4/1985-Present Faculty in Pharmacology, University of Nevada, School of Medicine
- 5/1981-5/1985 Laboratory instruction of UCSD Physiology/Pharmacology Program  
Medical and Graduate Students
- 9/1978-5/1981 Adjunct Clinical Instructor, University of the Pacific School of  
Pharmacy, Clinical Clerkship Program, San Diego Region
- 9/1978-5/1981 Adjunct Clinical Faculty, University of Southern California Clinical  
Internship Program, San Diego Region

**TEACHING EXPERIENCE** (*continued*)

- 9/1979-4/1980 Instructor of Pharmacology, National University, San Diego, CA.  
 8/1975-6/1977 Teaching Assistant, University of the Pacific, Stockton, California.  
 Biochemistry Lab (Dr. F. Sayre). Cell & Tissue Culture (Dr. D. Pace)

**Current BOARDS**

**President Elect and Member of the Board**, American Heart Association, Nevada Chapter,  
 Western States Affiliate

**Past BOARDS**

**Member of the Board**, *Integrated Clinical Services*, University of Nevada School of Medicine  
 Clinical Practice Plan  
 Voting Member, Southern Regional Executive Committee (2010-2017)  
 Voting Member, Northern Regional Executive Committee (2010-2017)  
 Treasurer, Northern Regional Executive Committee (2017)

**EDITORIAL EXPERIENCE**

**Editor-in-Chief**, *Proceedings of the Western Pharmacology Society* [ISSN: 0083-8969]. Elected  
 2/1/2003; to 6/30/2012. Responsible for reviews, editing and publication of the annual Proceedings  
 of the Society.

**Editorial Board Member**; *Annals of Pharmacotherapy* [ISSN: 1060-0280]. 7/1/2003-7/1/2008.  
 Handling manuscript reviews in the area of clinical pharmacology.

**Editorial Board Member**; *Journal of Signal Transduction* [ISSN: 2090-1739; eISSN: 2090-1747].  
 9/27/2009-7/2017. Handling manuscripts in all areas of signaling in mammalian cells and tissues.

**Associate Editor (2004-2008)**, *Access Medicine*; Goodman & Gilman for on-line pharmacology web-  
 based text of the 11<sup>th</sup> Edition of *Goodman & Gilman's Pharmacological Basis of Therapeutics*, McGraw-  
 Hill Publishers.

**Author/Editor**, "*Goodman & Gilman's Manual of Pharmacology and Therapeutics*" Student text book *in  
 press*, McGraw-Hill, Buxton, IL, Blumenthal, D and Brunton LL, Parker, K. Editors, pp. 1-1219.

**Author**, Goodman & Gilman Textbook, "*The Pharmacological Basis of Therapeutics*". McGraw-Hill  
 [ISBN: 0-07-1345469-7] for the 11<sup>th</sup> Edition. Chapter 1 : Pharmacodynamics and Pharmacokinetics:  
 The Dynamics of Drug Absorption, Distribution, Action and Elimination *and* Appendix I: Principles of  
 Prescription Order Writing and Patient Compliance.

For the 12<sup>th</sup> Edition: Buxton, I.L.O. and Leslie Z. Benet. *Chapter 2*, Pharmacokinetics. In:  
*Goodman and Gilman's The Pharmacologic Basis of Therapeutics*. 12<sup>th</sup> Edition, 2009, Ed:  
 L.L.Brunton. McGraw-Hill, New York.

For the 12<sup>th</sup> Edition: Buxton, I.L.O. *Appendix 1*, Principles of Prescription Order Writing and  
 Patient Compliance. In: *Goodman and Gilman's The Pharmacologic Basis of Therapeutics*. 12<sup>th</sup>  
 Edition, 2009, Ed: L.L.Brunton. McGraw-Hill, New York.

For the 13<sup>th</sup> Edition: Buxton, I.L.O. *Chapter 2*, Pharmacokinetics. and *Appendix 1*, Principles of  
 Prescription Order Writing and Patient Compliance. In: *Goodman and Gilman's The  
 Pharmacologic Basis of Therapeutics*. 13<sup>th</sup> Edition, 2017 *in press*, Ed: L.L.Brunton. McGraw-Hill,  
 New York.

**MAJOR ACADEMIC PROJECTS**

Planning Dean, University of Nevada, School of Pharmacy. Lead role in planning for curriculum, staffing, budget, recruitment and governance. Proposal to include UNR and UNLV as equal partners in a statewide program granting the PharmD degree. Presented to and approved by the Regents of the NSHE August 2000, and again in 2004. The school remains unfunded due to the down-turn in the Nevada economy and will require future legislative action.

President, University of Nevada Campus Pharmacy Services. Supervision of pharmacy business and clinical operations for the School of Medicine.

**FORMAL TEACHING ACTIVITIES**

**Medical Pharmacology (Block Curriculum) Content Coordinator:** Core basic science course in the MD curriculum taken in the spring semester of the sophomore year. Seventy-two students per year are taught in both the lecture and problem-solving small group format in the blocks in both years one and two that total one-hundred-fifty hours of instruction. Dr. Buxton is the content coordinator and teaches in several sections of the course; Basic Principles, Pharmacokinetics, Autacoids and Eicosanoid Pharmacology and NSAID Pharmacology, Toxicology, Drug side effects. Dr. Buxton also provides therapeutic correlation of basic science in pharmacology for Diabetes, Rheumatoid Arthritis, Gout, Hypertension and Drugs in the Elderly. Dr. Buxton's student evaluations are in the excellent range from 4.3 to 4.5 on a 1-5 scale. Dr. Buxton has been given an evaluative rating of Excellent in teaching continuously since first presenting lectures to medical students in Nevada in 1985.

**Molecular Pharmacology (PHAR 710) Course Coordinator from inception till 2013:** Fall semester, three units. Course details the development of our current understanding of receptor signal transduction in mammalian systems. Designed for graduate students earning the PhD and interested in careers in biomedical research and development in academia or industry. The course focuses on the molecular biochemistry of receptor structure; mass action considerations governing ligand-receptor binding interactions; molecular pharmacology of transduction of the receptor signal and specific considerations of receptors as pharmaceutical targets.

**Reproductive Pharmacology (PHAR 770):** Spring semester, three units/semester; graduate student lectures and discussion in placental organization and function, parturition and problems of Pregnancy.

**Medical Student Clerkship (MED 651): Basic Science Correlations.** Mentoring for medical students in the third year during their OB/Gyn clerkship. One student in 2019.

**Molecular Cell Biology (CMB 710):** Spring semester, four units. Advanced studies of the structure and function of cells provided for PhD students in Cell & Molecular Biology, Cell & Molecular Pharmacology and Physiology, and Biochemistry Graduate Programs. Dr. Buxton contributes lectures in Receptor Signal Transduction during eight hours of lecture.

**Cancer Biology (Micro 787):** Fall semester, three units. Contributing lectures in the area of metastasis and angiogenesis in the invasion and progression of breast and other human cancers.

**Experimental Biochemistry II (BCH 702):** Fall, Spring and Summer semesters, three units/semester. Graduate student laboratory rotation in preparation of dissertation research for the PhD degree. Dr. Buxton is both mentor and instructor of record providing students with research experience and advising students on the selection of rotation experiences.

**Senior Thesis (BCH 407-408):** Fall/Spring (3+3 units). Laboratory research project required of undergraduate biochemistry majors (capstone course). Students participate in current research projects and prepare abstracts and research papers of their work as appropriate.

**FORMAL TEACHING ACTIVITIES** (*continued*)

**Cellular and Molecular Pharmacology (PHAR 799):** Fall, Spring and Summer semesters, eight units/semester; one student in 2019. Teaching of PhD candidates in the laboratory.

**Dissertation (BCH 799; CMB 799):** Fall, Spring and Summer semesters, eight units/semester. Teaching of PhD students in the laboratory.

**PAST COURSES**

**Introduction to Human Pharmacology (PHAR 400/600):** Spring semester, three units.

Undergraduate elective for BS students in the sciences taught by Dr. Buxton (47 hours; selected years). The Introduction to Human Pharmacology course addresses the basic scientific principles that govern the disposition of drugs in the body, the fundamental principles that determine the action of drugs on specific cellular and non-cellular targets and details the mechanism of action(s) and therapeutic usefulness of specific agents associated with particular organ systems or diseases. Though based on the lecture format, self-directed learning and group discussions are employed to permit the most effective and enjoyable format for learning. The class benefits students interested in the health professions such as pharmacy, medicine or nursing as well as graduate study in the areas of pharmacology and physiology.

**OB/Gyn Residency: Basic Science Correlations:** Year-round required course. Dr. Buxton serves as consultant to residents on the basic science aspects of required reading and preparation of resident presentations.

**RESEARCH ACTIVITIES****Regulation of Contraction Associated Targets in Myometrium by S-Nitrosation**

Discovery of the molecular mechanisms subserving human uterine quiescence during pregnancy and their dysregulation in spontaneous preterm labor is the objective of my research. We are testing the hypothesis that failure of preterm human myometrium to relax to nitric oxide (NO) is the result of dysregulated S-nitrosation of specific smooth muscle contractile proteins.

Our long-term goal is to find new effective tocolytics to treat women who enter labor too soon. Preterm labor leads to preterm delivery, a global problem accounting for 75% of fetal morbidity and mortality. No drugs reliably prevent labor in patients who enter labor preterm, thereby allowing their pregnancies to go to term. Therapeutic approaches to manage spontaneous preterm labor (SPTL) are employed without clear evidence of benefit for acute or maintenance tocolysis.

NO-mediated relaxation of myometrium is cGMP-independent. Preterm myometrium fails to relax to NO. Discovering the mechanism of action of S-nitrosated contractile proteins can suggest new therapeutic targets to manage SPTL. We propose that gestational quiescence until term results from regulated post-translational S-nitrosation of myosin light chain kinase (MLCK), the regulatory light chain (MYL9) and profilin-1 (PFN1). Addition of NO relaxes term, but not preterm laboring tissues as a result of S-nitrosation differences that alter the function of these CAPs in SPTL.

We have also proposed that in women, uterine quiescence during gestation until term is the result of regulated S-nitrosation of connexin 43 (Cx43) following endogenous, regional production of S-nitrosoglutathione (GSNO). GSNO relaxes term, but not preterm laboring tissues as a direct result of decreased Cx43 S-nitrosation due to increased GSNO reductase activity that results in altered connexin hemichannel activity.

Discovering the effect of regulated S-nitrosations on the mechanism of contractile protein action in term tissues, term tissues from patients in labor and in SPTL (with controls for gestational timing, tocolytic and antenatal steroid use, infection, and gestational length) will establish whether or not NO is an endogenous relaxation signal. Comparison of this S-NO fingerprint with that measured following



relaxation of the tissue by NO addition in each pregnancy state is novel because SPTL is not simply early labor, will likely be influenced by infection and/or gestational length and because NO-induced relaxation of spontaneous and oxytocin-induced contractions of preterm myometrium is blunted. S-nitrosation differences between labor and SPTL point to altered quiescence mechanisms. Completion of this research will suggest therapeutic strategies for the treatment of SPTL such as the S-nitrosogluthathione reductase that regulates S-nitroso protein levels and is known to provide therapeutic benefit in asthma and for which an inhibitor is in development.

**Stretch-Activated 2-pore Potassium Channels in Preterm Labor.** In 2005 our lab was the first to discover expression of two stretch-activated potassium channels, TRAAK and TREK-1 in human myometrium and demonstrated that the TREK-1 channel is gestationally regulated. We were funded for this work by the *March of Dimes* and the *Bill and Melinda Gates Foundation* (the first gates Research Grant ever awarded at UNR). The objective of this research is to contribute to an understanding of the probable cause(s) of preterm labor in some women that may possess dysfunctional TREK-1 channels. Preterm birth remains a significant health issue in industrialized nations accounting for 12.5% of all live births in the United States and 80% of all perinatal complications and death. The incidence of preterm birth is unacceptably high. Tocolytic agents do not work. Prematurity costs over 30 billion annually and causes unacceptable morbidity and mortality. We must better understand the physiological mechanisms of pregnancy in women if we are to discover new approaches to the treatment of preterm labor.

The stretch-activated channels make up a unique subset of K<sup>+</sup> channels that are mechano-sensitive and belong to a family of channels characterized by four transmembrane segments and two pore (2P) domain regions. TREK-1 (TWIK-related K<sup>+</sup> channel), and TRAAK (TWIK-related arachidonic acid-stimulated K<sup>+</sup> channel) channels are activated by free fatty acids, nitric oxide and increased membrane tension, each of which occur with pregnancy. These channels play an essential role in setting the resting membrane potential of the muscle cell. Thus, the possibility that TREK-1 is involved in the maintenance of relaxation of the human uterine smooth muscle prior to the onset of labor is of interest and we have discovered genetic variants of the channel in women that deliver preterm. These gene variants encode channels that are non-functional and dimerized with full-length TREK-1 leading to blockade of the TREK-1 current.

We hypothesize that SAK channels are gestationally regulated and maintain uterine quiescence prior to the onset of labor. Thus, activation of these channels by stretch, nitric oxide and/or arachidonic acid or its metabolites during pregnancy maintains hyperpolarization of the uterine smooth muscle helping to sustain relaxation and thereby prevent organized contractions. In women who commence labor too soon with the absence of premature rupture of membranes or intrauterine infection, there is a failure of TREK-1 based on the expression of variant channels that are non-functional, dysregulated or uncoupled and thus, pro-contractile forces cannot be overcome.

**Origins of Uterine Dysfunction.** While studying the functional effect of cholesterol withdrawal from uterine smooth muscle we discovered that the uterine muscle is activated by this treatment while other smooth muscle is depressed. Cholesterol overloading resulted in depression of myometrium. This result suggested the possibility that dysfunctional labors that occur in obese women may be the result of hypercholesterolemia. Labor progression is delayed in obese women and associated with complications and use of oxytocin (OT). We treated guinea pig myometrium to remove cholesterol expecting suppression of spontaneous activity and uncoupling of agonist specific relaxation as has been demonstrated in other muscles. Treatment of myometrium with 15 mM  $\beta$ -MeCD however led to enhancement of spontaneous activity that was further increased following a second  $\beta$ -MeCD treatment. This result was unexpected. Our findings suggest that cholesterol selectively uncouples relaxation signaling. We propose that suppression of myometrial activity by hypercholesterolemia may be the mechanism underlying uterine dysfunction in obese women.

**Regulation of Breast Cancer-mediated Angiogenesis.** This project has been funded by the *Clayton Foundation for Research* and the *Congressionally Directed Medical Research, Breast Cancer Program, and the Women's Health Research Grant Program*. The goal of our research is to delineate the role of extracellular Nucleotide Diphosphate Kinase (NDPK/NM23) and its regulation of nucleotide levels in human breast cancer angiogenesis. Human breast cancer cells secrete exosomes, minute membrane encapsulated vesicles that contain a factor that supports the growth, differentiation, and permeability of endothelial cells *in vitro* consistent with a pro-angiogenic potential that subserves breast cancer metastasis. Using LC-MS/MS proteomic methods, we discovered that human breast cancer cell exosomes contain NM23. We have identified a pharmacophore for the development of inhibitors of this enzyme factor (NDPK) and find these compounds to be anti-angiogenic. Learning how exosomal NDPK and its regulation of extracellular nucleotides, blocked by catechin gallates, can induce breast cancer angiogenesis will reveal new therapeutic targets in the treatment of breast cancer and its lethal metastatic spread. Extracellular purine nucleotides have recently emerged as a novel class of proliferative agents with a putative role in cancer and angiogenesis. Our data demonstrate that P2Y receptor activation promotes a significant pro-angiogenic response by transactivating the VEGF receptor. Coupled with our discovery of the generation and action of nucleotides in the blood stream, *The Nucleotide Axis Hypothesis*, progress on the aims described here may help explain aspects of cancer metastasis heretofore unrecognized. Progress on this work has appeared in the *British Journal of Cancer, Cancer Letters, Cancers*, and a patent has been issued.

In collaboration with C Iosef, we discovered that the methyl transferase EZH2, the transcription factor NF $\kappa$ B and the long non-coding RNA, NKILA are linked functionally and this led us to hypothesize that their interaction could impact patient responses to EZH2 inhibitors suggesting the development of novel therapeutics for NF $\kappa$ B-mediated metastasis. Our preliminary results suggest the incorporation of glycemic regulation to combat the harmful effects on noncancerous breast epithelial cells following delivery of these adjuvants. The findings from the study will be significant because they will lead to improved treatment for breast cancer patients that reduces adverse side effects while maximizing the efficiency of EZH2 inhibitors in patients with high BMI (>30) and type-2 diabetes (T2D).

### EXPERT WITNESS ACTIVITIES

Dr. Buxton is an experienced expert in the field of medical pharmacology and has served as an expert in cases ranging from wrongful death to testamentary capacity, capital murder, and medical malpractice. Dr. Buxton has expertise in both the scientific and regulatory aspects of pharmaceutical and medical practice including pharmaceutical compounding, active ingredient solubility and storage; evidence-based medical practice, actions of drugs in the human body, their therapeutic, unwanted, adverse and toxic effects and outcomes, the pharmacogenomic basis of adverse drug reactions and standard of care in medicine and pharmacy.

#### Recent Cases:

In 2017, Dr. Buxton was retained to offer testimony to the California State Board of Appeals in a criminal matter involving wrongful death and violence caused by prescription medication.

In 2013 and 2014, Dr. Buxton provided expert witness services in litigation in Nevada involving pharmacy training, staffing, compensation, and disciplinary practices that contribute to pharmacy errors that harm patients.

In 2012 and 2013, Dr. Buxton provided expert witness services for the defense looking to avoid the death penalty in a double homicide case involving the use by the defendant of synthetic cannabinoids.

In 2012, Dr. Buxton provided expert witness services to defendant's attorney in a medication adverse reaction case involving sedative hypnotics.

In 2011-2012, Dr. Buxton provided expert witness services to defendant's attorney involving the dispensing of an adulterated drug product.

In 2009-2010, Dr. Buxton provided expert witness in a wrongful death case. The case was filed in Second District Court, State of Nevada. Buxton was retained by plaintiffs' attorney to consult on the proximate cause of death and the standard of medical and pharmacy practice.

In 2008, Dr. Buxton provided expert opinion on behalf of the defendant in a matter filed in the District Court, Clark County, Nevada involving a pharmacy services provider.

In 2007, Dr. Buxton provided expert opinion in a wrongful death matter filed in the Circuit Court of the 11th District in and for Miami-Dade County, Florida. Dr. Buxton was retained on behalf of the defendant a health care provider and its physicians.

In 2006, Dr. Buxton was retained to examine prescription records and evaluate the potential that a driver with multiple claims for damages from automobile accidents was chronically impaired.

In 2005, Dr. Buxton rendered an opinion on behalf of the plaintiff in a medical malpractice case involving prescription medications.

#### **UNIVERSITY FUNDRAISER**

**Planning and Development Grant for the University of Nevada Cell Cytometry Center**

Barbara Geanoli Foundation, \$380,000, 1997-1998.

**Capital Campaign, Pennington Medical Education Building**

Redfield Foundation, \$500,000, 2001-2002.

**University of Nevada School of Pharmacy**

Campaign: \$275,000 (pledges and gifts) 1998-2004

**University of Nevada, Reno. Proteomics Center (*assisted*)**

Equipment: \$1,250,000, 2014

**Research Gift, Department of Pharmacology 2016**

Equipment: \$200,000

**CURRENT FUNDING** (Principal Investigator/Co-investigator)***Awarded Grants***

- Regulation of CAP Protein S-Nitrosation in Preterm Labor. NIH R01 HD091114-01A1. PI Buxton 10/2018-09/2022; \$1,968,000 total costs.
- EZH2 inhibition and regulators of NFkB and NKILA represent a novel breast cancer therapy. NIH-NCI Huntsman GMap grant 2018-2019 (\$20,000). PI S. Duan, Mentor Buxton.

***Pending Grants***

- Discovery of Molecular Targets Underlying Human Preterm Labor: Mechanisms of Dysfunctional Relaxation. NIH R01 HD101405-01. PI Buxton 4/2020-9/2024; \$1,938,000 Total.
- EZH2 inhibition alters NFkB immune-homeostasis and the anti-tumoral capacity of NKILA. NIH R21 PI Iosef, Co-I Buxton. 4/2019-9/2021; \$275,000 direct costs.

***Recently Completed Grants***

- Exosomal NM23 in Breast Cancer Metastasis UNSOM Women's health Grant 7/01/2015-6/30/2017; \$240,000 direct
- Super-Resolution Microscopy: Leica DMI8 with SR GSD 3D System UNSOM Women's Health Research Program 7/01/2015-6/30/2016; \$420,000
- Cell Biology of Signaling Across Membranes NIH 8P20GM103554-02 (Von Bartheld PI/Buxton Mentor), 4/2012e- 3/2017; \$5,000,000

**HONORS AND AWARDS**

- Health Care Heroes Innovator Award 2016 Nevada Business Magazine
- University of Nevada Foundation Professor 2013
- Regents Researcher Award, 2011. Statewide Award, NSHE
- Vada Trimble Outstanding Graduate Mentor Award, 2011
- E.W. Richardson Excellence in Teaching Award, School of Medicine, *Nom.* 2010
- UNR Outstanding Researcher of the Year Award 2008
- E.W. Richardson Excellence in Teaching Award, *Nom.* 2002, 2008.
- Regents Graduate Advisement Award: UNR, *Nom* 2002
- Fellow, AHA Council on Basic Cardiovascular Sciences, 2001
- UNR Researcher of the Year, *Nom.* 1997.
- "Heart of Gold Award" AHA, Las Vegas 1995
- NIH New Investigator, 1984-1987
- NIH Postdoctoral Trainee 1981-1984
- Rho Chi Research Award, UOP, 1977
- Dami Foundation Award, UOP, 1976

**PROFESSIONAL ASSOCIATIONS**

- American College of Clinical Pharmacy
- Am. Assoc. of Colleges of Pharmacy
- American Society for Pharmacology & Experimental Therapeutics
- American Society for Biochemistry & Molecular Biology
- American Physiological Society
- Human Proteome Society (HUPO)
- Society Delegate: United States Pharmacopeal Convention, 1985-1995; 2010-2015
- Alliance for Cellular Signaling
- American Heart Association
- Sigma Xi Research Society
- Society for Gynecological Investigation
- New York Academy of Sciences
- Am. Association for the Advancement of Science
- International Society for Analytical Cytology 1988-1995
- Am. Assoc. Medical Colleges: Ed. Affairs
- AMSPC (Pharmacology Chairs Group)
- AM. Association for Cancer Research

**PROFESSIONAL POSITIONS**

- Member of the Board, UNSOM *Integrated Clinical Services Inc.* 2011-2017
- Member, *Northern Regional Executive Committee*, School of Medicine Practice
- Member, *Southern Regional Executive Committee*, School of Medicine Practice
- Academic Health Center Task Force, UNSOM-UMC 2010
- Director, School of Medicine Performance Compensation Plan 1995-2014
- Vice Chair, Research Committee of the AHA (MWPRC 1994)
- Chairman, AHA National Affiliate Study Section A (1995-96 Vascular Wall Biology)
- President Elect, American Heart Association, Nevada Affiliate 1992-1993
- Chair, Research Allocations Committee, AHA, Nevada 1990-92
- President, American Heart Association, Nevada Affiliate 1993-1995
- Member, Board of Directors, AHA, Nevada Affiliate 1990-1997.
- Member, Executive Committee, AHA Nevada Affiliate, 1992-1997.
- Member, Research Allocations Committee, AHA, Nevada 1989-96
- Member; ACCP Research Affairs Committee 1987-1988; 1997; Credentials Committee 1990-1993.
- Councilor, Western Pharmacology Society, 2000-2002
- President, Western Pharmacology Society, 2002-2003
- Editor-in-Chief & Treasurer, Western Pharmacology Society, 2003-Present
- Member, Science Advisory Board, Bioinformatics, LLC. 2001-Present
- Member, The Gerson Lehman Group Council of Healthcare Advisors, 2002

**ADVANCED TRAINING**

- HPLC Methods & Applications, Hewlett Packard, Pleasanton, California 1989.
- Operator Course, Coulter EPICS Elite ESP cytometer/cell sorter, FL, 1998.
- Course in Apoptosis, FASEB Annual Meeting, San Francisco, CA, 1998.
- Course in Flow Cytometry Methods, Bowdoin, Maine, 1998.
- Ideas for Professors: Effective College Teaching, Reno, 1999.
- Course in Functional Genomics, FASEB Annual Meeting 2000

**CURRENT ACADEMIC COMMITTEES**

- Chair, Radiation Safety Committee, University of Nevada, Reno
- Member, Laboratory Safety Committee, University of Nevada, Reno
- Member Clinical Decision Making Educational Group, University of Nevada, Reno School of Medicine

**PAST ACADEMIC COMMITTEES**

- University Academic Standards Committee (1985-1987)
- University Human Subjects Committee (1986-1992)
- School of Medicine Search Committee: Chairman of Surgery (1987-1988)
- School of Medicine Search Committee: Chairman of OB/GYN (1989-1991)
- School of Medicine Library Committee (1989-1992)
- University of Nevada, Research Advisory Board (1989-1991)
- University of Nevada Search Committee: Radiation Health Physicist (1989-1990)
- Department of Pharmacology Search Committee: Assistant Professor (1989)

**PAST ACADEMIC COMMITTEES** *(continued)*

- Chairman, Generalist Initiative, Basic Science Task Force (1991-1992)
- Chairman, CMPP Graduate Student Recruitment and Admissions (1990-1995)
- Member, Personnel Committee of the School of Medicine (1992-1994)
- University of Nevada Search Committee: Exercise Physiologist (1991-1992)
- Chairman, Personnel Committee of the School of Medicine (1992-1994)
- Chairman, Basic Science Chairs Committee, UN, School of Medicine (93-97)
- Chair, Medical Student Research Comm., School of Medicine (1993-97) Chairman, School of Medicine Research Committee (1995-1997)
- Member, Science and Technology Day Committee, UNR (1993-1996)
- UCCSN, Search Committee: Director of Environmental Health and Safety (1994)
- University of Nevada, Search Committee: Professor of Biochemistry (1994)
- School of Medicine, Faculty Steering Committee (1994-1996)
- Member, University LCME Accreditation Self-Study Committee: Finance (1996-97)
- Member, CMPP Graduate Student Recruitment and Admissions Committee (1996-1998)
- Member, School of Medicine Search Committee; Senior Associate Dean (1996-1997)
- Member, School of Medicine Computers in Medical Education Working Group
- Co-Chair, President's Task Force, School of Pharmacy (1998-2004)
- School of Medicine Radiation Hazards Committee (1987-1998)
- Member, Search Committee, Research Director, Sanford Center for Aging (1998)
- Member, Search Committee, Ass. Prof., Speech Pathology & Audiology (1998)
- Member, UNSOM Education Building Fundraising Committee; Education Building (1997-2002)
- Member, Search Committee, Assistant Professor of Biochemistry, (1999-2000)
- Advisory Board Member, University of Nevada, Reno Excellence in Teaching Program (2000-2003)
- Member, University of Nevada Medical Admissions Committee (2001-2005)
- Member, Planning Committee; Interdisciplinary Graduate Program. Molecular Biosciences and Biotechnology (2002-2003)
- Chairman, Personnel Committee of the School of Medicine (2004-2005)
- Member, Personnel Committee of the University of Nevada (2004)
- Member, UNSOM Faculty Senate, Faculty Development Subcommittee (2004)
- Member, School of Medicine Executive Committee (2005-2015). Member, Health Science Center Planning Committee (2006)
- Member, Scholarship Committee, Sanford Center for Aging. (2002-2009)
- Member, Nevada System of Higher Education Radiation Safety Committee. 2000-2015.
- Chair, Nevada System of Higher Education, Radiation Safety Committee. 2015-present
- School of Medicine Course Coordinators Committee: Year 1-2, 2008-present.
- Selection Committee; UNSOM; Chairman, Obstetrics and Gynecology. 2010.
- Selection Committee; UNSOM; Vice President for Health Sciences and Dean of the School of Medicine. 2010.

**PAST ACADEMIC COMMITTEES** *(continued)*

- Curricular Reform Task Force UNSOM; 2010-2011.
- Search Committee; UNSOM; Director, Marketing and Communications, 2012
- Search Committee; UNSOM; Director, Faculty Compensation/Productivity, 2012
- Member, LCME Reaccreditation Steering Committee, 2016-2017
- Co-Chair, Educational Resources Committee, LCME Reaccreditation 2016-2017

**PEER REVIEW**Grant Reviewer

- Research Committee of the American Heart Association (MWPRC 1988-1995)
- Ad Hoc Member, NIH Study Section (SSS - Fluorescence Techniques; 1989)
- Ad Hoc Member, NIH Study Section (Biochemical Endocrinology, 1992)
- Ad Hoc Reviewer, Genentech Fellowship in Pharmacotherapy, 1992, 1993.
- Reviewer, Election of Fellows, ACCP, '92, '93
- Member, NIH Study Section, CV Sciences, (1993-1995)
- Chairman, National Affiliate Study Section A (1995 Vascular Wall Biology)
- Reviewer; Cottrell New Investigator Awards, Research Corporation, 1998-99
- Member, NIH Review Panel, RCMI Program DRR 1999.
- Reviewer, US Army Breast Cancer Research, Cell Signaling Section, 1999
- Hatch Research Grants: Biochemistry (1989-97, 2000-2004)
- Ad Hoc Reviewer: VA Merit Awards, 2001
- Member, Collaborative Research Panel, CA Breast Cancer Program, 2000-2002.
- Reviewer, Excellence in Diversity Graduate Fellowships, UNR, 2002-3.
- Proposal Referee for The Wellcome Trust, London, England 2002-2007.
- Community Grants. Susan G. Komen for the Cure. 2008
- NIH Study Section Member; Pregnancy and Perinatology. Fall 2008
- Ad Hoc Reviewer, UK Action Medical Research, 2008
- NIH Study Section Reviewer ,ZRG1 EMNR-C Challenge Grants Panel 15, 2009
- NIH Study Section Reviewer 2010/08 ZRG1 EMNR-C (55) 06/29/2010; PN 2011-2012.
- Proposal Referee for The Wellcome Trust, London, England 2010-2012.
- Medical Research Grant Reviewer for the State of Arizona. 2014
- NIH Special Emphasis Panel. Obstetric-Fetal Pharmacology Research Centers (OPRC) ZHD1 DSR-A 50 1, April 2015-2016
- FDA Review Panel advisory Preparatory Meeting, Clarus Therapeutics. 12/2017
- Member, NIH Study Section Reviewer, ZRG1 EMNR-C (02). 2018.
- Action Medical Research for Children. "Born too Soon: Flagship Campaign, United Kingdom Research Project Reviewer 2019.

**PEER REVIEW** (*continued*)Manuscript Reviewer (16 manuscripts reviewed in 2018)

- American Journal of Obstetrics and Gynecology (since 1994)
- Journal of Pharmacology & Experimental Therapeutics (since 1984)
- American Journal of Physiology (since 1985)
- Journal of Applied Physiology (since 1996)
- Journal of Physiology (London; since 1997)
- Journal of Cardiovascular Pharmacology (since 1985)
- Circulation (since 1992)
- Circulation Research (since 1998)
- Journal of Biological Chemistry (since 1988)
- Life Sciences (since 1986)
- Pharmacotherapy (since 1989)
- Pharmacological Reviews (since 1992)
- Nature-Laboratory Investigation (Since 2017)
- Annals of Pharmacotherapy (since 1992); Editorial Board Member, Clinical Pharmacology (2003-2008)
- The Journal of Cell Biology (since 1992)
- Clinical & Experimental Pharmacology and Physiology (since 1993)
- Regulatory Peptides (1996-1998)
- Molecular Pharmacology (since 1989)
- Experimental Aging Research (since 2000)
- Proceedings, Western Pharmacology Society Editor-in-Chief since 2003.
- The Medical Letter (since 2003)
- American Journal of Pharmaceutical Education (since 2006)
- Journal of Clinical Pathology (since 2010)
- Nature 2014
- British Journal of Medicine and Medical Research

Scientific Abstract Reviewer

- Society for Reproductive Investigation, Annual Meeting (1997-2016)
- American College of Clinical Pharmacy, Scientific Sessions (1983-88; 1994-96)
- American Heart Association National Annual Meeting & Scientific Sessions (1993-2000)
- Western Pharmacology Society, Annual Meeting & Scientific Sessions, 2003-2010

Program Reviewer

- Site Visit Reviewer, NIH Program Project in Cellular Fluorescence Techniques. *PI*: D. Lansing Taylor, Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA; On-site review 1989
- FDA Preparation Review Panel Member, Nashville Tennessee, 2017.
- NIH Program Project in Endothelial Cell Gene Transplantation. *PI*: Fritz H. Bach, Depart. of Surgery, Harvard Medical School and Deaconess Hospital, Boston, MA; 1997
- American Heart Association New Hampshire Affiliate, Reaffiliation Site Visit 1994-1995
- NIH-NCRR Core Facility in Toxicology and Flow Cytometry; RCMI Principal Investigator: Alfred Nyanda, Department of Pharmacology Meharry Medical College, Nashville, On-Site Review, December 1999.
- March of Dimes. Research Grants 2019; Clinical Science. Panel Review Member. On line reviews 2019.



**RESEARCH FUNDING HISTORY** (funded as Principal Investigator or Co Investigator)

- Subcellular Compartmentation of Hormone Action in Heart. Training in Cardiovascular Pharmacology. NIH NRSA HL O7444, 4/81-6/84.
- Mechanisms of  $\alpha_1$ -Adrenoceptors on Cardiac Myocytes. NIH R23 HL 32928, PI: Buxton 7/84-6/87, \$105,000 *direct costs*.
- Development of a Cellular Model of Mammalian Ventricle. UCSD BRSG, Faculty Research Grant, PI: Buxton (6-510124) 1984 \$2,272 *direct costs*.
- Mechanisms of  $\alpha_1$ -Adrenoceptors on Cardiac Myocytes. NIH RO1 HL35416, PI: Buxton 7/87-6/91, \$310,453 *direct costs*.
- Activation of Cardiomyocyte Phosphodiesterase. AHA Nevada Affiliate Grant-in-Aid, PI: Buxton 7/85-6/86, \$15,895 *direct costs*.
- Compartmentation of Hormone Action in 3T3-L1 Adipocytes. UNR-RAB, Junior Faculty Award PI: Iain Buxton 7/86-6/87, \$9,500 *direct costs*.
- Hormone Signal Transduction in Cardiac Myocytes. AHA Affiliate Grant-in-Aid, PI: Buxton 7/86-6/88, \$32,533 *direct costs*.
- Regulation of Calcium Action in the Heart. Max Baer Heart Fund, PI: Buxton 5/87-9/87, \$5,000 *direct costs*
- Gradient HPLC. NIH Small Instrumentation Grant. NIH S15 HL 39506, PI: Iain Buxton 7/87-6/88, \$15,487 *direct costs*.
- Phillips CM10 Transmission Electron Microscope. NIH Shared Instrumentation Grant, NIH S10 RR 03453 Co-PI 10/86-9/87, \$188,370 *direct costs*.
- Automated Fluorescence Analysis of Cells. NIH Shared Instrumentation Grant, NIH S10 RR 04160 Co-PI 10/87-9/88, \$246,000 *direct costs*.
- Purineric Mechanisms in Cardiac Blood Vessels. UNR-RAB Award, PI: Buxton 4/90-3/91, \$5,000 *direct costs*.
- Receptor-Signal Transduction in the Vasculature in Diabetes. ADA National Research Program, PI: Buxton 7/88-6/90, \$69,828 *direct costs*.
- Receptors for Adenyl Purines in Uterus. UNR-RAB Award, PI: Buxton 5/89-4/90, \$5,000 *direct*.
- Radioactive Flow Detector for HPLC. NIH Small Instrumentation Grant NIH S15 HL 41739, PI: Buxton 7/88-6/89, \$16,500 *direct costs*.
- Quantitative Fluorescence Detection System. NIH Shared Instrumentation Grant, NIH S10 RR 05876, PI: Buxton 12/89-11/91, \$100,000 *direct costs*.
- Fluorescence Imaging Laboratory. Facilities Enhancement; UNR, VPAA, PI: Buxton 1/91-11/92, \$16,000 *direct costs*.
- Real-Time Fluorescence Video Imaging of Calcium Distributions in Living Cells. Reno Cancer Center, PI: Buxton 10/91-9/93, \$4,000 *direct costs*.
- Role of Adenyl Purines in Myometrial Function. NIH RO1 HD 26227 9/89 - 12/94, PI: Buxton \$569,897 *direct costs*.
- Receptor-signal Transduction in Colonic Muscle. NIH PO1 DK 41315 (Project 4 PI: Buxton) 4/94-3/95, \$116,000 *direct costs*.
- The Role of Ecto-ATP Generation in Breast Cancer Metastasis. PI: Buxton; Reno Cancer Foundation, 1994, \$3,000 *direct*.
- Receptor-Signal Transduction in Colonic Muscle. NIH PO1 DK 41315 (Project 4 PI: Buxton), 4/89-3/94, \$456,000 *direct costs*.
- Acquisition of a Quadrapole Mass Spectrometer. NSF DIR-9102839 Equipment Grant, Buxton: Principal User 20%, \$304,322 *direct costs*.

**RESEARCH FUNDING HISTORY** (funded as PI or Co I continued)

- Cell and Tissue Culture Core B: Receptor-Signal Transduction in Colonic Muscle. NIH PO1 DK 41315, (Director Core B; I. Buxton) 4/89-3/95, \$480,000 *direct costs*
- Bio-Rad MRC-600 Confocal Imaging System. NIH Shared Instrumentation Grant; NIH S10 RR 06507-01 Buxton: Principal User 20%, \$135,000 *direct costs*.
- Digital Camera for Cell Motion Analysis. PI: Buxton Reno Cancer Foundation, 10/95-9/96, \$3,400 *direct costs*.
- The Effect of Age on the Purinergic Axis of Cardiac Blood Vessels. PI: Buxton, Sanford Center for Aging, 11/95-10-96 \$10,000 *direct costs*.
- Role of ATP in Vascular Neuroeffector Processes. NIH RO1 HL 38126, Dr. D. Westfall, PI; Buxton Co-Investigator, 10% effort, 4/92-4/97 \$497,644 *direct costs*.
- Postjunctional Mechanisms in Airway Hyperreactivity. NIH RO1 HL 48183, Dr. Gerthoffer, PI; 10% effort, 2/92-1/97 \$636,673 *direct costs*.
- Automated DNA Sequenator (ABI 310; \$65,000.00). PI: Buxton; Gianoli Foundation, 1997.
- Fluorescence-Activated Cell Sorting (Coulter Epix; \$380,000.00). PI: Buxton; Gianoli Foundation, 1997
- Molecular Basis of Nitric Oxide Action in Primate Myometrium. NIH R29 HD33430, Dr. M. Bradley, PI; Buxton Co-I, 5% effort, 4/96 - 3/98 \$505,050 *total costs*.
- Purinergic Mechanisms in Cardiac Endothelial Cells. American Heart Association, National Grant-in-Aid Program 96006430; 1996-99 PI: Buxton \$132,000 *total costs*.
- Pre and In-flight Countermeasures to Sarcopenia. PI: Buxton, Nevada Space Grant Program; 9/02-8/03, \$4,200 *direct costs*.
- Role of Ecto-ATP Generation in Breast Cancer Metastasis. Clayton Foundation for Research NV-03 1/95-12/06 \$1,250,000 *total costs*; 05-06 \$83,332 *total costs*.
- Functional Compartmentation of Nucleotide Receptors in Endothelial Cells. Robert Z. Hawkins Foundation 8/15/05 – 8/14/06; \$22,500 *direct costs*.
- Roche Pharmaceuticals WPS Pgm. Support 2004-2006; \$25,000.
- Purinergic Mechanisms in Coronary Blood Vessels. NIH RO1 HL56422-01 & 2/96-11/02 (*Percentile Ranking 1.5*) \$1,249,694 *total costs*.
- Control of Rectoanal Motility. NIH 1R01 DK 054490. PI Keef; Buxton, 5% effort, 8/00–7/02 \$850,000 *direct costs*.
- AHA Meeting Grant: WPS Annual Meeting 2/2/2003-2/6/2004, \$2,000
- NV Biomedical Resources Infrastructure Network. NIH BRIN 2002-2003 Core Use Grants, \$8,000 *direct costs*.
- Cloning and Expression of the Coronary P2y Receptor. Robert Z. Hawkins Foundation 8/15/01e– 7/31/04; \$69,500 *direct costs*.
- Regulation of Smooth Muscle Myosin Phosphatase in Microgravity. NASA, \$15,820 *direct costs*, 3/1/04-2/28/05.
- CSI-6000 Health Station Performance Study: AMI/ANSI Standards (SP-10): Computerized Screening Inc. \$6,500, Buxton PI; 2007.
- 2007 Annual Meeting Program Support for Western Pharmacology Society: NIH Office of Rare Diseases \$15,000.

**RESEARCH FUNDING HISTORY (funded as PI or Co I continued)**

- Stretch-Activated 2-Pore K<sup>+</sup>-Channels, TREK-1 and TRAAK in Preterm Labor. March of Dimes, 3/07 – 3/10; PI: Buxton \$301,386 *direct costs*.
- Effective Treatment to Prevent Preterm Delivery. Gates Grand Challenges. Round-6, Phase I, 5/1/11e- 3/31/13.
- Regulation of Myometrial Relaxation: Agonist-specific cGMP Action. NIH RO1 HD053028; 2007-2013; \$1,300,000 Inc. ARRA Supplement; *direct costs*. PI: Buxton.
- Stretch-Activated Two-Pore Potassium Channel Variants in Preterm Labor. MOD 2010-2013) PI: Buxton, \$394,226 *total cost*
- Post-Translational S-nitrosation of Therapeutic Targets in Pregnancy and Labor. NIH 1U54GM 104944-01. CTR Pilot \$50,000 1/2014-12/2014.

**RESEARCH FUNDING HISTORY (Mentor/Sponsor)**

- Purinergic Receptor-mediated Angiogenesis in Breast Cancer. CDMRP BCRP Grant 10207692. PI: N. Yokdang, Mentor Buxton, \$84,000 *direct costs*.
- The Human Myometrial Nitroproteome in Pregnancy and Labor. PhRMA Found. 2012-2014, \$60,000 Craig Ulrich, Mentor Buxton.
- Precollege Science Education in Nevada. Howard Hughes Medical Institute, HHMI #72594-537601, 7/94-6/99; \$200,000 *direct costs*.
- Washoe County Precollege Science Initiative. Washoe County School District. PI: Buxton 1996-1999. \$54,000 *direct costs*.
- Cell and Molecular Cancer Research Training in Nevada. NIH T32 CA 09563 PI: D. Hudig. Buxton; Co-I. 12/97-11/03.
- Vascular Smooth Muscle in Microgravity. NASA EPSCoR Student Fellowship Grant. Erica Gipson, \$8,000 *direct costs*.
- Pre-Doctoral Training Award, B. Oxhorn, Agonist-Specific ATP Release from Endothelial Cells. NIH F31 NR07379, 1998-2002, \$95,000 *direct costs*.
- Pre-Doctoral Training Award, Robert Kaiser, Cloning and Characterization of a P2y4-like Uridine Receptor from Endothelial Cells. AHA Western States Affiliate, 2000-2002, \$43,000 *direct costs*.
- Post-Doctoral Training Award, Michael Bradley, Adenosine A1 Receptors in Myometrium. F32HD07448-02, 1990-93, \$80,000 *direct costs*.
- Post-Doctoral Training Award, S. Yang, ATP Release from Endothelial Cells. AHA-Nevada, 1990-92, \$40,000 *direct costs*.
- Pre-Doctoral Training Award, Dennis Cheek, Purinergic Regulation in Cardiac Blood Vessels. NIH F31 NR06867, 93-96, \$90,000 *direct costs*.
- Post-Doctoral Training Award, Dennis Cheek, Purine Metabolism by Cardiac Endothelial Cells. AHA-Nevada, 1994-95, \$22,000 *direct*.
- Vascular Smooth Muscle in Microgravity. NASA EPSCoR Student Fellowship Grant. Erica Gipson 2002, \$8,000 *direct costs*.
- Purinergic Regulation of Breast Cancer Metastasis. INBRE Undergraduate Fellows Program Whitney Law 2005; \$5,000 *direct*.
- Stretch-Activated 2-pore Potassium Channels in Myometrium. INBRE Undergraduate Fellows Program. Eric Hansen 2006; \$5,000 *direct costs*.
- TREK-1 Currents in Uterine Myocytes. INBRE Undergraduate Fellows Program. Mike Lee 2013; \$5,000 *direct costs*.

**RESEARCH FUNDING HISTORY** (*Mentor/Sponsor*)

- Angiogenic Mechanisms; 3D Culture. INBRE Undergraduate Fellows Program. Katie Speirs 2011-13; \$10,000 direct costs.
- Purinergic Receptor-Mediated Angiogenesis in Breast Cancer. CDMRP BCRP Grant 10207692. PI: N. Yokdang, 2010-2013; Mentor Buxton, \$84,000 direct costs.
- EZH2 inhibition and regulators of NFκB and NKILA represent a novel breast cancer therapy. NIH-NCI Huntsman GMap grant 2018. Suzann Duan, Mentor Buxton.
- Proteomic Discovery in Human Myometrium. PhRMA Foundation Predoctoral Fellowship. 2010-2013 \$75,000.
- Integrin Regulation of Stretch-Activated Myometrial Signaling During Pregnancy and Labor. NIH HD067342 7/2011-6/2016, PI Burkin, Mentor Buxton; \$689,669 direct

**UNDERGRADUATE TRAINING IN RESEARCH**

- Dr. Buxton regularly takes medical students into the lab for research rotations in the summer between their freshman and sophomore years. Thirty-five students have been mentored from 1986 through the present.
- Dr. Buxton is a Research Mentor for the undergraduate major in Biochemistry. Students engage in a two semester research experience and write an Undergraduate Thesis, and present their work in a public forum at the end of the academic year. Forty-eight students have been mentored since 1987 to the present.
- Dr. Buxton serves as a mentor for students majoring in Biochemistry, Biophysics and Molecular Biology from Whitman College, Wala Wala, Washington and Pharmacy students from Washington, Utah and Colorado.

**GRADUATE PROGRAM AFFILIATIONS & TRAINING OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS:**

- Founding Member, Cell and Molecular Pharmacology and Physiology, School of Medicine, University of Nevada, Reno
- Member and Director (*past*), Biochemistry Graduate Program, Colleges of Medicine, Science and Agriculture, University of Nevada, Reno
- Member, Cell and Molecular Biology Graduate Program, Colleges of Medicine, Science and Agriculture, University of Nevada, Reno

**Graduate Training:** (➤ denotes Dr. Buxton as Major Advisor)

<b>Name</b>	<b>Program</b>	<b>Role</b>	<b>Date Received</b>
➤ Merton A. Smith	M.D./Ph.D. (Pharm.)	Advisor	Ph.D. (1989)
➤ Kurt O. Doggwiler	Pharmacology	Advisor	Ph.D. (1991)
Padraig Hart	Pharmacology/Physiology	Member	Ph.D. (1994)

Dawn Duval	Pharmacology/Physiology	Member	Ph.D. (1994)
John Dover	Chemistry	Member	Ph.D. (1996)
➤ Karri Kuenzli	Pharmacology/Physiology	Advisor	Ph.D. (1996)
➤ Dennis Cheek	Pharmacology/Physiology	Advisor	Ph.D. (1996)
Jeanette McHugh	Pharmacology/Physiology	Member	Ph.D. (1996)
Shelly VonBerg	Speech Pathology/Audiology	Member	M.S. (1996)
Christopher Porada	Pharmacology/Physiology	Member	Ph.D. (1998)
Rich Eigenheer	Biochemistry	Member	Ph.D. (2001)
➤ Jasmine Vittori	Cell & Molecular Biology	Advisor	M.S. (W)
Leah Skladany	Speech Pathology/Audiology	Member	Ph.D. (2001)
Nicole Kiel	Speech Pathology/Audiology	Member	M.S. (2000)
Jennifer Dreyer-Ladue	Speech Pathology/Audiology	Member	M.S. (2000)
Brett Martin	Pharmacology/Physiology	Member	M.S. (1999)
Lorraine Wolf	Speech Pathology/Audiology	Member	M.S. (1999)
Peter Wolf (nr)	Speech Pathology/Audiology	Member	M.S. (1999)
Rebecca E. Dendauw	Speech Pathology/Audiology	Member	M.S. (1999)
➤ Robert Kaiser	Biochemistry	Advisor	Ph.D. (2002)
➤ Brian Oxhorn	Pharmacology/Physiology	Advisor	Ph.D. (2002)
➤ Stephen Tichenor	Pharmacology/Physiology	Advisor	Ph.D. (2004)
➤ Jennifer N. Mazzone	Cell & Molecular Biology	Advisor	M.S. (2004)
Kimberly Baker	Cell & Molecular Biology	Member	Ph.D. (2004)
➤ Sharif Rumjahn	Biochemistry	Advisor	Ph.D. (2008)
Vincent Lombardi	Biochemistry	Member	Ph.D. (2006)
Sonemany Salinthone	Cell & Molecular Biology	Member	Ph.D. (2006)
➤ Jennifer N. Tichenor	Cell & Molecular Biology	Advisor	Ph.D. (2008)
➤ Mark Gore	U. Colorado, PharmD Pgm.	Advisor	Pharm.D.(2007)
Sunny Xiang	Pharmacology/Physiology	Member	Ph.D. (2008)
Tim O'Donnell	Pharmacology/Physiology	Member	Ph.D. (W)
Sreenivasa Anugu	Chemistry	Member	Ph.D. (2009)
Michael Mouradian	Biochemistry	Member	Ph.D. (2012)
➤ Nucharee Yokdang	Cell & Molecular Biology	Advisor	Ph.D. (2011)
➤ Craig Ulrich	Biochemistry	Advisor	Ph.D. (2012)
➤ Yi-Ying Wu	Biochemistry	Advisor	Ph.D. (2013)
➤ Scott Barnett	Pharmacology/Physiology	Advisor	Ph.D. (2017)
➤ Senny Wong	Biochemistry	Advisor	Ph.D. (2018)
➤ Suzanne Duan	Pharmacology/Physiology	Advisor	Ph.D. (2019)

**Training of Postdoctoral Fellows:**

<b>Name/Fellowship</b>	<b>Doctoral Program/Year</b>	<b>Current Position</b>
➤ Lubo Zhang, Ph.D. 1990-1993	Pharmacology Iowa State University, Ames, 1989	Professor Loma Linda Univ. College of Medicine, CA
➤ Michael Bradley, Ph.D. 1990-1993	Physiology USC, Los Angeles, 1990	Professor of Biology, Newman Univ. Division of Science
➤ Shumei Yang, Ph.D. 1991-1993	Chemistry, Iowa State Univ. Ames, Iowa, 1991	Professor, Chemistry Cal State University, CA
➤ Elizabeth Berge, M.D. 1992-1993	Medicine, University of Nevada, Reno, 1992	Adj. Assoc. Professor OB/Gyn UNSOM, Las Vegas, NV
➤ James Barber, M.D. 1993-1994	Medicine, University of Nevada, Reno, 1993	Adj. Assoc. Professor OB/Gyn UNSOM, Las Vegas, NV
➤ Sandra Brave, Ph.D. 1993-1996	Pharmacology, King's College London, UK 1993	Senior Scientist Burroughs Wellcome, UK
➤ W. Zaman, M.D., Ph.D. 1994-1996	Biochemistry Kyushu Univ. Japan 1993	Associate Member, Sanjay Gandhi Medical Institute, Lucknow, India
➤ S. Mathew, M.D., Ph.D. 1996-1997	Medicine, Biochemistry Univ. of Nevada Reno, 1996	Associate Professor Pediatrics UNSOM, Reno, NV
➤ D.J. Cheek, Ph.D. 1996-1997	Pharmacology University of Nevada, Reno, 1996	Professor TCU Nursing School Fort Worth, TX
➤ L. Jones, Pharm.D. 2004-2005	Purdue University, 2002 College of Pharmacy	Associate Professor, Loma Linda College of Pharmacy, California
➤ S. Rumjahn, Ph.D. 2008-2011	University of Nevada 2008 Pharmacological Sciences	Research Scientist, Charles River Labs, Reno, Nevada
➤ Nate Heyman, Ph.D. 2010-2012	University of Arizona, 2007 Physiology and Biophysics	Assistant Professor, California Baptist Univ., Riverside California
➤ Heather R. Burkin, Ph.D. 2010-2012	University of Illinois, 2003 Reproductive Biology	Assistant Professor, Univ. of Nevada, Dept. of Pharmacology
➤ Joseph Tellez, Ph.D. 2011-2012	University of Nevada, 2010 Biology	Postdoctoral Scholar, Univ. of California, Davis Cancer Center
➤ Chad Cowles, Ph.D. 2012-2016	University of Nevada, 2012 Biomedical Engineering	Postdoctoral Fellow, Univ. of Arizona, Dept. of Pharmacology

**PUBLICATIONS****Books**

Brunton, L.L., Parker, K., Blumenthal, D. and Buxton, I.L.O. *The Goodman and Gilman Manual of Pharmacology and Therapeutics* (First Edition.), McGraw-Hill, New York, 2007.

**Journals Published as Editor-in-Chief**

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 46:pgs. 1-205, 2003. WPS, Reno, NV.

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 47: pgs. 1-235, 2004. WPS, Reno, NV.

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 48: pgs. 1-220, 2005. WPS, Reno, NV

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 49: pgs. 1-235, 2006. WPS, Reno, NV

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 50: pgs. 1-239, 2007. WPS, Reno, NV

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 51: pgs. 1-147, 2008. WPS, Reno, NV

Buxton, I.L.O. (Editor) *Proceedings of the Western Pharmacology Society*. Volume 52: pgs. 1-131, *online open access: <http://www.medicine.nevada.edu/wps/vol52.html>* (2009). WPS, Reno, NV

**Book Chapters/Invited Reviews**

Buxton, I.L.O. and Barnett, S.D. (2018) Nitric Oxide and S-Nitrosoglutathione. Chpt. 14: In, Glutathione Leopold Flohé, Ed. CRC Press. Published October 8, 2018 ISBN 9780815365327.

Buxton, I.L., Chapter 2, Pharmacokinetics In: Goodman & Gilman's, The Pharmacological Basis of Therapeutics. McGraw-Hill [ISBN: 978-1-25-958473-2] 13<sup>th</sup> Edition, (2018), Eds. L.L. Brunton, Hilal-Dandan, R. and Knollmann, B.C.

Buxton, I.L. Appendix I. Prescription Writing and Patient Compliance In: Goodman & Gilman's, The Pharmacological Basis of Therapeutics. McGraw-Hill [ISBN: 978-1-25-958473-2] for the 13<sup>th</sup> Edition, (2018), Eds. L.L. Brunton, Hilal-Dandan, R. and Knollmann, B.C.

Buxton, I.L.O. and Leslie Benet. *Chapter 2*, Pharmacokinetics. In: Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 12<sup>th</sup> Edition, 2009, Ed: L.L. Brunton. McGraw-Hill, New York.

Buxton, I.L.O. *Appendix 1*, Principles of Prescription Order Writing and Patient Compliance. In: Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 12<sup>th</sup> Edition, 2009, Ed: L.L. Brunton. McGraw-Hill, New York.

Buxton, I.L.O. *Chapter 1*, Pharmacokinetics and Pharmacodynamics: The Dynamics of Drug Absorption, Distribution, Action and Elimination. Pg. 1-39 In: Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 11<sup>th</sup> Edition, 2005, Eds: L.L. Brunton, J.S. Lazo and K.L. Parker. McGraw-Hill, New York.

Buxton, I.L.O. *Appendix 1*, Principles of Prescription Order Writing and Patient Compliance. Pg. 1777-1786 In: Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 11<sup>th</sup> Edition, 2005, Eds: L.L. Brunton, J.S. Lazo and K.L. Parker. McGraw-Hill, New York.

**PUBLICATIONS*****Book Chapters/Invited Reviews (continued)***

Buxton, I.L.O. Rethinking Drug Action in Light of Current Models of Receptor Pharmacology. November 2005, Goodman and Gilman's *The Pharmacologic Basis of Therapeutics*. 11<sup>th</sup> Edition OnLine at Access Medicine (<http://www.accessmedicine.com/updatesContent.aspx?aid=1000643>).

Matthews, J., Pingle, M., Sullivan, R., Ferguson, P., Rogers, J.E. and Buxton, I.L.O. (2005) Invited Review: Economic justification for a Public School of Pharmacy: Lessons for Nevada. *Proc. West. Pharmacol. Soc.* 48:1-12.

Buxton, I.L.O. (2003) Invited Review: What is it about the uterus anyway? *Proc. West Pharmacol. Soc.* 46: 1-8.

Pathophysiology. Advanced Practice in Acute and Critical Care. AACN Clinical Issues Vol. 11(2) pp. 157-331, (May 2000), Editors: Cheek, D.J. and Buxton, I.L.O.

Zhang, L. and Buxton, I.L.O. (1998) Measurement of phosphoinositols and phosphoinositides using radio-high-performance liquid chromatography flow detection. *Methods in Molecular Biology*: Humana Press 105:47-64.

Buxton, I.L.O. and Cheek, D.J. (1995) On the origin of extracellular ATP in cardiac blood vessels: A dual role for endothelium. In: *Proceedings 5th. International Symposium on Adenosine and Adenine Nucleotides*: Ed. L. Bellardinelli and A. Pelleg, Kluwer, MA, PP. 193-198.

Buxton, I.L.O. Westfall, D.P. and Schiemann, W.P. A role for adenosine in myometrial function? In: *Role of Adenosine and Adenine Nucleotides in the Biological System*. Ed: S. Imai and M. Nakazawa, Elsevier, Amsterdam (1991), Chapter 45, Pg. 499-506.

Westfall, D.P., Sedaa, K.O., Shinozuka, K., Bjur, R.A. and Buxton, I.L.O. (1990) ATP as a cotransmitter. In: *The Biological Actions of ATP* (Dubiak and Fedan, Ed.) *Annals of the New York Academy of Science*. 603: 300-310.

Buxton, I.L.O., Walther, J. and Westfall, D.P. (1990)  $\alpha$ -adrenergic receptor-stimulated release of ATP from cardiac endothelial cells in primary culture. In: *The Biological Actions of ATP* (Dubiak and Fedan, Ed.) *Annals of the New York Academy of Science*. 603: 503-506.

Bierkamper, G.G. and Buxton, I.L.O. Neurotoxicology of Organotin Compounds In: Biological Effects of Heavy Metals. Vol I Ed. E.C. Foulkes, CRC Press, Boca Raton, FL, (1989) pp.97-165.

Buxton, I.L.O. and Brunton, L.L. (1988) Characterization of hormone receptors on the adult cardiac myocyte. In: *Biology of the Isolated Cardiac Myocyte*. Ed. W.A. Clark, Elsevier Publishing Co., New York. pp. 90-107.

Buxton, I.L.O. (1988) Alpha<sub>1</sub>-adrenergic receptor signal transduction in the adult rat cardiac myocyte In: *Biology of the Isolated Adult Cardiac Myocyte*. Ed. W.A. Clark, Elsevier Publishing Co., New York, Pg. 248-252.

Buxton, I.L.O. and Brunton L.L. (1986) Compartmentation of hormone action in mammalian cardiomyocytes. In: *Advances in Experimental Biology and Medicine*, Ed. N. Bratbar V. 194 Pg. 117- 127, Plenum, New York.

Buxton, I.L.O. (1983) The use of drugs in renal failure. In: Critical Care Nursing Review, Ed. by B. Meador. Medical Economics Publication, Oradell, New Jersey, Chapter 23.



**PUBLICATIONS*****Professional News Letters/Letters to the Editor/Book Reviews***

Buxton I.L.O. (1979) Rebound phenomena following abrupt withdrawal of propranolol. Veterans Administration, San Diego, *Drug Information Newsletter* 2:2,1-4.

Buxton, I.L.O. (1993) Adenyl purines: Neurotransmitters and local hormones. *ACCP report* 13: 12.

Buxton, I.L.O. (1996) HHMI Awards. *Science* 271: 895.

Buxton, I.L.O. (2004) Clinical Pharmacology 9<sup>th</sup> Edition. A Book Review, *The Annals of Pharmacotherapy*, 38:906-907.

***Original Research Data-Base & World Wide Web Contributions***

Buxton, I.L.O., Kaiser, R.A. and Malmquist, N.A. (2001) AfCS PID A001677 Mini Molecule Page: Nucleoside Diphosphate Kinase A. Alliance for Cellular Signaling. <http://www.cellularsignaling.org>.

Buxton, I.L.O. and Malmquist, N.A. (2001) AfCS PID A001678 Mini Molecule Page: Nucleoside Diphosphate Kinase B. Alliance for Cellular Signaling. <http://www.cellularsignaling.org/>.

Kaiser, R.A. and I.L.O. Buxton (2001) [AY017306](#) *Cavia porcellus* nucleoside diphosphate kinase A (NDPK-A) mRNA, complete cds. Gen Bank Sequence on NCBI: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list\\_uids=12700712&dopt=GenBank](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=12700712&dopt=GenBank).

Mazzone, J., Kaiser, R.A. and I.L.O. Buxton (2001) [AY040849](#) *Homo sapiens* large conductance calcium-activated channel subfamily M alpha member 1 (KCNMA1) mRNA, complete cds. Gen Bank Sequence for BK $\alpha$  on NCBI: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Nucleotide&list\\_uids=15215552&dopt=GenBank](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Nucleotide&list_uids=15215552&dopt=GenBank).

Mazzone, J., Kaiser, R.A. and I.L.O. Buxton (2001) [AF395661](#) *Homo sapiens* potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 mRNA, complete cds. Gen Bank Sequence SK4 on NCBI; [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Nucleotide&list\\_uids=15029375&dopt](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Nucleotide&list_uids=15029375&dopt).

Mazzone, J., Kaiser, R.A. and I.L.O. Buxton (2001) [AF397175](#) *Homo sapiens* small conductance calcium-activated potassium channel (KCNN2) mRNA, complete cds. GenBank Sequence for SK2 on NCBI; [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Nucleotide&list\\_uids=15082147&dopt=GenBank](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Nucleotide&list_uids=15082147&dopt=GenBank).

**Original Research Data-Base & World Wide Web Contributions (continued):**

Mazzone, J., Kaiser, R.A. and I.L.O. Buxton (2001) [AY044441](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=15422166&dopt=GenBank) Homo sapiens potassium large conductance calcium-activated channel (KCNMB1) mRNA, complete cds. Gen Bank Sequence for BKB (MB1) on NCBI: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list\\_uids=15422166&dopt=GenBank](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=15422166&dopt=GenBank).

Mazzone, J., Kaiser, R.A. and I.L.O. Buxton (2001) [AY049734](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=15983750&dopt=GenBank) Homo sapiens smallconductance calcium-activated potassium channel SK3 (KCNN3) mRNA, complete cds. Gen Bank Sequence for SK3 on NCBI: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list\\_uids=15983750&dopt=GenBank](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=15983750&dopt=GenBank).

**Original Research Articles** \* Contributed as Principal Experimentalist

Paul, D., Leffert, H.L., Sato, G. and Holley R.W. (1972) \*Stimulation of DNA and protein synthesis in fetal-rat liver cells by serum from partially hepatectomized rats. *Proc. Natl. Acad. Sci. U.S.A.* 69(2):374-7.

Leffert, H.L. and Paul, D. (1973) \*Serum dependent growth of primary cultured differentiated fetal rat hepatocytes in arginine-deficient medium. *J. Cell Physiol.* 81(1):113-24.

Leffert, H.L. (1974) \*Growth control of differentiated fetal rat hepatocytes in primary monolayer culture. VII. Hormonal control of DNA synthesis and its possible significance to the problem of liver regeneration. *J. Cell Biol.* 62(3):792-801.

Leffert, H.L. (1974) \*Growth control of differentiated fetal rat hepatocytes in primary monolayer culture. V. Occurrence in dialyzed fetal bovine serum of macromolecules having both positive and negative growth regulatory functions. *J. Cell Biol.* 62(3):767-79.

Koch, K. and Leffert, H.L. (1974) \*Growth control of differentiated fetal rat hepatocytes in primary monolayer culture. VI. Studies with conditioned medium and its functional interactions with serum factors. *J. Cell Biol.* 62(3):780-91.

Sell, S., Nichols, M.; Becker, F.F. and Leffert, H.L. (1974) \*Hepatocyte proliferation and alpha 1-fetoprotein in pregnant, neonatal, and partially hepatectomized rats. *Cancer Res.* 34(4):865-71.

Main, A.R., Soucie, B., Buxton, I.L.O. and Arnic, A. (1974) On the purification of cholinesterase. *Biochem. J.* 143: 733-744.

Buxton, I.L.O. and Brunton, L.L. (1983) Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. *J. Biol. Chem.* 258: 10233-10239.

Bell, J.D., Buxton, I.L.O. and Brunton, L.L. (1984) An isotope dilution assay for glycerol. *Anal. Biochem.*, 139: 305-308.

Saglikes, Y., Massry, S.G., Kunitoshi, I., Brautbar, N., Barndt, R., Brunton L.L., Buxton, I.L.O., Vlachakis, N. and Campese, V.M. (1985) Effect of phosphate depletion on blood pressure and vascular reactivity to norepinephrine and angiotensin II in rat. *Am. J. Physiol.* 248: F93-F99.

Buxton, I.L.O. and Brunton, L.L. (1985) Direct analysis of  $\beta$ -adrenergic subtypes on intact adult ventricular myocytes of the rat. *Circ. Res.* 56: 126-132.

**PUBLICATIONS****Original Research Articles (continued)**

- Buxton, I.L.O., Rozansky, D., Brunton, L.L. and Motulsky, H.J. (1985) Effects of Na<sup>+</sup> on the muscarinic cholinergic receptor of rat ventricular myocytes. *J. Cardiovasc. Pharmacol.* 7: 476-481.
- Buxton, I. L.O. and Brunton, L.L. (1985) Action of the cardiac  $\alpha_1$ -adrenergic receptor: activation of cyclic AMP degradation. *J. Biol. Chem.* 260: 6733-6737.
- Bell, J. D., Buxton, I. L.O. and Brunton, L.L. (1985) Enhancement of adenylate cyclase activity in S49 lymphoma cells by phorbol esters: putative effect of C-kinase on  $\gamma_S$ -GTP-catalytic subunit interaction. *J. Biol. Chem.* 260: 2625-2628.
- Buxton, I. L.O. and Brunton, L.L. (1985) B-adrenergic receptor subtypes and cellular compartmentation of cyclic AMP-dependent protein kinase in cardiomyocytes. *Biochem. International* 11: 137-144.
- Brown, J.H., Buxton, I. L.O. and Brunton, L.L. (1985)  $\alpha_1$ -adrenergic and muscarinic cholinergic stimulation of phosphoinositide hydrolysis in adult rat cardiomyocytes. *Circ. Res.* 57: 532-537.
- Buxton, I. L.O. and Brunton, L.L. (1986)  $\alpha$ -adrenergic receptors on rat ventricular myocytes: characteristics and linkage to cAMP metabolism. *Am. J. Physiol.* 251:H307-H313.
- Buxton, I. L.O. (1986) Regulation of cAMP metabolism in adult ventricular cardiac myocytes: effect of histamine. *Proc. West Pharmacol. Soc.* 29: 55-58.
- Hammond, K.H., White, F.G., Buxton, I. L.O., Saltystein, P., Flynn, S., Brunton, L.L. and Longhurst, J.C. (1987) Increased myocardial  $\beta$ -receptors changes and adrenergic responses in hyperthyroid pigs. *Am. J. Physiol.* 252: H283-H290.
- Khoyi, M.A., Westfall, D.P. and Buxton, I.L.O. (1988) Norepinephrine and potassium induced calcium translocation in rat vas deferens. *J. Pharm. Exp. Ther.* 246: 917-923.
- Smith, M.A., Buxton, I.L.O. and Westfall, D.P. (1988) Pharmacological classification of receptors for adenylyl purines in guinea pig myometrium. *J. Pharmacol. Exp. Ther.* 247: 1059-1063.
- Smith, M.A., Silverstein, J.L., Westfall, D.P. and Buxton, I. L.O. (1989) Dissociation between adenosine receptors and adenylate cyclase in the smooth muscle of guinea pig myometrium. *Cell Signalling* 1: 357-365.
- Khoyi, M.A., Smith, M.A., Buxton, I. L.O. and Westfall, D.P. (1989) Factors involved in the generation of tension during contraction to high potassium in the rat vas deferens. *Cell Signalling*, 1: 595-605.
- Doggwiler, K.O. and Buxton, I. L.O. (1990) Does the inositol phosphate signaling pathway function in the heart? A comparison of inositol lipid turnover in cardiac and smooth muscle. *Proc. West. Pharmacol. Soc.* 33: 111-115.

**PUBLICATIONS****Original Research Articles (continued)**

Schiemann, W.P., Walther, J.M. and Buxton, I.L.O. (1990) On the ability of endogenous adenosine to regulate purine nucleoside receptor binding of antagonists in smooth muscle membranes. *J. Pharmacol. Exp. Ther.* 255: 886-892.

Buxton, I.L.O. and Schiemann, W.P. (1991) A<sub>1</sub> adenosine receptor stimulation of IP<sub>1</sub> degradation in myometrial smooth muscle. *Proc. West Pharmacol. Soc.* 34: 261-268.

Schiemann, W.P., Westfall, D.P. and Buxton, I.L.O. (1991) Smooth muscle adenosine A<sub>1</sub> receptors couple to disparate effectors by distinct G-proteins in pregnant myometrium. *Am. J. Physiol.* 261: E141-E150.

Schiemann, W.P., Doggweiler, K.O. and Buxton, I.L.O. (1991) Action of adenosine in estrogen primed nonpregnant guinea pig myometrium: Characterization of the smooth muscle receptor and coupling to phosphoinositide metabolism. *J. Pharmacol. Exp. Ther.* 258: 429-437.

Schiemann, W.P. and Buxton, I.L.O. (1991) Adenosine A<sub>1</sub> receptor coupling to phosphoinositide metabolism in pregnant guinea pig myometrium. *Am. J. Physiol.* 261: E665-672.

Zhang, L., Horowitz, B. and Buxton, I.L.O. (1991) Muscarinic receptors in canine colonic circular smooth muscle: I. Coexistence of M<sub>2</sub> & M<sub>3</sub> receptor subtypes. *Mol. Pharmacol* 40: 943-951.

Zhang, L. and Buxton, I.L.O. (1991) Muscarinic receptors in canine colonic circular smooth muscle: II. Signal transduction. *Mol. Pharmacol* 40: 952-959.

Zhang, L., Keef, K.D., Bradley, M.E. and Buxton, I.L.O. (1992) Action of  $\alpha_{2A}$ -adrenergic receptors in circular smooth muscle of canine proximal colonic. *Am. J. Physiol.* 262: G-517-524.

Ward, S.M., Dalziel, H.H., Bradley, M.E., Buxton, I.L.O., Keef, K.D., Westfall, D.P. and Sanders, K.M. (1992) Involvement of cyclic GMP in non-adrenergic, non-cholinergic inhibitory neurotransmission in dog proximal colon. *Br. J. Pharmacol.* 107:1075-1082.

Ozaki, H., Zhang, L., Buxton, I.L.O., Sanders, K.M. and Publicover, N.G. (1992) Negative feedback regulation of excitation-contraction coupling in gastric smooth muscle. *Am J. Physiol.* 263:C1160-C1171.

Buxton, I.L.O., Cheek, D.J., Eckman, D.M., Westfall, D.P. Sanders, K.M. and Keef, K.D. (1993) NG-nitro-L-arginine methylester (L-NAME) and other alkyl esters of arginine are muscarinic receptor antagonists. *Circulation Research* 72: 387-395.

Zhang, L. and Buxton, I.L.O. (1993) Protein kinase regulation of muscarinic receptor signaling in colonic smooth muscle. *Br. J. Pharmacol.* 108: 613-621.

Smith, T.K., Ward, S.M., Zhang, L., I.L.O. Buxton, Gerthoffer, W.T., Sanders, K.M. and Keef, K.D. (1993) B-adrenergic inhibition of electrical and mechanical activity in canine colon: Role of cAMP. *Am. J. Physiol.* 264: G708-G717.

**PUBLICATIONS****Original Research Articles (continued)**

**PUBLICATIONS****Original Research Articles (continued)**

Bradley, M.E., Kuenzli, K. and Buxton, I.L.O. (1993) Adenosine-stimulated contraction in nonpregnant guinea pig myometrium does not involve cyclooxygenase. *J. Pharmacol. Exp. Ther.* 264: 1033-1039.

Zhang, L., Bradley, M.E. and Buxton, I.L.O. (1993) Inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate binding sites in smooth muscle. *Br. J. Pharmacol.* 109: 905-912.

Khoyi, M.A., Dalziel, H.H. Bjur, R.A., Gerthoffer, W.T., Zhang, L., Buxton, I.L.O. and Westfall, D.P. (1993)  $[Ca^{2+}]_i$ -sensitive,  $IP_3$ -independent  $Ca^{2+}$  influx in the smooth muscle of rat vas deferens revealed by procaine. *Br. J. Pharmacol.* 110: 1353-1358.

Eckman, D., Weinert, J., Buxton, I.L.O. and Keef, K.D. (1994) Cyclic GMP independent relaxation and hyperpolarization with acetylcholine in guinea pig coronary artery. *Br. J. Pharmacol.* 111: 1053-1060.

Yang, S., Cheek, D.J., Westfall, and Buxton, I.L.O. (1994) Purinergic axis in cardiac blood vessels: Agonist mediated release of ATP from cardiac endothelial cells. *Circulation Research* 74: 401-407.

Duckles, S.P. and Buxton, I.L.O. (1994) Neuropeptide Y potentiates norepinephrine-stimulated inositol phosphate production in the rat tail artery. *Life Sciences* 55:103-109.

Shuttleworth, C.W.R., Weinert, J.S., Sanders, K.M. and Buxton, I.L.O. (1995) Detection of nitric oxide release from canine enteric neurons. *J. Autonomic Nervous System* 56: 61-68.

Zhang, L., Bradley, M.E. and Buxton, I.L.O. (1996) Inositol phosphate binding sites and their likely role in calcium regulation in smooth muscle. Invited Review: *International J. Biochemistry* 27: 1231-1248.

Yang, S., Talbot, J.N., Buxton, I.L.O. and Bradley, M.E., (1996) Evidence for a desecrate UTP receptor in cardiac endothelial cells. *Br. J. Pharmacol.* 117:1572-1578.

Kuenzli, K.A., Bradley, M.E. and Buxton, I.L.O. (1996) Cyclic GMP-independent effects of nitric oxide in guinea pig uterine contractility. *Br. J. Pharmacol* 119: 737-743.

Smith, A.D., Cheek, D.J., Buxton, I.L.O. and Westfall, D.P. (1997) Competition of adenine nucleotides for a 1,3- $[^3H]$ -dipropyl-8-cyclopentylxanthine binding site in vas deferens. *Exp. Pharmacol. And Physiol.* 24:492-497.

Kuenzli, K., Buxton, I.L.O. and Bradley, M.E., (1998) Guanylyl cyclase is not required for nitric oxide relaxations in monkey myometrium. *Br. J. Pharmacology.* 124: 63-68.

Bradley, K.K., Buxton, I.L.O. Barber, J.E., McGaw, T. and Bradley, M.E. (1998) Nitric oxide relaxes human myometrium by a cGMP-independent mechanism. *Am. J. Physiol. Cell* 275: C1668-1673.

Oxhorn, B.C., Cheek, D.J. and Buxton, I.L.O. (2000) On the role of nucleotides and nucleosides in the regulation of blood flow. *AACN Clinical Issues* May 11(2): 241-251.

Buxton, I.L.O., Crow, W. and Mathew, S.O. (2000) Regulation of uterine contraction: Mechanisms in preterm labor. *AACN Clinical Issues* May 11(2): 271-282.

**PUBLICATIONS****Original Research Articles (continued)**

Buxton, I.L.O., Kaiser, R.A., Malmquist, N.A. and Tichenor, S. (2001) NO-induced relaxation of labouring and non-labouring human myometrium is not mediated by cGMP. *Br. J. Pharmacol.* 134: 206-214.

Buxton, I.L.O., Kaiser, R.A., Oxhorn, B.C. and Cheek, D.J. (2001) Evidence supporting the *Nucleotide Axis Hypothesis*: ATP Release and metabolism by coronary endothelium. *Am. J. Physiol: Heart and Circulatory* 281:H1657-1666.

Anzinger, J., Malmquist, N.A., Gould, J. and Buxton, I.L.O. (2001) Secretion of a nucleoside diphospho kinase (Nm23-H2) by cells from human breast, colon, pancreas and lung tumors. *Proc. West Pharmacol. Soc.* 44:61-63.

Tangredi, J.F. and Buxton, I.L.O. (2001) Hypertension as a complication of topical testosterone therapy. *Annals of Pharmacotherapy* 35:1205-1207.

Tichenor, S., Malmquist, N.A. and Buxton, I.L.O. (2001) Actions of S-nitroso N-acetyl penicillamine and 3-morpholinonydonimine may involve disparate signaling pathways in myometrial smooth muscle. *Proc. West Pharmacol. Soc.* 44:53-56.

Malmquist, N.A., Anzinger, J.J., Hirzel, D. and Buxton, I.L.O. (2001) Ellagic acid inhibits nucleoside diphosphate kinase-b activity. *Proc. West Pharmacol. Soc.* 44: 57-59.

Kaiser, R.A. and I.L.O. Buxton (2001) Endothelium-dependent, MRS2179-independent actions of uridine 5'-triphosphate in guinea pig aorta. *Proc. West Pharmacol. Soc.* 44:49-51.

Oxhorn, B.C., Wadia, R. and Buxton, I.L.O. (2001) Caspase-3 is localized to endothelial caveolar domains. *Proc. West Pharmacol. Soc.* 44:45-48.

Kaiser, R.A. and Buxton, I.L.O. (2002) Nucleotide-mediated relaxation in guinea pig aorta: Selective inhibition by MRS2179. *Br. J. Pharmacol.* 135:537-545.

Oxhorn, B.C. and Buxton, I.L.O. (2002) Isolation and characterization of large numbers of endothelial cells for studies of caveolar signaling. *Journal of Microvascular Research* 64:302-315.

Tichenor, S.D., Buxton, I.L.O., Johnson, P., O'Driscoll, K. and Keef, K.D. (2002) Excitatory motor innervation in the canine rectoanal region: Role of changing receptor populations. *Br. J. Pharmacol.* 137:1321-1329.

Kaiser, R.A., Andrews, G., Oxhorn, B.C. and Buxton, I.L.O. (2002) Functional compartmentation of endothelial P2Y receptor signaling. *Circulation Research* 91:292-299.

Mazzone, J.N., Kaiser, R.A. and Buxton, I.L.O. (2002) Calcium-Activated potassium channel expression in human myometrium: Effect of pregnancy. *Proc. West Pharmacol. Soc.* 45:184-186.

Mazzone, J. and Buxton, I.L.O. (2003) Changes in small conductance potassium channel expression in human myometrium during pregnancy measured by RT-PCR. *Proc. West Pharmacol. Soc.* 46: 74-77.

**PUBLICATIONS****Original Research Articles (continued)**

- Oxhorn, B.C. and Buxton, I.L.O. (2003) Caveolar compartmentation of caspase-3 in cardiac endothelial cells. *Cellular Signalling* 15:489-496.
- Tichenor, S. and Buxton, I.L.O. (2003) Dissociation of cGMP and relaxation in myometrial smooth muscle: Effects of S-Nitroso N-acetylpenicillamine and 3-morpholiosyndonimine. *Cellular Signalling* 15:763-772
- Buxton, N.D., Kaiser, R.A. and Buxton, I.L.O. (2003) Vascular actions of the polyphenolic catechin gallate EGCG: Endothelium-dependent contraction and relaxation. *Proc. West Pharmacol. Soc.* 46:37-38.
- Buxton, I.L. (2003) What is it about the Uterus Anyway? *Proc. West. Pharmacol. Soc.* 46:1-8.
- Kaiser, R.A. and Buxton, I.L.O. (2004) Nucleotides in the blood stream. *Proc. West. Pharmacol. Soc.* 47:5-15.
- Buxton, I.L.O. (2004) Regulation of uterine function: A biochemical conundrum in the regulation of smooth muscle relaxation. *Molecular Pharmacology* 65:1051-1059.
- Matthews, J., Pingle, M., Sullivan, R., Ferguson, P., Rogers, J.E. and Buxton, I.L.O. (2005) *Invited Review*: Economic justification for a public school of pharmacy: Lessons for Nevada *Proc. West. Pharmacol. Soc.* 48: 1-12.
- Tichenor, J.N., Hansen, E.T. and Buxton, I.L.O. (2005) Expression of stretch-activated potassium channels in human myometrium. *Proc. West. Pharmacol. Soc.* 48: 44-48.
- Oxhorn, B.C., Sanguinetti, A.R., Mastick, C.C. and Buxton, I.L.O. (2005) c-Abl is required for staurosporine-induced caspase activity. *Proc. West. Pharmacol. Soc.* 48: 110-117.
- Buxton, I.L.O. and Vittori, J.C. (2005) Cholesterol depletion enhances both spontaneous and agonist-evoked uterine smooth muscle contractions in a reversible manner. *Proc. West. Pharmacol. Soc.* 48: 126-128.
- Rumjahn, S.M, Baldwin, K. and Buxton, I.L.O. (2007) P2Y receptor-mediated angiogenesis via vascular endothelial growth factor receptor 2 signaling. *Proc. West. Pharmacol. Soc.* 50: 58-60.
- Rumjahn, S.M, Javed, M.A., Wong, N., Law, W.E. and Buxton, I.L.O. (2007) Purinergic regulation of angiogenesis by human breast carcinoma-secreted NDPK *Br. J. of Cancer* 97(10):1372-80.
- Buxton, I.L.O., Adams, J.Q., Gore, M. and Sullivan, C.R. (2007) Validation of the CSI Health Station 6K Blood Pressure Kiosk<sup>®</sup> *Proc West Pharmacol Soc* 50: 180-183.
- Buxton, I.L., Duan, D. (2008) Cyclic GMP/protein kinase G phosphorylation of Smad3 blocks transforming growth factor-beta-induced nuclear Smad translocation: a key antifibrogenic mechanism of atrial natriuretic peptide. *Circ Res.* 102(2):151-3.
- Buxton, I.L.O. (2008) Nitric oxide stimulation of cGMP accumulation in myometrial cells from pregnant women is antagonized by oxytocin. *Proc. West. Pharmacol. Soc.* 51: 78-82.
- Buxton, I.L.O. and Anzinger, J.J. (2008) Agonist-specific regulation of inositol phosphate metabolism in cardiac endothelial cells. *Proc. West. Pharmacol. Soc.* 51: 23-26.

**PUBLICATIONS****Original Research Articles (continued)**

Buxton, I.L.O. (2008) Inhibition of nm23 gene product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs. *Proc. West. Pharmacol. Soc.* 51: 30-34

Rumjahn, S.M, Yokdang, N, Baldwin, K.A., Thai, J. and Buxton, I.L.O. (2009) Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis. *Br. J. of Cancer* 100: 1465-1470.

Yokdang, N., Buxton, N.D. and Buxton, I.L.O. (2009) Measurement of human breast tumor cell-secreted shNDPK-B in a murine breast cancer model suggests its role in metastatic progression. *Proc. West. Pharmacol. Soc.* 52: 88-91.

Buxton, ILO, Yokdang, N. and Matz, R.M. (2010) Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. *Cancer Letters* 291:131-141.

Buxton, I.L.O., Singer, C.A., and Tichenor, J.N. (2010) Regulation of stretch-activated two-pore potassium channels in human myometrium in pregnancy and labor. *PLoS One* Aug 25;5(8). pii: e12372.

Buxton, I.L., Milton, D.L., Barnett, S., Tichenor, S.D. (2010) Agonist-specific compartmentation of cGMP action in guinea pig myometrium. *J. Pharmacol. Exp. Ther.* Oct;335(1):256-63. PMID: 20811500.

Yokdang, N., Tellez, J., Tian, H., Norvell, J., Barsky, S.H., Valencik, M. and Buxton, I.L.O. (2011) A Role for nucleotides in support of breast cancer angiogenesis: Heterologous receptor signaling. *British Journal of Cancer*, May 10;104(10):1628-40. PMID: 21505453.

Buxton, I.L.O., Heyman, N., Wu, Y-Y, Barnett, S. and Ulrich, C. (2011) A role for stretch-activated potassium currents in the regulation of uterine smooth muscle contraction. *Acta Pharmacologica Sinica* 32(6):758-64. PMID: 21642947

Yokdang, N. and Buxton, I.L.O. (2011) Extracellular NM23 signaling in breast cancer: *Incommodus Verum. Cancers* 3: 2844-2857 doi: 10.3390.

Ulrich, C., Quillici, D., Schegg, K., Woolsey, R., Nordmeier, A. and Buxton, I.L.O. (2012) The uterine smooth muscle S-nitrosoproteome in pregnancy. *Mol. Pharm.* 81: 143-153.

Wu, Y-Y, Singer, C.A. and Buxton, I.L.O. (2012) Variants of stretch-activated 2-pore potassium channel TREK-1 associated with preterm labor in humans. *Biology of Reproduction* 87(4):96. PMID: 22811574

Burkin, H., Rice, M., Sarathy, A., Thompson, S., Singer, C.A. and Buxton, I.L.O. (2013) Integrin upregulation and localization to focal adhesion sites in pregnant human myometrium. *Reproductive Sciences* 20(7):804-12. PMID 23298868.

Heyman, N.S., Cowles, C.L., Barnett, S.D., Wu, Y-Y, Singer, C.A., Leblanc, N. and Buxton, I.L.O. (2013) Regulation of TREK-1 currents in smooth muscle cells from pregnant human myometrium. *Am. J. Physiology* 15;305(6):C632-42. PMID: 23804201

Ulrich, C., Quillici, D.R., Schlauch, K.A. and Buxton, I.L.O. (2013) The human uterine smooth muscle S-nitrosoproteome fingerprint in pregnancy, labor and preterm labor. *Am. Journal of Physiology, Cell Physiology* 305(8):C803-16. PMID: 23948706.



**PUBLICATIONS****Original Research Articles (continued)**

Ulrich, C., Quilici, D.R., Schlauch, K.A. and Buxton, I.L.O. (2015) Proteomic Network Analysis of Human Uterine Smooth Muscle in Pregnancy, Labor, and Preterm Labor. *Integrative Molecular Medicine* 2(4): 261-269.

Buxton, ILO and Nordmeier, S. (2015) Rethinking NM23: An extracellular role for NDPKinase in breast cancer. *Integrative Cancer Science and Therapeutics*. 2(3): 153-157.

Ulrich, C., Quilici, D.R., Schlauch, K.A., Burkin, H.R. and Buxton, I.L.O. (2015) LC/MS/MS Analysis of the Human Uterine Smooth Muscle S-nitrosoproteome Fingerprint in Pregnancy, Labor, and Preterm Labor, *Data Brief*. Aug 1;4:591-4. doi: 10.1016/j.dib.2015.07.031

Yokdang, N., Wong, S., Spiers, K., Burkin, H.R. and Buxton, I.L.O. (2015) Blockade of Nucleoside Diphosphate Kinase or its Endothelial Target Slows Breast Cancer Growth and Metastasis. *Integrative Cancer Science and Therapeutics*. 2(4): 192-200.

Cowles, C.L., Wu, Y-Y., Barnett, S.D., Lee, M.T., Burkin, H.R. and Buxton, I.L.O. (2015) Alternatively Spliced Human TREK-1 Variants Alter TREK-1 Channel Function and Localization. *Biology of Reproduction* Sep 23. pii: biolreprod.115.129791.PMID 26400398.

Barnett, S.D. and Buxton, I.L.O. (2017) The Role of S-Nitrosoglutathione Reductase (GSNOR) in Disease and Therapy. *Critical Reviews in Biochemistry and Molecular Biology*. Jun;52(3):340-354. doi: 10.1080/10409238.2017.1304353. Epub 2017 Apr 10.

Barnett, S.D., Smith, C., Ulrich, C., Baker, J. and Buxton, I.L.O. (2018) S-Nitrosoglutathione Reductase Underlies the Dysfunctional Relaxation to Nitric Oxide in Preterm Labor. *Nature-Scientific Reports*. Apr 4;8(1):5614. doi: 10.1038/s41598-018-23371-w..

Copley-Salem, C., Ulrich, C., Quilici, D., Schlauch, K., Buxton, I.L.O., and Burkin, H.R. (2018) Mechanical strain induced phospho-proteomic signaling in uterine smooth muscle cells. *Journal of Biomechanics*. May 17;73:99-107. doi: 10.1016/j.jbiomech.2018.03.040. Epub 2018 Mar 30.

Ulrich, C., Burkin, H.R., Quilici, D., Buxton, I.L.O. and Schlauch, K. (2018) Isobaric TMT 10-plex labeled MultiNotch MS3 analysis of human uterine smooth muscle shows differences in protein expression patterns in disparate states of human pregnancy. *PLoS One*. In press

Barnett, S. D., and Buxton, I.L.O. (2018) Hiding in Plain Sight: Nebivolol Exhibits Strong Tocolytic Properties. *Journal of Cellular and Molecular Medicine*. 2018 Dec;22(12):6391-6395. doi: 10.1111/jcmm.13883

Duan S., Chan, W.K., Oman, A., Basile, D.P., Alvira, C.M., Buxton, I.L.O. and Iosef, C. (2019) NF- $\kappa$ B/NKILA signaling modulates the anti-cancerous effects of EZH2 inhibition. *J. Cellular and Molecular Medicine*. Jul 7: 1-11; PMID: 31282094.

**Original Research Articles (submitted, in revision or in preparation)**

Duan, S., Nordmeier, S., Bynes, A.E. and Buxton, I.L.O. (2018) Exosome-mediated purinergic signaling contributes to host microenvironment plasticity and metastasis in triple negative breast cancer. *Molecular Cancers*, In Revision.

Ulrich, C., Barnett, S., Burkin, H. and Buxton, I.L.O. Nitrosation of the TREK-1 Potassium Channel on CYS 207 leads to Channel Activation: Evidence for the cGMP-independent effect of NO-mediated Uterine Relaxation. *Science* (in preparation).

**Research Abstracts**

- Buxton, I.L.O. (1969) Hybridization of two species of *Xenopus*. Presented: *S. Cal. Acad. Sci. Ann. Meeting*, Pasadena, CA.
- McGowan, J., Buxton, I.L.O. and Sayre F. (1976) Amino acid balance and protein synthesis. *Am. Chem. Soc. Abstracts* 172 *ACS: Abstract Biol.* 214.
- Buxton, I.L.O. and Brunton, L.L. (1982) Compartmentation of cyclic AMP and protein kinase in mammalian cardiomyocytes. *Fed. Proc.* 41: 1726.
- Buxton, I.L.O. and Brunton, L.L. (1982) Compartmentation in mammalian cardiomyocytes. *Drug. Intel. Clin. Pharm.* 16: 736.
- Buxton, I.L.O. and Brunton, L.L. (1983)  $\beta$ -receptor subtypes,  $Ca^{+2}$  flux and activation of particulate cyclic AMP-protein kinase in cardiomyocytes. *Fed. Proc.* 42: 2253.
- Brunton, L.L. and Buxton, I.L.O. (1984) Hormonally specific activation of cAMP-protein kinase in subcellular compartments of mammalian cardiomyocytes. *Adv. Cyclic Nucleotide Res.* 17A: 149.
- Buxton, I.L.O., Rozansky, D. and Motulsky, H.J. (1984) The effects of  $Na^{+}$  on the cholinergic muscarinic receptor of rat myocardium. *Fed. Proc.* 43: 872.
- Brunton, L.L. and Buxton, I.L.O. (1985)  $\alpha_1$ -receptors on adult rat cardiomyocytes: Effects of GTP on agonist affinity and relationship to cyclic AMP (cAMP) and cAMP-protein kinase (cAMP-PK). *Fed. Proc.* 44(3): 880.
- Buxton, I.L.O., Watson, M.J. and Brunton, L.L. (1985) Mechanism of action of the cardiac  $\alpha$ -receptor: activation of cyclic AMP (cAMP) degradation. *Fed. Proc.* 44(3): 780.
- Brown, J.H., Solski, P., Buxton, I.L.O. and Brunton, L.L. (1985) Phosphoinositide turnover in rat cardiomyocytes is stimulated through an  $\alpha$ -adrenergic receptor. *Fed. Proc.* 44(3): 508.
- Bell, J.D., Buxton, I.L.O. and Brunton, L.L. (1985) Phorbol ester enhances adenylate cyclase activity in S49 lymphoma cells. *Fed. Proc.* 44(3): 696.
- Terman, B.I., Buxton, I.L.O. and Insel, P.A. (1985) Photoaffinity labeling at the cardiac  $\alpha_1$ -adrenergic receptor. *Fed. Proc.* 44(3): 1472.
- Goldberg, D.I., Buxton, I.L.O., and Khoo, J.C. (1985) Activation of myocardial hormone-sensitive lipase (HSL) and cholesterol esterase by cAMP-dependent protein kinase (cA-PK). *Fed. Proc.* 44(3): 1892.
- Buxton, I.L.O. and Bowen, S.M. (1986) Histamine receptors on adult rat cardiomyocytes: antagonism of  $\alpha$ -1 receptor stimulation of cAMP degradation. *Fed. Proc.* 45(3): 217.
- Dunkin, B.J., Silverstien, J.L., Eckert, K.H. and Buxton, I.L.O. (1987) Phorbol ester attenuates both cyclic AMP and inositol trisphosphate accumulation in a smooth muscle cell line. *Clin. Res.* 35: 103A.
- Buxton, I.L.O. (1987)  $\alpha_1$  receptor stimulation of inositol trisphosphate formation in the adult rat cardiac myocyte is inhibited by phorbol ester. *Fed. Proc.* 46: 1623.
- Smith, M.A., Buxton, I.L.O. and Westfall, D.P. (1987) Classification of adenosine receptor in guinea pig uterus. *Fed. Proc.* 46(2): 6577.

**PUBLICATIONS****Research Abstracts (continued)**

Smith, M.A., Westfall, D.P. and Buxton, I.L.O. (1988) Direct analysis of purine receptors in the smooth muscle of guinea pig myometrium. *FASEB J.* 2: 1132.

Doggwiler, K.O. and Buxton, I.L.O. (1988) Characterization of receptors for adenosine and ATP on the adult cardiac myocyte. *FASEB J.* 2:1809.

Buxton, I.L.O. (1988)  $\alpha$ -adrenergic mechanisms in cardiac endothelial cells: release of adenylyl purine. *FASEB J.* 2: 711.

Buxton, I.L.O. and Casey, K.M. (1988)  $\alpha$ -adrenergic receptors in the circular muscle of dog colon. *Gastroenterology* 95: 894.

Khoyi, M.A., Smith, M.A., Buxton, I.L.O. and Westfall, D.P. (1988) Effects of  $K^+$  on calcium influx and inositol trisphosphate (IP<sub>3</sub>) generation in the rat vas deferens. *The Pharmacologist* 30: A138.

Schiemann, W.P., Westfall, D.P. and Buxton, I.L.O. (1989) The adenosine A<sub>1</sub> receptor in pregnant guinea-pig myometrium. *FASEB J.* 3: A1285.

Doggwiler, K.O. and Buxton, I.L.O. (1989) Inositol phospholipids and inositol phosphates in cardiac myocyte signal transduction. *FASEB J.* 3: A1297.

Casey, K.M. and Buxton, I.L.O. (1989)  $\alpha$ -adrenergic receptors in circular muscle of canine colon. *Proc. West Pharmacol. Soc.* 32: 330.

Buxton, I.L.O., Schiemann, W., Smith, M. and Westfall, D.P. (1989) Receptor-signal coupling of the smooth muscle purine nucleoside receptor subserving contraction in guinea pig myometrium changes during pregnancy. *NIH Dialog in Science: Purine Nucleosides and Nucleotides in Cell Signaling*. Bethesda, MD.

Buxton, I.L.O., Walther, J. and Westfall, D.P. (1990)  $\alpha$ -adrenergic receptor stimulated release of ATP from cardiac endothelial cells in primary culture. *Annals of the New York Academy of Science. Biological Actions of Extracellular ATP: Abst.* 13C-II.

Doggwiler, K.O. and Buxton, I.L.O. (1990) Does inositol-1,4,5-trisphosphate signaling function in the heart? *Proc. West Pharmacol. Soc.* 33: 111.

Schiemann, W.P. and Buxton, I.L.O. (1990) Adenosine receptor mediated inositol phosphate metabolism in uterine smooth muscle. *Proc. West Pharmacol. Soc.* 33: 287.

Buxton, I.L.O. and Walther, J. (1990) ATP release from endothelial cells is associated with IP<sub>3</sub> formation and increased  $[Ca^{+2}]_i$  accumulation. *Proc. West Pharmacol. Soc.* 33: 274.

Buxton, I.L.O. Walther, J. and Westfall, D.P. (1990) Purinergic mechanisms in cardiac blood vessels: Stimulation of endothelial cell  $\alpha_1$  receptors in vitro by the neurotransmitter norepinephrine leads to the rapid release of ATP and its subsequent breakdown to adenosine. *Heart and Vessels* S4: 27.

Zhang, L. and Buxton, I.L.O. (1991) M<sub>2</sub> & M<sub>3</sub> muscarinic receptors coexist in canine colonic smooth muscle. *FASEB J.* 5: A1586.

Buxton, I.L.O. and Schiemann, W.P. (1991) Purinergic receptor coupling to IP-1 dephosphorylation in smooth muscle from guinea pig uterus. *FASEB J.* 5: A796.

**PUBLICATIONS****Research Abstracts (continued)**

- Bradley, M.E. and Buxton, I.L.O. (1991) Adenosine stimulated increases in intracellular calcium in cultured guinea pig uterine smooth muscle cells. *J. Cell Biol.* 115: 22a.
- Smith, T.K., Ward, S.M., Buxton, I.L.O., Frey, B.W., Zhang, L., Sanders, K.M. and Keef, K.D. (1991) Effects of  $\beta$ -receptor stimulation through the thickness of the circular muscle of the canine proximal colon: Role of cAMP. *Gastroenterology* 98: A559.
- Zhang, L., Bradley, M.E. and Buxton, I.L.O. (1991) Characterization of Inositol 1,4,5-triphosphate and Inositol 1,3,4,5-tetrakisphosphate binding sites in canine colonic smooth muscle. *J. Cell Biol.* 115: 250a.
- Yang, S. and Buxton, I.L.O. (1991) ATP release from cardiac endothelial cells is mediated by a variety of receptors. *J. Cell Biol.* 115: 365a.
- Bradley, M.E., Kuenzli, K.A. and I.L.O. Buxton (1992) Adenosine stimulated contraction in isolated, non-pregnant myometrium may not require prostaglandin production. *FASEB J.* 6: A429.
- Zhang, L. and Buxton, I.L.O. (1992) Effects of protein kinases on muscarinic responses in canine colonic circular smooth muscle. *FASEB J.* 6: A4047.
- Zhang, L., Gerthoffer, W.T. and I.L.O. Buxton (1992) Inhibition of canine colonic motility by 5-hydroxytryptamine. 2nd. International Symposium on Serotonin. Houston, TX 9-15-92.
- Cheek, D.J., Eckman, D.M., Buxton, I.L.O. and Keef, K.D. (1992) N<sup>G</sup>-Nitro L-arginine methyl ester and other alkyl esters of L-arginine are muscarinic antagonists. *Gastroenterology* 103:(4) 1382.
- Zhang, L. Gerthoffer, W.T. and Buxton, I.L.O. (1992) The action of 5-hydroxytryptamine on canine colonic motility. *Gastroenterology* 103:(4) 1380.
- Gerthoffer, W.T., Hamelin, M., Buxton, I.L.O. and Zhang, L. (1992) Mechanisms of contractile system sensitization of circular smooth muscle of canine colon. *Gastroenterology* 103:(4) 1381.
- Buxton, I.L.O., Cheek, D.J., Westfall, D.P and Yang, S. (1993) Characterization of an ecto-nucleoside diphosphate kinase on the cardiac endothelial cell. *Biophysical Journal* 2(2):A236.
- Russell, S.N., Horner, M.A., Westfall, D.P., Buxton, I.L.O. and Horowitz, B. (1993) Characterization and functional expression of the ATP receptor in vas deferens smooth muscle. *Biophysical Journal* 2(2):A84.
- Buxton, I.L.O. and Zhang, L. (1993) Serotonin receptors in canine colonic circular smooth muscle: inhibition of contraction. *FASEB J.* 7(3) A27.
- Zhang, L., Horowitz, B., Zhong, S. and Buxton, I.L.O. (1993) Characterization of muscarinic receptors in canine colonic longitudinal smooth muscle. *FASEB J.* 7(3) A26.
- Yang, S., Cheek, D.J. and Buxton, I.L.O. (1993) Characterization of an ecto-nucleoside diphosphate kinase activity on cardiac endothelium. *Proc. West. Pharmacol. Soc.* 36: 391.
- Zhang, L. and Buxton, I.L.O. (1993) Adenosine and purine nucleotides relax uterine artery in late pregnancy. *Proc. West. Pharmacol. Soc.* 36: 392.

**PUBLICATIONS****Research Abstracts** (continued)

Buxton, I.L.O. and Duckles, S. (1993) Neuropeptide Y potentiates norepinephrine-stimulated inositol phosphate production in the rat tail artery. *Proc. West. Pharmacol. Soc.* 36: 339.

Kuenzli, K.A., Bradley, M.E. and Buxton, I.L.O. (1993) Relaxation by nitric oxide in pregnant and nonpregnant guinea pig uterus. *Proc. West. Pharmacol. Soc.* 36: 361.

Weinert, J., Dalziel, H.H., Bradley, M.E., Westfall, D.P. and Buxton, I.L.O. (1993) Binding studies of the P<sub>2</sub> receptor subclasses present in tenia coli and vas deferens. *Proc. West. Pharmacol. Soc.* 36: 387.

Eckman, D.M., Cheek, D., Buxton, I.L.O. and Keef, K.D. (1993) Comparison of the actions of acetylcholine and L-nitrosocysteine in the guinea pig coronary artery. *Proc. West. Pharmacol. Soc.* 36: 346.

Cheek, D.J., Yang, S. and Buxton, I.L.O. (1993) Nucleoside diphosphate kinase (NDPK) and adenylate kinase (AdK) activities on K562 human leukemia cells are *ecto*-enzymes. *Proc. West. Pharmacol. Soc.* 36: 340.

Weinert, J., Sanders, K.M. and Buxton, I.L.O. (1993) Highly sensitive direct measurement of nitric oxide. *The Pharmacologist* 35(3):162.

Yang, S. and Buxton, I.L.O. (1993) Purinergic and pyrimidinergetic regulation of cytosolic free Ca<sup>2+</sup> ([Ca<sup>2+</sup>]<sub>i</sub>) in single guinea pig cardiac endothelial cells. *The Pharmacologist* 35(3):140.

Cheek, D.J., Yang, S. and Buxton, I.L.O. (1993) Uridine diphosphate does not inhibit the *ecto*-nucleoside diphosphate kinase of cardiac endothelial cells. *The Pharmacologist* 35(3):158.

Bradley, M.E. and Buxton, I.L.O. (1993) Simultaneous measurement of force and intracellular calcium in nonpregnant guinea pig myometrium. *The Pharmacologist* 35(3):153.

Shuttleworth, C.W.R., Weinert, J., Sanders, K.M. and Buxton, I.L.O. (1994) Evidence for nitric oxide release from canine colon. *Proc. West. Pharmacol. Soc.* 37: 182.

Cheek, D.J. and Buxton, I.L.O. (1994) Endothelial cells express extracellularly-directed nucleoside diphosphate (NDPK) and adenylate kinase (AdK) activities. *Proc. West. Pharmacol. Soc.* 37: 179.

Kuenzli, K.A., Bradley, M.E. and Buxton, I.L.O. (1994) Nitric oxide relaxation of uterine smooth muscle is not dependent upon elevations in intracellular cGMP. *FASEB J.* 8: A367.

Bradley, M.E., Kuenzli, K.A. and Buxton, I.L.O. (1994) Inhibition of spontaneous activity by adenylyl purines in monkey uterine smooth muscle. *FASEB J.* 8: A91.

Pearce, W.J., White, C.R., Zhang, L. and Buxton, I.L.O. (1994) Simultaneous measurements of force and IP<sub>3</sub> accumulation in newborn and adult cerebral arteries. *FASEB J.* 8: A557.

Ketcham, W., Eckman, D.M., Buxton, I.L.O. and Keef, K.D. (1994) Scorpion venom contains a specific blocker of the endothelium-derived hyperpolarizing factor (EDHF) pathway in guinea pig coronary artery. *Clin. Research* 42(1) 16A-1.

Barta, G.E.A., Bradley, M.E. and I.L.O. Buxton (1994) Adenosine modulation of oxytocin-induced contraction in nonpregnant human myometrium. *Clin. Research.* 42(1) 16A-5.

**PUBLICATIONS****Research Abstracts (continued)**

- Shuttleworth, C.W.R., Weinert, J., Buxton, I.L.O. and Sanders, K.M. (1994) Detection of nitric oxides released from canine proximal colon. *Gastroenterology* 106(4) A840.
- Cheek, D.J. and Buxton, I.L.O. (1994) Nucleoside diphosphate kinase (NDPK) and adenylate kinase (AdK) are expressed as *ecto*-enzymes on cardiac endothelial cells. *Drug Development Research* 31(4): 255.
- Buxton, I.L.O. (1994) On the origin of extracellular ATP in cardiac blood vessels: A dual role for endothelium. *Drug Development Research* 31(4): 252.
- Bradley, M.E., Kuenzli, K.A. and Buxton, I.L.O. (1994) Inhibition of spontaneous activity by adenylyl purines in monkey uterine smooth muscle. *Drug Development Research* 31(4): 254.
- Brave, S. R., Bradley, M.E. and Buxton, I.L.O. (1995) Role of phosphodiesterases in regulation of colonic motility. *Biophysical Journal* 68: A278.
- Cheek, D.J. and Buxton, I.L.O. (1995) Extracellular ATP generation in guinea pig coronary artery: Role of extracellularly directed kinases. *Proc. West. Pharmacol. Soc.* 38: 159.
- Buxton, I.L.O. (1995) Novel mechanisms of purine nucleotides in coronary artery. *Proc. West. Pharmacol. Soc.* 38: 153.
- Bradley, M.E., Kuenzli, K.A. and Buxton, I.L.O. (1995) Nitric oxide induced relaxation in uterine smooth muscle. *Proc. West. Pharmacol. Soc.* 38: 155.
- Probert, C.B., Buxton, I.L.O. and Bradley, M.E. (1995) Evidence for a distinct pyrimidinergic receptor in coronary endothelial cells. *J. Invest. Med.* 43:(S) 102A.
- Kuenzli, K.A., Bradley, M.E. and Buxton, I.L.O. (1995) Agonist-induced contractions are relaxed by nitric oxide in an agonist- and tissue-specific manner in pregnant and nonpregnant guinea pig uterus. *Biophysical Journal* 68: A388.
- Kuenzli, K.A., Buxton, I.L.O. and Bradley, M.E. (1996) Nitric oxide modulates monkey uterine contractile activity via TEA-sensitive guanylyl cyclase-independent mechanism. *J. Soc. Gynecological Invest.* 3(2): 337A, 559.
- Hudson, S.A.F., Cheek, D. J. and Buxton, I.L.O. (1996) A role for the Nm23 gene product in human breast cancer metastasis. *Journal of Investigative Medicine* 44(1): A64.
- Smith, A.D., Cheek, D.J., Buxton, I.L.O. and Westfall, D.P. (1996) Competition of ATP for [<sup>3</sup>H]DPCPX binding in rat vas deferens. *FASEB Journal* 10(3): 919.
- Bradley, M.E., Probert, C.B. and Buxton, I.L.O. (1995) Evidence for a discrete UTP receptor in cultured coronary endothelial cells. *FASEB* (Presented at the ASPET Colloquium in Atlanta GA, 1995; Reported in *J. Pharmacology and Exp. Ther.* 277:1-9).
- Bradley, M.E., Kuenzli, K.A., Barber, J.E. and Buxton, I.L.O. (1995) Nitric oxide induced changes in cGMP and tension in human and monkey myometrium. *Biophysical Journal.* 68: A389.
- Smith, A.D., Cheek, D.J., Buxton, I.L.O. and Westfall, D.P. (1996) Binding of the adenosine A1 receptor antagonist, [<sup>3</sup>H]DPCPX, to an atypical purinoceptor in rat vas deferens. *Proceedings of the Western Pharmacology Society* 39: 100.

**PUBLICATIONS****Research Abstracts** (continued)

Bradley, M.E., Kuenzli, K.A., Barber, J.E., McGaw, T. and Buxton, I.L.O. (1997) Involvement of  $\text{Ca}^{2+}$ -activated potassium channels, and not cGMP, in nitric oxide relaxation of human myometrium. *The Pharmacologist* 39(1): A174, p53.

Sullivan, L.T., Schooley, D.A. and Buxton, I.L.O. (1998) Helicokinin II stimulates  $\text{IP}_3$  accumulation in the convoluted Malpighian tubule of the tobacco hornworm (*Manduca sexta*). *FASEB Journal* 12(4):A126.

Martin, S., Kaiser, R., Bradley, M.E. and Buxton, I.L.O. (1998) Nitric oxide-mediated relaxation of oxytocin-induced contraction in human uterus is cGMP-independent and blocked by  $\text{Ca}^{2+}$ -activated potassium channel inhibitors. *FASEB Journal* 12(4):A141.

Buxton, I. L. O. and Cheek, D. J. (1998) The purinergic axis hypothesis: Evidence in intact heart of the functional expression of ADP-kinase. *FASEB Journal* 12(4):A188.

Satterwhite, J., Duffy, J. and Buxton, I.L.O. (1998) Human breast cancer cells in culture express a nucleoside diphosphate kinase and generate extracellular ATP. *FASEB Journal* 12(4):A441.

Buxton, I.L.O. (1998) The Purinergic Axis Hypothesis: Evidence of endothelium-dependent release of ATP in coronary artery. *Vascular Biology* 98. AHA Meeting Abstracts A33:9.

Buxton, I.L.O. (1998) Evidence in support of a purinergic axis in cardiac blood vessels of Guinea pig. Keystone Symposium: Endothelium. Lake Tahoe, Nevada, 1998.

Zhang, L., Yang, S., Gerthoffer, W. T. and Buxton, I.L.O. Serotonin suppresses intracellular calcium and contraction of canine colon: A role for cyclic nucleotide. *Naunyn-Schmiedeberg's Archives of Pharmacology* 358 (1) Suppl 1: R103, 1998.

Buxton, I.L.O. (1998) The Purinergic Axis Hypothesis: Evidence of agonist-specific release of ATP in a tissue culture model of endothelium. *Proc. West. Pharmacol. Soc.* Volume 41: T-10, p44.

Zhang, L., Yang, S., Horowitz, B. and Buxton, I. L. O.: Muscarinic receptor subtypes and their signaling pathways in colon longitudinal smooth muscle. *Naunyn-Schmiedeberg's Archives of Pharmacology* 358(1) Suppl: R84, 1998.

Buxton, I.L.O. and Cheek, D. J. (1998) Agonist-mediated ATP release in coronary artery: Evidence in support of the Purinergic Axis Hypothesis. *The Physiologist* 41(4): 276.

Buxton, I.L.O. and Zhong, Q (1999) 3-Hydroxy-2-methyl-5-[(phosphonoxy) methyl]-4-pyridinecarboxaldehyde inhibits P2y1 and P2y2 but not P2y4 receptor mediated calcium release in cardiac endothelial cells. *Proc. West. Pharmacol. Soc.* Volume 42: 137.

Satterwhite, J. and Buxton, I.L.O. (1999) Human breast cancer cells secrete Nm23h2 a nucleoside diphosphate kinase. *Proc. West. Pharmacol. Soc.* Volume 42: 140.

Tichenor, S., Oxhorn, B.C. and Buxton, I.L.O. (1999) Cellular release of ATP is correlated with expression of CFTR but not P-glycoprotein., *Proc. West. Pharmacol. Soc.* Volume 42: 133.

Keef, K.D., Tichenor, S.D. and Buxton, I.L.O. (1999) Motor innervation of the rectoanal region. 17<sup>th</sup> International Symposium on Gastrointestinal Motility, Bruges Belgium. September, 1999.

Netski, D., Hudig, D., Buxton, I.L.O., Zhong, Q., Grinsell, Kozel, T. and Washburn, R. (1999) *Proceedings*, International Conference on Cryptococcosis, London, 7, p148.

**PUBLICATIONS****Research Abstracts (continued)**

- Pritchard, M., Zhang, Q., Buxton, I.L.O., St. Jeor, S. and Pari, G.S. (1999) Construction of a human cytomegalovirus null mutant: Genetic evidence that UL84 is essential for viral replication. *Proceedings, 24<sup>th</sup> International Herpesvirus Workshop*. Abst: 8.004.
- Brecke, R.L., Nie, M., Buxton, I.L.O. and Pardini, R.S. (2000) Dietary menhaden oil induces apoptosis and decreases growth of human ovarian carcinoma in athymic mice. *Proceedings of the American Association for Cancer Research* 41:850 (abstr#5401) 2000.
- Buxton, I.L.O., Oxhorn, B.C., Kaiser, R. and Cheek, D.J. (2000) The nucleotide axis hypothesis in coronary artery. *Proc. West. Pharmacol. Soc.* 43: 126.
- Anzinger, J. and Buxton, I.L.O. (2000) Regulation of inositol phosphate metabolism in cardiac endothelial cells. *Proc. West. Pharmacol. Soc.* 43: 112.
- Hirzel, D.J., Malmquist, N. and Buxton I.L.O. (2000) Nm23h2 inhibition by angiostatin derived from PC3 cell conditioned medium. *Proc. West. Pharmacol. Soc.* 43: 127.
- Oxhorn, B.C., Hirzel, D.J., Zhong, Q. and I.L.O. Buxton (2000) Large-scale production of endothelial cells for studies of compartmentation of signaling. *FASEB Journal* 14(8): A1561.
- Roesler, T. and Buxton, I.L.O. (2000) NO stimulation of cGMP accumulation in myometrial cells from pregnant women is antagonized by oxytocin. *FASEB Journal* 14(8): A1499a.
- Tichenor, S.D., Buxton, I.L.O. and Keef, K.D. (2000) Excitatory motor innervation in the canine rectoanal region: Role of changing postjunctional receptor populations. *FASEB Journal* 14(8): A1498.
- Kaiser, R.A. and Buxton, I.L.O. (2000) The Nucleotide Axis Hypothesis: Role of endothelial UTP receptors. *FASEB Journal* 14(8): A1538.
- Kaiser, R.A., Wiley, C., Martin, S. and Buxton, I.L.O. (2000) Characterization of myometrial smooth muscle potassium channels: Search for the cGMP-independent action of NO. *FASEB Journal* 14(8): A1499b.
- Buxton, I.L.O., Kaiser, R. and Oxhorn, B.C. (2000) On the *Nucleotide Axis Hypothesis* in coronary artery. *FASEB Journal* 14(8): A1562.
- Anzinger, J. and Buxton, I.L.O. (2000) Agonist-specific regulation of inositol phosphate metabolism in cardiac endothelial cells. *FASEB Journal* 14(8): A1482.
- Hirzel, D.J., Malmquist, N. and Buxton, I.L.O. (2000) Nm23h2 inhibition by angiostatin derived from PC3 cell conditioned medium: Failure of the commercial compound. *FASEB Journal* 14(8): A11543.
- Oxhorn, B.C. and Buxton I.L.O. (2001) Caspase-3 co-purifies with caveolar domains in cardiac endothelial cells. *Proc. West. Pharmacol. Soc. Pharmacology 2001* PO-368 Page 130.
- Buxton, I.L.O., Kaiser, R.A., Malmquist, N.A. and Tichenor, S. (2001) Nitric oxide signaling in laboring and non-laboring human myometrium: Role of cGMP. *Proc West Pharm Soc. Pharmacology 2001* OP-48 Page 67.
- Tichenor, S., Malmquist, N.A. and Buxton, I.L.O. (2001) Disparate signaling of nitric oxide donors in myometrial smooth muscle. *Proc West Pharm Soc. Pharmacology 2001* OP-47 Page 66. Awarded Top Honor as Outstanding Oral Presentation of the Meeting
- Kaiser, R.A. and Buxton, I.L.O. (2001) P2y4 receptors regulate endothelial cell calcium release and smooth muscle relaxation in guinea pig aorta. *Proc. West. Pharmacol. Soc. Pharmacology 2001* OP-82 Page 74.



**PUBLICATIONS****Research Abstracts (continued)**

Anzinger, J.J., Malmquist, N.A. and Buxton I.L.O. (2001) Intimations on the role of nucleoside diphosphate kinase in the biology of metastatic tumors. I: A secreted phospho-Nm23-H2 is common to disparate tumors. *Proc. West. Pharmacol. Soc. Pharmacology 2001* PO-376 Page 132.

Malmquist, N.A., Anzinger, J.J. and Buxton I.L.O. (2001) Intimations on the role of nucleoside diphosphate kinase in the biology of metastatic tumors. II: Secreted phospho-Nm23-H2 is inhibited by hexahydrodiphenic acid-dilactone. *Proc. West. Pharmacol. Soc. Pharmacology 2001* PO-382 Page 133. Awarded Top Honor as Outstanding Poster Presentation of the Meeting

Tichenor, S.D. and Buxton, I.L.O. (2002) Nitric Oxide-induced relaxation in guinea pig myometrium: It's a SNAP. Submitted to the 45<sup>th</sup> Annual Meeting of the Western Pharmacology Society, Mazatlan, Mexico.

Kaiser, R.A. and Buxton, I.L.O. (2002) P2Y Signalling sensitivity to cholesterol sequestration in guinea pig aorta. Submitted to the 45<sup>th</sup> Annual Meeting of the Western Pharmacology Society, Mazatlan, Mexico.

Mazzone, J.N., Kaiser, R.A. and Buxton, I.L.O. (2002) Cloning of calcium-activated potassium channels: Solving the nitric oxide dilemma. Submitted to the 45<sup>th</sup> Annual Meeting of the Western Pharmacology Society, Mazatlan, Mexico.

Mazzone, J.N. and Buxton, I.L.O. (2003) Real-time PCR studies of calcium-activated potassium channels in human myometrium. *Proc. West. Pharmacol. Soc.* 46: 188. Awarded Top Honor as Outstanding Poster Presentation of the Meeting

Kaiser, R.A., Buxton, N.D., Gebur, M. and Buxton, I.L.O. (2003) Endothelium-dependent actions of the polyphenolic catechin gallate EGCG involve both contracting and relaxing factors. *Proc. West. Pharmacol. Soc.* 46: 201.

Tichenor, S., Malmquist, N.A., Mauzey, J. and Buxton, I.L.O. (2003) Dissociation of the guanylyl cyclase pathway in myometrial smooth muscle: Effects of S-nitroso N-acetyl-penicillamine and 3-morpholinopyridone. *Proc. West. Pharmacol. Soc.* 46: 39.

Buxton, I.L.O. and Tichenor, S.D. (2004) Functional compartmentation of cyclic GMP-PKG and myosin phosphatase in myometrium. Oral Presentation, 51<sup>st</sup> Annual Meeting of the Society for Gynecological Investigation, Houston Texas.

Mazzone, J.N. and Buxton, I.L.O. (2004) Down Regulation of Apamin Sensitive Ca<sup>2+</sup>-Activated Potassium Channels in the Human Myometrium during Pregnancy. *Proc. West Pharmacol. Soc.* 47: 165a.

Rumjahn, S.M and Buxton, I.L.O. (2004) Effects of endostatin, EGCG and ellagic acid on angiogenic and metastatic potential of human breast cancer cells. *Proc. West Pharmacol. Soc.* 47: 170a.

Tichenor, S.D. and Buxton, I.L.O. (2004) Compartmentation of cGMP signaling in human myometrium. *Proc. West Pharmacol. Soc.* 47: 154a.

Rumjahn, S.M and Buxton, I.L.O. (2004) Inhibitory effects of epigallocatechin gallate and ellagic acid on the angiogenic potential of human endothelial cells and growth of human breast cancer cells. Gordon Research Conference: Cancer Models and Mechanisms, Salve Regina University, RI.

**PUBLICATIONS****Research Abstracts (continued)**

Rumjahn, S.M and Buxton, I.L.O. (2005) Inhibitors of MDA-MB-435s human breast cancer cell secreted NM23 prevent angiogenic stimulation *in vitro*. Research Presentation at: Gordon Research Conference: Angiogenesis and Microcirculation, Salve Regina University, RI.

Vittori, J.C. and Buxton, I.L.O. (2005) Cholesterol removal enhances both spontaneous and agonist-evoked uterine smooth muscle contractions in a reversible manner. *Proc. West Pharmacol. Soc.* 48: 179-1

Rumjahn, S.M. and Buxton, I.L.O. (2005) Epigallocatechin gallate and ellagic acid inhibit the angiogenic potential of CD31<sup>+</sup> human endothelial cells. *Proc. West Pharmacol. Soc.* 48: 179-2  
Awarded Top Honor as Outstanding Poster Presentation of the Meeting

Tichenor, J.N., Tichenor, S.D. and Buxton, I.L.O. (2005) Compartmentation of cGMP action in myometrial signaling domains: I. Effects of uroguanylin on particulate guanylyl cyclase. *FASEB Journal* 19(4) A538.

Buxton, I.L.O., Tichenor, J.N. and Tichenor, S.D. (2005) Compartmentation of cGMP action in myometrium signaling domains: II. Expression of both PKGI and PKGII in human myometrium. *FASEB Journal* 19(4): A538.

Tichenor, J.N., Gipson, E.K., Tichenor, S.D. and Buxton, I.L.O. (2005) Organization of the myometrial signaling domain explains the failure of global elevation of cGMP to relax the uterus. *Proc. West Pharmacol. Soc.* 48: 179-3.

Gipson, E.K., Tichenor, J.N., Tichenor, S.D. and Buxton, I.L.O. (2005) Compartmentation of cGMP signaling in human myometrium: III. Expression of multiple isoforms of myosin phosphatase myosin binding subunit. *FASEB Journal* 19(4): A538-9.

Vittori, J.C., Roberts, D.L. and Buxton, I.L.O. (2005) Reversible effects of cholesterol on myometrial contraction are consistent with a role for hypercholesterolemia in uterine dysfunction. *FASEB Journal* 19(4): A537-8.

Rumjahn, S.M. and Buxton, I.L.O. (2005) Effects of Endostatin, epigallocatechin gallate and ellagic acid on the angiogenic potential of CD31<sup>+</sup> human endothelial cells. *FASEB Journal* 19(4): A550.

Rumjahn, S. and Buxton, I.L.O. (2006) Nm23 secreted by human breast cancer promotes angiogenesis. *Proc. West Pharmacol. Soc.* 49:193.

Rumjahn, S. and Buxton, I.L.O. (2006) Inhibitors of nm23 suppress MDA-MB-435 human breast carcinoma mediated angiogenesis *in vitro*. *FASEB Journal Abstracts* 462.2.

Tichenor, J.N., Hansen, E.T. and Buxton, I.L.O. (2006) Expression of TREK and TRAAK is differentially regulated during pregnancy in humans. *FASEB Journal Abstracts* 426.14.

Tichenor, J.N., Hansen, E.T. and Buxton, I.L.O. (2006) Two-pore potassium channel expression in human myometrium. *Proc. West Pharmacol. Soc.* 49:193.

Tichenor, J.N., Hansen, E.T. and Buxton, I.L.O. (2007) Stretch-activated potassium channels in human myometrium. *Reproductive Sciences.* 14(1) 230A.

Tichenor, J.N., Hansen, E.T. and Buxton, I.L.O. (2007) Blockade of stretch-activated 2-pore K<sup>+</sup> channels by tarantula toxin modulates uterine contractions. *Proc. West Pharmacol. Soc.* 50: 230.

**PUBLICATIONS****Research Abstracts (continued)**

- Rumjahn, S. and Buxton, I.L.O. (2007) Breast cancer cells secrete an angiogenic factor that activates endothelial P2Y<sub>1</sub> receptors. *Proc. West Pharmacol. Soc.* 50: 207.
- Jeanblanc, C., Xiang, S., Duan, D., and Buxton, I.L.O. (2008) Mitochondrial GSH levels are decreased in hearts from CFTR-knockout mice. *Proc. West. Pharmacol. Soc.* 51: 99-100.
- Milton, D., Dennemeyer, S. and Buxton, I.L.O. (2008) Co-immunoprecipitation of cGMP-protein kinase type I & II and myosin phosphatase suggest a role for their functional interaction in human uterine quiescence at term. *Proc. West. Pharmacol. Soc.* 51: 103-104.
- Tichenor, J.N., McGlothlin, K. and Buxton, I.L.O. (2008) Dissociation of mRNA and protein levels for human myometrial TREK-1 suggests a non-genomic role for TREK-1 expression during labor. *Proc. West. Pharmacol. Soc.* 51: 95.
- Yokdang, N., Rumjahn, S.M. and Buxton, I.L.O. (2008) Endothelial P2Y receptors transactivate endothelial VEGF receptors consistent with a role in angiogenesis stimulation. *Proc. West. Pharmacol. Soc.* 51: 96.
- Rumjahn, S.M., Baldwin, K. and Buxton, I.L.O. (2008) Purinergic regulation of angiogenesis via vascular endothelial growth factor receptor 2 signaling. *Proc. West. Pharmacol. Soc.* 51: 97.
- Rumjahn, S.M., Tichenor, J.N., and Buxton, I.L.O. (2009) Functional expression of stretch-activated potassium channels (TREK-1) in pregnant human and guinea pig myometrium. *Proc. West. Pharmacol. Soc.* 52, A5
- Yokdang, N., Cui, T., Thai, J., Rumjahn, S.M. and Buxton, I.L.O. (2009) The activation of P2Y<sub>1</sub> nucleotide receptor mediated breast cancer angiogenesis via transphosphorylation of VEGF receptor-2 Accepted abstract *Proc. West. Pharmacol. Soc.* 52, A4.
- Wu YY, Buxton ILO, (2010) TREK-1 splice variants may lead to failure of human myometrial relaxation and contribute to preterm labor. *Proc West Pharmacol. Soc.* 53, San Diego.
- Ulrich CC, Buxton ILO (2010) S-Nitrosylation in human myometrial smooth muscle. *Proc West Pharmacol. Soc.* 53, San Diego.
- Yokdang, Wu YY, and Buxton, I.L.O. (2010) The release of extracellular NDPK-B from human breast cancer cells acts as an angiogenic factor *in vivo*. *Proc West Pharmacol. Soc.* 53, San Diego.
- Wu, Y-Y, Singer, C.A. and Buxton, I.L.O. (2011) Trek-1 splice variants may lead to failure of human myometrial relaxation and contribute to preterm labor. FASEB J EB2011 Abstracts A435, Page 391.
- Heyman, N., Barnett, S., Wu, Yi-Ying, Singer, C.A., Leblanc, N., Hume, L. and Buxton, I.L.O. (2011) TREK-1 currents in smooth muscle cells from pregnant human myometrium. FASEB J EB2011 Abstracts A434, Page 391.
- Ulrich, C., Nordmeier, A., Schegg, K., Quilici, D. and Buxton, I.L.O. (2011) Discovery of the nitro-proteome in human myometrium. FASEB J EB2011 Abstracts B206, Page 302.

**PUBLICATIONS****Research Abstracts (continued)**

- Buxton, I.L. (2011) Purinergic mechanisms in breast cancer metastasis. ASCO, San Francisco, 2011
- Burkin, H.R., Singer, C.A. and Buxton, I.L. (2012) Integrin localization to focal adhesion sites in pregnant human myometrium. Accepted Abstract, SGI Reproductive Sciences, 19: 29A T246.
- Ulrich, C. and Buxton, I.L. (2012) The myometrial nitroproteome in pregnancy. Accepted Abstract, SGI Reproductive Sciences, 19: 30A T268.
- Wu, Y-Y, Singer, C.A. and Buxton, I.L. (2012) Splice variants of the K2P channel TREK-1 associated with preterm labor. Accepted Abstract, SGI Reproductive Sciences, 19: 30A T270.
- Heyman, N., Barnett, S. and Buxton, I.L. (2012) Characterization of human myometrial TREK-1 potassium channel currents. Accepted Abstract, SGI Reproductive Sciences, 19: 29A, T-255.
- Ulrich, C., Quilici, D., Schegg, K., Buxton, I.L.O., Scott Barnett, and Nathanael Heyman (2012) The uterine smooth muscle S-nitrosylproteome in pregnancy and functional effects of S-nitrosoglutathione FASEB J March 29, 2012 26:985.3
- Wong, S., Yokdang, N., Speirs, K. and Buxton, I.L.O. (2013) Purinergic mechanisms in breast cancer development: A role for nucleoside diphosphate kinase. FASEB J April 9, 27:1104.9
- Barnett, S.D., Ulrich, C., Baker, J. and Buxton, I.L.O. (2013) The role of S-nitrosylated profilin-1 and myosin regulatory light chain 9 in human myometrial contractile dynamics. FASEB J April 9, 27:879.1
- Burkin, H. and Buxton, I.L.O. (2014) Differential expression of integrins, ECM molecules, and signaling proteins in the term and preterm human myometrium. Session Info: Poster Session: Basic Parturition, Prematurity Thursday, March 27, [T-017] 10:00 am.
- Copley-Salem, C, Ulrich, CC, Quilici, D, Schlauch, K, Burkin, HR, and Buxton, ILO. Stretch Induced Phosphoproteomic Signaling Networks in Pregnant Human Myometrial Cells. Reproductive Sciences, vol. 21, no. 3, pp. 138A
- Chad L Cowles, Yi-Ying Wu, Cindy Valverde, Michael T Lee, Heather R Burkin, Iain LO Buxton [T-030] Characterization of Variants of Stretch-Activated 2-Pore Potassium Channel TREK-1. Poster Session: Basic Parturition, Prematurity, Thursday, March 27, 2014, 10:00 am.
- Craig C Ulrich, David R Quilici, Karen Schlauch, Heather R Burkin, Iain LO Buxton[S-033] Proteomic Network Analysis of Human Uterine Smooth Muscle in Pregnancy, Labor, and Preterm Labor. Poster Session: Basic Parturition, Prematurity Saturday, March 29, 2014, 10:00 am.
- Chad L Cowles, Michael T Lee, Heather R Burkin, Iain LO Buxton. Characterization of TREK1 Currents in Freshly Isolated Myocytes. *Reproductive Sciences* S-109 333a, 2015
- Scott D Barnett, Craig Ulrich, Josh Baker, Iain LO Buxton. Role of S-Nitrosated Myosin Regulatory Light Polypeptide 9 in Uterine Smooth Muscle Contraction. *Reproductive Sciences* S-107 332a, 2015
- Senny Wong, Katie Spiers, Suzann Duan, Iain LO Buxton. MDA-MB-231 Cell Exosomes Contain Nucleoside Diphosphate Kinase. *Reproductive Sciences* T-041, 121a, 2015

**PUBLICATIONS****Research Abstracts (continued)**

Iain L. O. Buxton, Craig Ulrich and Heather R. Burkin. Nitric Oxide-Mediated Relaxation of Spontaneously Active and Agonist-Evoked Contraction of Human Pregnant Myometrium is Blunted in Preterm Tissues. *SSR Abstracts* 198a, pg. 79, 2015

Craig C. Ulrich, Christian Copley-Salem, David Quilici, Karen Schlauch, Iain L. Buxton and Heather R. Burkin. Stretch Induced Phosphoproteomic Signaling Networks in Pregnant Human Myometrial Cells Highlight the Importance of the Integrin Signaling Pathway. *SSR Abstracts* 199a, pg. 79, 2015

Heather R. Burkin, Carolina B. Wandscheer, Craig C. Ulrich and Iain L. Buxton. MMP2 and MMP9 Expression and Upregulation in Preterm Myometrium. *SSR Abstracts* 200a, pg. 80, 2015.

Ulrich, Craig C., Christian Copley-Salem, David Quilici, and Heather R. Burkin. (Buxton Lab Group) Global Phosphoproteomic Signaling Network Changes During a Biaxial-Stretch Model of Human Uterine Distension. *Reproductive Sciences*, vol. 22, pp. 336A-336A, 2015.

Cowles, C., Burkin, H., Ulrich, C., Lee, M. and Buxton, I.L.O. Transport of Nitric Oxide in Human Uterine Myocytes. *Reproductive Sciences* 23(1) 216A. 2016

Ulrich, C., Copley-Salem, C., Von Schimmelmann, K., Buxton, I.L.O. and Burkin, H. mTOR signaling is activated in response to myometrial stretch: Implications for preterm labor. *Reproductive Sciences* 23(1) 217A. 2016

Barnett, S.D., Burkin, H. and Buxton, I.L.O. GSNOR expression and Regulation in preterm laboring myometrium. *Reproductive Sciences* 23(1) 299A. 2016

Suzann Duan, Senny Nordmeier, Iain L.O. Buxton. Exploring the metastatic potential of exosomal NM23 signaling using a triple negative breast cancer model in mice. *AACR Abstracts*, 4175, 2016.

Senny Nordmeier, Suzann Duan, Iain L.O. Buxton. Purinergic regulation of tumor-mediated angiogenesis: A role for exosomal NM23. *AACR Abstracts*, 3396, 2016.

Nordmeier, S, Duan, S, and Buxton, ILO. Exosomal NM23 Mediates Purinergic Regulation of Breast Cancer Angiogenesis [abstract]. In: *Molecular Biology of the Cell*; 2016 Dec 3-7; San Francisco, California (CA); ASCB; 2016.

Salem, CC, Ulrich, C, Quilici, D, Woosley, R. Buxton, IL and Burkin, HR Isobaric TMT 10-plex Labeled MultiNotch MS3 Analysis of Human Uterine Smooth Muscle in Disparate States of Pregnancy; *Journal of The American Society for Mass Spectrometry*, Volume 27, Supplement 1, pp 1–266. 2016

Suzann Duan, Senny Nordmeier, Iain L.O. Buxton. Establishing the involvement of exosomal NM23 in pro-angiogenic communication between triple negative breast cancer cells and their vascular targets. In: *Mol. Bio. Cell* 27, page 1977. American Society for Cell Biology Annual Meeting; 2016 Dec 3-7; San Francisco, CA.

Iain L. O. Buxton, Craig Ulrich, Scott D. Barnett, and Heather R. Burkin. Altered S-Nitrosation of Contractile Proteins Underlies Dysfunctional Quiescence in Human Preterm Labor. *Pelvic Floor Society Meeting*, Charleston, SC December 2016.

**PUBLICATIONS****Research Abstracts (continued)**

Craig Ulrich, Carolina Wandscheer, Christian Copley Salem, Veronica Arinze, Jenny Wong, Iain Buxton, Heather Burkin, 49th Annual Meeting, MMP2 and MMP9 Expression and Influence on Contraction in Pregnant Human Myometrium. Society for the Study of Reproduction, San Diego, CA, United States. (July 19, 2016).

Craig Ulrich, Veronica Arinze, Christian Copley Salem, Iain Buxton, Heather Burkin. MMP2/9 Upregulation in Preterm Laboring Uterine Myometrium May Exacerbate Contractility. Biology of Reproduction a552 Abstracts 2017.

Craig Ulrich, Christian Copley Salem, David Quilici, Rebekah Woosley, Iain Buxton, Heather Burkin, Karen Schlauch. Isobaric TMT 10-plex labeled MultiNotch MS3 analysis of biological and technical variance in human uterine smooth muscle tissue. ASMS, TP613 2017

Barnett, S., Lambert, J. Maged, V., Petereit, J., Ulrich, C., Buxton, I.L. and Burkin, H. (2018) Association of GSNOR Levels with Preterm Birth in African American Women and Therapeutic Potential of GSNOR Inhibition. Mountain West CTR-IN Consortium Annual Meeting June 11-12, 2018. Las Vegas, NV.

**PATENTS**

US Patent: Polyphenol Inhibition of Nucleoside Diphosphate Kinase-B Activity and Cancer Metastasis. December 30, 2009; Patent No. 7,678,549.

US Patent Pending: GSNOR Inhibition in Preterm Laboring Myometrium restores quiescence: Prevention of Spontaneous Preterm Birth.

**INVITED LECTURES*****Invited Leadership Presentations:***

Organization and Management Structures for Research & Practice in Schools of Pharmacy: Role of the Dean. New Mexico Health Sciences Center, Albuquerque, April 25, 2002.

Development of a New School of Pharmacy Under Revised ACPE Accreditation Guidelines. Samuel Merritt College, Oakland California, July 2008.

***Invited Research Presentations:***

Mechanisms of Dysfunctional Quiescence in Spontaneous Preterm Labor. Invited Plenary, Society for Reproductive Investigation, Myometrial Satellite, Orlando Florida, March 2017.

Therapeutic Inhibition of GSNOR in the Management of Preterm Labor. Platform Presentation at the 3<sup>rd</sup> Annual Clinical Translational Research Meeting (CTR-IN), Las Vegas, NV June 2016.

Intimations on the Metastatic Process in Breast Cancer: *Incommodus Verum* Invited Speaker, (the International Congress of the NDPKinase/Nm23/awd Gene Family a New Frontier in Cell and Cancer Biology. July 31<sup>st</sup>-Aug. 4<sup>th</sup>, 2013. Boston University, Boston, Massachusetts, USA

Current Research in Pharmacology and Medicine Milan Institute, October, 2012

New Therapeutic Targets in the Regulation of Myometrial Relaxation. Department of Obstetrics and Gynecology, University of Colorado, Denver. October 11, 2011.

*Incommodus Verum: Extracellular Nm23 Signaling in Breast Cancer.* Plenary Lecture. Western Pharmacology Society Annual Meeting, Mexico City, Mexico, May 16, 2011

Suppression of Breast Cancer Metastasis by Polyphenols. Plenary Lecture, Western Pharmacology Society Annual Meeting, San Diego, February 8, 2010.

Regulation of human uterine relaxation at term by stretch-activated potassium channels. Plenary Lecture, Western Pharmacology Society Annual Meeting, Acapulco, Mexico, February 12<sup>th</sup> 2009.

The Physiology of Pregnancy and Parturition. Obstetrics and Gynecology Department, University of Nevada School of Medicine, April 2006

Functional Organization of Myometrial Relaxation Signaling During Labor in Humans. Myometrial Satellite Symposium; Annual Society for Gynecological Investigation Meeting 2005.

Departmental Research Rounds, Regulation of Uterine Contraction in Prematurity, Obstetrics and Gynecology Department, University of Nevada School of Medicine, April 2005

Regulation of Relaxation Signaling in Human Myometrium Plenary Lecture, Western Pharmacology Society Annual Meeting, Honolulu, Hawaii, January 25<sup>th</sup> 2004.

New Therapeutic Targets in Preterm Labor Research Grand Rounds. Department of Obstetrics and Gynecology, University Medical Center, Las Vegas, NV. October, 2001.

Nitric Oxide Signaling in the Human Pregnant Myometrium. IUPS; XXXIVth International Congress of Physiological Sciences, from Molecule to Malady, Satellite Meeting; Physiology of Pregnancy and Parturition, Auckland, New Zealand, August 2001.

Mechanisms in Vascular Regulation Texas Tech University of the Health Sciences, Amarillo, March 2000.

Role of Nm23 in Human Breast Cancer Metastasis University of Nevada Las Vegas/UNSOM Research Conference, Las Vegas, Nevada, June 1999.

Agonist-mediated ATP Release in Coronary Artery: Evidence in Support of the Purinergic Axis Hypothesis *Conference on Endothelial Regulation of Vascular Tone: Molecular to Integrative Physiology*; American Physiological Society, Augusta, Georgia, 1998.

Role of Protein S-nitrosations in the Regulation of Myometrial Function Invited Lecture, Society for the Study of Reproduction, Puerto Rico, June 20, 2015.

Mammalian Cloning and the Future of Medicine and Society. A scientific primer delivered to the Trustees of the University of Nevada, Reno Foundation, 1997.

The Purinergic Axis in Blood Vessels. University of Maryland, School of Pharmacy, Baltimore, Maryland, July 1997.

Cyclic GMP-Independent Actions of Nitric Oxide in Human Myometrium. Loma Linda School of Medicine, Department of Physiology, Division of Perinatal Biology, Loma Linda, CA, April 1997.

Origin, Sources and Fates of Nucleotides in the Coronary Vasculature. University of Nevada Las Vegas, Invited Seminar, Department of Biology, Las Vegas, Nevada, June 1997.

Nucleotide Regulation of the Coronary Vasculature. University of California Davis, Division of Cardiovascular Sciences, Department of Medicine, October 1996.

On the Nucleotide Axis in Cardiac Blood Vessels. Basic Pharmaceutical Sciences, West Virginia University School of Pharmacy, July 1996.

The Purinergic Axis in Cardiac Blood Vessels. Department of Pharmaceutical Sciences, University of Montana, Missoula, April 1996.

Endothelial Cell Purinergic Mechanisms in Coronary Arteries. Department of Pharmacology, Quillen College of Medicine, Johnson City, Tennessee, April, 1996.

A Role for NO in the Onset of Labor. Symposium; Regulation of Onset of Labor (Chair, I.L.O. Buxton) Society for Gynecological Investigation, Annual Meeting, Philadelphia, 1996

Novel Mechanisms of Purine Nucleotides in Coronary Artery. Symposium; The Purinergic Axis in Blood Vessels. Western Pharmacology Society. Maui Intercontinental, Hawaii. January, 1995.

On the Origin of Extracellular ATP in Cardiac Blood Vessels: A Dual Role for Endothelium. Fifth International Symposium on Adenosine and Adenine Nucleotides. Philadelphia, Penn. May, 1994.

A Purinergic Axis in Blood Vessels. Symposium; *The Role of Adenosine Triphosphate in Peripheral and Central Neurotransmission.* Experimental Biology, Anaheim, Cal. April, 1994.

A Role for Adenyl Purines in Myometrial Function. Loma Linda School of Medicine, Department of Physiology, Division of Perinatal Biology, Loma Linda, CA. June 1993.

Role of Adenyl Purines in Myometrial Function. Department of Pharmacology, University of California, San Diego, December 1992.

Adenosine Receptor Mechanisms in Parturition. Division of Perinatal Biology, Loma Linda School of Medicine, February 1992.

The Role of Adenyl Purines in Myometrial Function. Fourth International Symposium on Adenosine and Adenine Nucleotides. Lake Yamanaka, Japan. May 1990.

$\alpha_1$ -adrenergic Receptor Signal Transduction in the Adult Rat Cardiac Myocyte. Biology of the Isolated Adult Cardiac Myocyte NHLBI RFA Meeting, Asilomar Conference Center, 1987.



**INVITED LECTURES*****Lectures Presented in Conjunction With Professional Continuing Education Programs:***

New Approaches to the Prevention of Preterm Delivery. March of Dimes Women's Health Symposium, Friday, November 19, 2010, Tuscany Suites and Casino, Las Vegas, NV.

Potassium Channel Variants in Spontaneous Preterm Labor. Ob-Gyn Resident Lecture Series, September 2009, Las Vegas, NV

Preterm Labor Treatment: Lack of Efficacy in Current Tocolytics. Continuing Education for Physicians and Nurses, Saint Mary's Perinatal Conference. October 2008, Reno, NV.

Two-Pore Potassium Channels: Basic Updates from Bench to Bedside. *Keynote Lecture* Continuing Education for Physicians and Nurses, Saint Mary's Perinatal Conference, "Autumn in the Sierra: Concepts in Perinatal Care Conference" October, 2007, Reno, NV.

Therapeutic Targets in the Treatment of Preterm Labor. Continuing Education for Physicians and Nurses, Saint Mary's Perinatal Conference, "Autumn in the Sierra: Concepts in Perinatal Care Conference" August, 2003, Reno, NV.

Pharmacotherapy of Joint Diseases. Continuing Education for Physicians and Pharmacists. UNR Department of Continuing Education Program, August, 1999, Reno, NV.

Pharmacology: Introductions to a Basic Medical Science Discipline: Howard Hughes Teacher Fellows Conference, University of Nevada School of Medicine, 1998.

Receptor Theory: The Road to How and Why: Howard Hughes Teacher Fellows Conference, University of Nevada School of Medicine, 1997.

Pharmacology in the Classroom: Howard Hughes Teacher Fellows Conference, University of Nevada School of Medicine, 1996.

Pharmacognosy: Drugs from Plants. Howard Hughes Teacher Fellows Conference, University of Nevada School of Medicine, 1995.

Humanizing Research. Presented to the American Heart Association Delegate Assembly, Las Vegas, Nevada September 1992.

Diabetes Research: The State of the Art Lecture to Physicians and Nurses sponsored by the American Diabetes Association, Las Vegas, Nevada, January 20, 1990.

The Biochemistry of Diabetic Blood Vessels. Lecture to Physicians. Annual Meeting, American Diabetes Association, Las Vegas, NV. May 1989.

Digoxin Use and Misuse: Toxicity and Pharmacokinetics. VA Medical Center Grand Rounds, San Diego, 1984.

Catecholamine Receptor Regulation of Inotropy in Mammalian Heart. Department of Medicine, University of California, Los Angeles, 1984.

Special Intensive Care Unit Pharmacology. American Lung Association, (Provided as Continuing Education credit for Nurses), 1982.

Amrinone in Congestive Cardiomyopathy. Pharmacy Grand Rounds, Veterans Administration Medical Center, 1980.

Propranolol in the Treatment of Angina Pectoris. Veterans Administration Medical Center, 1979. (Provided as Continuing Education credit for Pharmacists.)

Biopharmaceutics and Pharmacokinetics. California Nursing Association, 1979. (Provided as Continuing Education credit for Registered Nurses.)

**Public Education/Awareness Lectures**

Curing Breast Cancer Invited Keynote Speaker. Annual Meeting, Nevada Chapter, Komen for the Cure, 2015.

The path to New Drug Development Invited remarks for the *Whittemore Peterson Institute* fundraising gala, October 2014.

Incommodus Verum: Failing to Understand Breast Cancer Then, What About Now? University of Nevada Honors Program Lecture Series, October, 2011.

Women's Health Research in Nevada Reno Soroptomists Club, April, 2007

Pharmacotherapy Advances in Health Care Delivery Reno Centennial Rotary Club, 2006.

Trouble with the Miracle. Presented to the Reno Lions Club, May 13, 2004.

Real Axis of Evil: Discovery of Pathways to Prevent Disease Sanford Center for Aging: Silver Series Lectures, February 2004.

Why They Couldn't Stop Your Labor. Presented to the Premi Support Group (A parents of premature infants support group), Reno, NV, June 2003.

Current Therapies for Cancer. Presented to the Sparks, NV Veterans of Foreign Wars Auxiliary, October, 1999.

**INVITED LECTURES****Public Education/Awareness Lectures (continued):**

Science and Medicine: Ethical Conundrums. Presented to the Sparks Sertoma Club, December, 1998.

Human Gene Cloning and Our Responsibility. Presented to the Trustees of the University of Nevada Foundation, November, 1997.

Science, Medicine, Ethics and Cloning. Public lecture given to the Sparks Chapter of the Rotary Club, June 1997.

Hello Dolly: Human Genetics in the 21<sup>st</sup> Century. Public lecture given to the Reno Chapter of the Rotary Club, April 1997.

Science and Ethics in the Age of Genetic Engineering. Public lecture given to the Universalist Christian Alliance, Reno, November 13, 1996.

Shaping a Healthy Future: The Anatomy and Physiology of the Heart and Blood Vessels. Public lecture given to Washoe County school teachers, Sparks Middle School, February 5, 1996.

The Human Genome Project: Where do we stand? A scientific lecture invited by the liberal clergy of the Truckee Meadows, March 13, 1996.

The Birth of a Baby: Trouble with the Miracle. Rotary Club: Reno Chapter, September 16, 1994.

Let the Beat Go On: Anatomy and Physiology of the Heart and Blood Vessels. University of Nevada School of Medicine: Mini Medical School 1994. Las Vegas. March 2<sup>nd</sup>, 1994; Reno, March 30<sup>th</sup>, 1994.

Cells: The Object of Our Fancy! University of Nevada School of Medicine: Mini Medical School 1993. Public Lecture, Las Vegas March 24, 1993; Reno, March 25, 1993.

The State of Cardiovascular Research in the United States. Fraternal Order of Eagles, State Meeting, 1986.